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DEVELOPMENT OF TUMOR TRAPPING ENHANCED BB2R-TARGETED
RADIOPHARMACEUTICALS FOR PROSTATE CANCER
Wenting Zhang
University of Nebraska, 2019
Supervisor: Jered C. Garrison, Ph.D.

ABSTRACT
The Gastrin-Releasing Peptide Receptor (BB2r) has been intensively investigated as a
cancer target over the years. Numerous diagnostic and therapeutic BB2r-targeted agents
have been developed for various solid tumors, including prostate cancers, due to the
high expression level of BB2r on neoplastic relative to normal tissues. The development
of those targeted agents have mainly utilized the modified c-terminal of bombesin(BBN),
a peptide that has nanomolar binding affinity to human BB2r. However, a major issue
that hinders the clinical translational potential of low-molecular weight, receptor-targted
agents, is their short residence time at tumor tissues due to the intrinsically high
diffusion and clearance rates.
Detailed in this dissertation is a comparison study investigating important biological
differences between two mouse models of prostate cancer and how these factors impact
the delivery of BB2r-targeted agents. Specifically, we have evaluated the impact of
differences in tumor vassculatur density, hypoxia burden and perfusion efficacy on
BB2r-targeted agent uptake and distribution. Furthermore, herein, we proposed two

iv

different

approaches

to

increase

the tumor

residualization of

BB2r-targeted

radiopharmaceutical agents, by developing chemical approaches to “trap” BB2r-targeted
agents in prostate cancer cells through adduct formation with macromolecules. First
proposed, BB2r-targted agents incorporating hydrophilic cysteine cathepsin (CC)
inhibitors was developed. Due to the high concentration of CCs found in endolysosomal
compartments, our agents have the ability to irreversibly bind to CCs after endocytosis.
Two analogs, based on BB2r-targeted agonist and antagonist separately, demonstrated
enhanced tumor retention and optimal tumor-to-non-target ratios compared to the
matching controls. The second approach focused on the hypoxic nature of prostate
cancer, which is due to the distorted architecture leading to the insuffucient delivery of
oxygen, and was examined as a mechanism to increase retention of BB2r-targeted
agents. Specifically, we explored the hypoxic-selectivity of a 2-nitroimidazole
phosphoramide nitrogen mustard (2-NIPAM), a potential tumor trapping agent which is
able to irreversibly bind to intracellular nucleophiles in hypoxic tissues.
Overall, we seek to determine the most suitable mouse model in evaluating the BB2rtargeted agents. We are also exploring strategies to elongate the retention time of BB2rtargeted agents in the prostate tumor tissues, thereby increasing the clinical translational
potential of these agents. Future works include: 1) synthesis and evaluation of 2-NIPAM
incorporated BB2r-targeted peptides in vitro and in vivo; 2) synthesis and assessment of
hydrophilic CC inhibitors integrated into other receptor-targeted analogs. Further work
is needed to demonstrate the feasibility and wide applicability of our strategies in
different receptor-targeted systems.
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CHAPTER 1. INTRODUCTION
1.1 Prostate Cancer and Gastrin-Release Peptide Receptor
It is estimated that prostate cancer was the second leading cause of death for men in
the United State in 2018 and accounts for 19% of new cancer cases alone, according to
the American Cancer Society 1. Prostate cancer is one of the most treatable malignancies
with a 98.2% 5-year survival rate if diagnosed early and the cancer remains localized.
The 5-year survival rate drops to 30% once metastasis begins 2. The Gastrin-releasing
peptide receptor, also known as the BB2 receptor (BB2r), is a G-protein coupled receptor
that upon activation works through the phospholipase C pathway to increase
intracellular concentration of the signaling molecules inositol phosphates, diacyl
glycerol and calcium 3. The BB2r is expressed in the human gastrointestinal tract and
central nervous system, and plays a role in release of gastrointestinal hormones 4,
epithelial cell proliferation 5, smooth muscle cell contraction 6, pancreatic enzyme
secretion 7 and other biological functions. Furthermore, BB2r is aberrantly overexpressed
in several human cancers such as lung, breast, colon and prostate cancers, possibly due
to constitutive receptor activation triggered by mutation

4, 8

. Elevated level of BB2r can

assist the proliferation and invasion of human cancerous cells, via the activation of
transcription factor Elk-1 and intermediate early gene c-fos
factor receptors (EGFR) pathway

10-11

9

and epidermal growth

. In prostate cancer, the increased expression of

BB2r activation can also stimulate the focal adhesion kinase (FAK)

12

and upregulate

2

intracellular adhesion molecule (ICAM)-1, which facilitates the tumor differentiation
and cancer cell-extracellular matrix attachment and tumor migration 13-14.
The BB2r has been intensively investigated as a clinical diagnostic and/or therapeutic
target for prostate, pancreatic, breast, colorectal and small-cell lung cancers, due to this
high expression of the receptor on tumor cells relative to normal tissues

. To date,

15-21

research have found that 38-72% of breast cancer, 72-85% of glioblastoma and 85-100%
of small-cell lung cancer have overexpressed BB2r 22. Specifically, for prostate cancer, it
is estimated that 63-100% of primary prostatic invasion carcinoma have high or very
high level of BB2r 23. The prostate cancer progression often starts from early-stage, in
which the growth and survival of the tumor is dependent on androgens. Androgen
ablation therapy can cause the suspension of prostate cancer progression, but eventually
the cancer is able to bypass its androgen dependence to become androgen-independent
24-25

. Among the prostate cancer patients have underwent androgen ablation therapy,

more than 50% of the androgen-independent prostate cancers have been shown to be
BB2r-positive 26. A study evaluating lymph node and bone metastasis of prostate cancer
have also shown BB2r expression in 85.7% and 52.9% of cases, respectively

. These

26

finding greatly implicate the potential of developing diagnostic and therapeutic agents
for BB2r-positive cancers.
Based on the research stated above, different approaches have been utilized to
develop BB2r-targeted agents. Studies employing BB2r antagonists either alone or with
other agents have exhibited anti-tumor growth effects. For instance, cytotoxic drugs (e.g.

3

doxorubicin and paclitaxel) has been conjugated to BB2r-targted analog, leading to the
specific inhibition of tumor cell proliferation 14; also, the BB2r antagonist (PD176252) coadministrated with EGFR inhibitor (erlotinib) showed a synergistic anti-tumor effect 27.
Another approach for the development of targeted diagnostics/therapeutics is to use
BB2r-targeted peptides labeled with radioisotopes. Numerous analogs have been
developed over the years, which are going to be discussed in the following contents in
detail.

1.2 Targeted Radiopharmaceutical Agents
In the past few decades, the development of radiopharmaceuticals for diagnostic and
therapeutic purposes has been widely explored. Targeted radiopharmaceutical agents
comprising radionuclide(s) and a targeting vehicle, delivering the radioisotope
specifically to tumor cells or other cells in the tumor microenvironment, have risen and
became the center of the field. A variety of radionuclides such as 68Ga, 64Cu,
90

Y,

177

Lu,

I and

123

F have been used for diagnosis and/or therapy

18

28-33

99m

Tc,

111

In,

. The overall

developmental strategy for targeted radiopharmaceuticals agents is mainly focused on
the optimization of the in vivo pharmacokinetics, particularly regarding achieving high
tumor-to-non-target (T/NT) ratios. The T/NT ratios are a good indicator of how efficient
the in vivo delivery of the agent to the tumor vs the clearance of the analog, and its
metabolites, from background, nontarget tissues. The higher the T/NT ratios for the
radiopharmaceutical the better the imaging contrast for diagnosis and more tolerable the
radiation damage to normal tissues during therapy 34. In addition, the residence time of
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the radiopharmaceuticals agents at the tumor sites is another important factor to be
considered. This is particularly true for therapeutic purposes given that residence for a
radiotherapeutic agents is going to directly correlate to the dose delivered to the tumors
of patients. With those issues in mind, various delivery vehicles have been designed,
synthesized and evaluated to date, including low- and high-molecular weight carriers.
These platforms have unique pharmaceutical properties and different applications, as
discussed below separately.

1.2.1 Antibodies-Based Radiopharmaceuticals
To date, there have been dozens of monoclonal antibody (mAb) (e.g. whole or
fragments) based radiopharmaceuticals under investigated for clinical cancer therapy,
including prostate cancer

. For instance, Zevalin® and Bexxar®, both are mAb that

35-38

targets the CD20 antigen, has been approved for the treatment of relapsed refractory B
cell non-Hodgkin lymphoma. There are also several ongoing clinical trials that utilize
high affinity mAb targeting prostate cancer biomarkers. To date, several of these trials
have achieved promising results

, such as Lu-177 or Bi-213 labeled J591 with anti-

39-41

prostate specific membrane antigen (PSMA) domain

42-43

and

131

I-labeled mAb CC49

against tumor-associated glycoprotein 72 (TAG72) for metastatic prostate cancer 44. The
development of tumor-specific antibodies-based radiopharmaceuticals have the
advantage of long blood circulation time (long half-life), which requires lower doses
upon administration

36, 45

. One major drawback with the production of monoclonal

antibodies, which often relies on the bacteria or mammalian cells, is relatively complex

5

when compared to synthetic small molecules. 46. Also, due to the high molecular weight
of mAbs, there are other negative issues such as the sequestration by reticuloendothelial
cells, slow tumor uptake and systematic clearance rates, which eventually cause adverse
non-target toxicity in patients 37.

1.2.2 Small Molecule-Targeted Radiopharmaceuticals
Different from antibody-based radiopharmaceuticals, small molecular weight agents,
including small molecules and peptides, have the advantage of rapid tumor targeting
and blood clearance, which leads to higher T/NT ratios. They can be synthesized
chemically and tolerate more harsh conditions (e.g. pH and temperature) upon
modification and radiolabeling 46. These low molecular weight agents are also less likely
to induce immunogenic response

. For prostate cancer, the standouts in the field are

47-48

small-molecule vehicles capable of targeting PSMA, which is highly expressed and well
characterized in almost all prostate cancers regardless of cancer stage
99m

49-51

. For example,

Tc-MIP-1404, demonstrated a high probability (90%) to detect PSMA-positive lesions

in patients with elevated prostate-specific antigen (PSA)

. In addition,

52

18

F-DCFBC,

another small molecular vehicle, has been evaluated and showed higher specificity for
detecting high-grade and larger-volume tumors (Gleason score 8 and 9) compared to
MRI

53

. Besides imaging, PSMA-targeted agents have also underwent studies for

therapeutic purposes and have yielded analogs capable of high radiotherapeutic
delivery to prostate tumor (e.g. 124/131I-labeled MIP-1095 and 177Lu-PSMA) 54-56.
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1.2.3 Peptide-Targeted Radiopharmaceuticals
Another frequently discussed category of targeted radiopharmaceuticals is peptidebased agents, in which our laboratory is most interested in studying

. Just like other

31, 57

targeted radiopharmaceuticals, these peptide-based radiotracers also target the receptors
that overexpressed on cancer cells or surrounding tissues. As mentioned before, the
peptide-based radio-agents usually display favorable pharmacokinetics such as rapid
targeting, fast plasma clearance and deep tumor penetration. But due to their intrinsic
instability in protease-rich bioenvironments, the development of peptide-based agents
often involved chemical modifications to enhance metabolic stability 58. The first FDAapproved

diagnostic

radio-peptide,

111

In-DTPA-octreotide

(OctreoScan),

targets

somatostatin receptors in patients with neuroendocrine tumors and showed great
targeting efficacy 31. Additionally, gastrin release peptide receptors (i.e. BB2r) has also
shown great potential for targeting tumors including prostate, breast and small-cell lung
cancers

31, 59

. Although there are a tremendous number of preclinical studies of BB2r-

targeted agonist, there has been limited clinical investigation/development due to the
lack of satisfactory outcomes, and undesired gastrointestinal side effects (e.g. abdominal
cramps) of the agonistic analogs

. Only recently, the successful development of

16, 60-66

BB2r-antagonist (e.g. RM2 and RM26), which have shown better clinical translation
potential, has revitalized the field and increased interest in BB2r-targeted agents for
detection and staging.

7

Many promising BB2r-targeting radiotracers, listed in Table 1.1, are currently
undergoing clinical evaluation. For instance, an ongoing Phase II clinical study uses
68

Ga-NeoBOMB1 as a diagnostic agent targeting BB2r-overexpressing cancers and more

than three Phase II clinical studies have been done by different groups evaluating the
feasibility of

68

Ga-RM2 as a diagnostic agent for patients with prostate cancer. These

BB2r-targeted antagonists have shown higher tumor specific uptake, good sensitivity to
detect both primary and metastatic prostate cancer and better T/NT contrast in patients
compared to BB2r-agonist. Representative images of ongoing clinical studies using these
new BB2r antagonists are shown in Figure 1.1.
Unfortunately, there are only few radiopharmaceuticals based on receptor-targeted
peptides (e.g.

68

Ga-DOTATATE) currently FDA approved for clinical usage, and a

clinically useful BB2r-targeted agent is not among them. One of the major challenges
preventing the clinical translation of peptide-based radiotracers is the short tumor
residence time of these low-molecular weight agents, due to their rapid degradation and
clearance by endogenous proteases and peptidases
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. Tumor retention is particularly

crucial for radiotherapeutic applications since accumulation/retention is closely tied to
deliverable therapeutic dose.

8

Table 1.1 Radiolabeled BB2r-targeted analogues that have been actively tested in clinical studies.
BB2r
Analogue

Sequence

IC50

Refs

(nM)
68

Ga-DOTA

68

Ga-DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-

RM2
68

Ga/177Lu-

Gly-His-Sta-Leu-NH2
68

Ga/177Lu-DOTA-p-aminomethylaniline-diglycolic acid-D-Phe-Gln-Trp-AlaVal-Gly-His-NH-CH[CH2-CH(CH3)2]2

NeoBOMB1
Antagonist

68

68

Ga-SB3

68

Ga-DOTA-p-aminomethylaniline-diglycolic acid-D-Phe-Gln-Trp-Ala-ValGly-His-NHEt

Ga–NOTA–

68

PEG3–RM26
64

Cu-CB-

TE2A-AR06
Agonist

68

Ga-BBN

64

Ga-NOTA-PEG3-D-Phe–Gln–Trp–Ala–Val–Gly–His–Sta–Leu–NH2

Cu-4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo(6.6.2)hexadecane)PEG4-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-LeuNH2]
68

Ga-NOTA-Aca-BBN(7–14)

7.7 ± 3.3

67-69

2.5 ± 0.2

70

1.5 ± 0.3

71

2.1 ± 0.5

72

5.5 ± 1.3

66

1.8 ± 0.7

72-73

9

A

B

C

D

E

F

Figure 1.1 PET/CT scan images of A) 68Ga-DOTA-RM2 67, B) 68Ga-NeoBOMB1 70, C) 68GaSB3 71, D) 68Ga-NOTA-PEG3-RM26, compared to BB2r-targted agonist E) 68Ga-BBN 72 and
F) 64Cu-CB-TE2A-AR06 66 in prostate cancer patients. D) and E) are images of the same
patient.
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1.3 Structure of BB2r-Targeted Agonist and Antagonist Radiopharmaceuticals
The bombesin (BBN) peptide shares a C-terminal binding region sequence homology
with gastrin releasing peptide (the endogenous ligand of BB2r), as illustrated in Figure
1.2. The developed BB2r-targeted agents are based on a variety of BBN-like peptides (i.e.
intact, truncated and modified) 23, 74-75. The typical structure of BB2r-targeted agonist and
antagonist are also shown in Figure 1.2, which generally includes a radioisotope, a
chelator, a linker and a peptide-based targeting vector. So far, the development of BB2rtargeted agents have largely utilized the BBN(7-14)NH2 sequence (Gln-Trp-Ala-Val-GlyHis-Leu-Met-NH2), which has nanomolar affinity to BB2r

. A series of reports have

76-79

identified alterations to the C-terminal fragment that result in antagonistic behavior
while still achieving high BB2r-binding affinity 76, 80-82. The BB2r antagonists often include
the unnatural amino acid D-Phe6 inserted before Gln7, a modification between His12Leu13, the elimination of Met14 and the substitution of Leu13-NH2 (e.g. Leu-OCH3 or Leu(CH2)3-CH3). To date, the potent BB2r-targeted antagonists (e.g. RM2 and RM26) having
the structures with the presence of D-Phe6, insertion of Statin between His12-Leu13, desMet14 and ended with NH2 showed substantially promising results, which are currently
under clinical evaluations 67-69, 72. For example, small cohort clinical studies have showed
that

68

Ga-RM2 can detect 72% (13/18 patients) of the breast tumor tissues

83

and 63%

(10/16 patients) of recurrent prostate cancers 69. Despite that BB2r-targeted antagonists
have demonstrated lower BB2r binding affinities relative to agonists and the
substantially lower rates of receptor-mediated endocytosis, which was originally
thought to be crucial for tumor uptake/residualization, studies have clearly

11

demonstrated the superiority of BB2r-targeted antagonists compared to agonists

.

84-88

The superiority of the BB2r-targeted antagonist may possibly be due to a higher number
of receptor binding sites compared to the agonist

. Other factors such as lower

89

disassociation constant (koff) and an increase in metabolic stability of antagonist relative
to agonists, also may possibly contribute to the unexpected higher retention in tumors 9092

.
Moreover, the chelators and linkers have also been demonstrated to impacts BB2r-

targeting and in vivo biodistribution. The linker/spacer, as a connecter between the
chelated radionuclide and the targeting peptide vector, is introduced to avoid the steric
inhibition of the radiometal-chelator moiety to the binding affinity of the targeting
vector. Moreover, it also greatly contributes to the alteration of the hydrophilicity and
the optimization the pharmacokinetic profiles of radio-peptide analogs. Amino acids,
carbohydrate groups, aliphatic hydrocarbons, aromatic derivatives, and polyethylene
glycol (PEG) are the most commonly used linkers for BB2r-targeted agents
conjugate containing no spacer,

111

93-95

. A

In-DOTA-BBN7-14NH2, demonstrated a 100-fold lower

BB2r-binding affinity compared to an analog having 8-carbon aliphatic spacer

.

96

Analogs with five to eight carbon atoms as a spacer showed similar BB2r-binding
affinity. Additionally, BB2r-targeted analogs having more hydrophilic linkers have also
exhibited substantial lower liver uptake 97-98. Additionally, it has been demonstrated that
the modification of charges on the peptide-pharmacophore can substantially impact the
binding affinity of the analogs. However, the structure-and-function relationship of
charges is not completely clear. Several studies has demonstrated that the negatively

12

charged linker showed more favorable pharmacokinetics and higher T/NT ratio than
positively charged linkers 99-101. For example, a significant increase of tumor uptake was
observed by introducing single negative charged linker ( 3hGlu) to

99m

Tc(CO)3-BBN

analogs compared to neutral ( 3hSer) and positively charged linker ( 3hLys)
counterparts

. On the contrary, another attempt to utilize positively charged linker

100

over neutral ones (glycine-4-aminobenzoyl) demonstrated that the positively charged
linkers resulted in a 1.5-fold increase in BB2r-binding affinity. However, this increased
didn’t significantly alter the tumor uptake, nor did it improve the T/NT ratios in vivo 87.
In other cases, opposite phenomenon has been observed. The analogs that have more
positive charges tend to have higher BB2r-binding affinity and more favorable in vivo
pharmacokinetics

. A comparison study of

102-103

68

Ga-BBN antagonists with various

chelators (NOTA, DOTA, NODAGA and DOTAGA) incorporated was performed

.

102

Examination of the local charge of Ga3+ complex with di-anionic NOTA, tri-anionic
NODAGA and DOTA, and tetra-anionic DOTAGA found out to be +1, 0, 0 and 1,
respectively. Consequently, the positively charged analogs demonstrated the highest
BB2r-binding affinity, followed by neutral analogs and the negatively charged exhibiting
the lowest affinity. The BB2r-affinity positively corelated with in vivo tumor uptake and
T/NT ratios.
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Gastrin-releasing Peptide

Lys-Ala-Leu-Val-Thr-Gly-Gly-Gly-Val-Ser-Val-Pro-Ala-His
Met-Tyr-Pro-Arg-Gly-Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2
1

2

4

3

6

5

7

9

8

10 11 12 13 14

Bombesin Peptide Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2
BB2r receptor binding region
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Figure 1.2 Classic structure of BB2r-targeted peptide-based radiopharmaceuticals.
The critical positions of the BB2r-targeted antagonists inducing antagonistic character
are indicated by color.
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1.4 Cystine Cathepsins and Its Inhibitors
Cystine cathepsins (CCs), a family of proteases that are largely contained in the
endolysosomal environment, are predominantly known for the contribution to
intracellular proteolysis and protein turnover. Meanwhile, these proteases are also
involved in diverse normal physiological processes, including cell proliferation,
migration and death

. Some of the CCs are constitutively expressed, for example,

104

Cathepsin B and L, which has been estimated to have very high concentrations (~1mM)
in endolysosomal compartments with each comprise up to 20% of the overall organelle
content

. In a variety of cancers, however, cancerous cells have exhibited aberrant

105

expression of CCs extracellularly, which has been identified to directly assist tumor
progression, migration, invasion and in some cases to facilitate tumor angiogenesis 104, 106.
It has been demonstrated that secreted Cathepsin B can degrade extracellular-matrix
materials, such as type IV collagen and fibronectin, in both neutral and acidic
environment

. Additionally, the upregulated expression of CCs has been positively

107

correlated with poor prognosis 108 and metastasis 109 of cancer patients.
Thus, over the years, CCs have been investigated as a potential target in preclinical
and clinical cancer research. Several strategies have been explored to block CCs activity,
such as antibodies and small-molecule inhibitors, to name a few. Based on the binding
mechanism

these small molecule CC inhibitors are generally classified as both

reversible and irreversible inhibitors, which the latter holds the most interest for our
laboratory. Representative structures of these inhibitors are shown in Figure 1.3. The

15

reversible inhibitor, with functionalities such as aldehydes, nitriles and cyclopropenones,
can reversibly form non-covalent interactions with the enzyme. On the contrary, the
irreversibly inhibitor, e.g. epoxysuccinates, vinyl sulfones and acyloxymethyl ketones
(AOMK), can bind to the CCs through covalent bonds, which have presented promising
clinical performance

110-114

. Our preliminary work using an AOMK inhibitor as a

trapping agent for neurotensin receptor-1 (NTR1) targeted analogs (Figure 1.4) has
successfully proven this trapping principle. The results obtained from this work clearly
demonstrated that the AOMK incorporated radio-peptides have a 2-fold enhancement in
tumor retention at 24h post-injection compared to the matching inactive (non-trapping)
control, without comprising the initial tumor uptake

. Additionally, among other

115

irreversible covalent inhibitors, another well-known and broad-targeting CC inhibitor is
E-64, which can form thiol-ether bonds to CCs
inhibitors as tumor imaging probe

119-121

116-118

. Although studies utilizing CCs

have been previously reported, in this

dissertation for the very first time, we are employing it as trapping agent to increase the
tumor residence time of our radioconjugates.
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Figure 1.3 Representative structures of irreversible and reversible cysteine cathepsin
protease inhibitors.
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Figure 1.4 Representative structure of a cysteine cathepsins inhibitor AOMK
incorporated NTR-1 targeted analogues. The AOMK derivative moiety is indicated in
red color.
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1.5 Tumor Hypoxia and Hypoxia Selective Trapping Agents (HSTA)
Tumor hypoxia results from the distorted vascular architecture found in tumors,
which consequently causes irregular blood flow, reduces the efficacy of oxygen and
other nutrients delivery to tissues. The partial pressure of oxygen (pO2) at sea level is
about 80-100 mmHg in human arterial blood and the median pO2 ranges from 24-66
mmHg in normal tissues (e.g. skeletal muscle)

122

. The critical pO2 value, which is the

point at which tissues are considered hypoxic, is estimated to be 8-10 mmHg in tumors
. The oxygen measured in prostate carcinoma is significant lower (mean pO2 = 6

123

mmHg) when compared to normal prostate tissue (mean pO2 = 26 mm Hg)

124-125

. The

median of 63% (n=247) of prostate tumors from patients presented the pO2 value to be
less than 10 mmHg 125.
Tumor hypoxia is a therapeutic concern due to it being strongly association with
tumor aggressiveness, resistance to chemotherapy and radiotherapy, and a good
indicator of poor prognosis of the patients

. Given this, tumor hypoxia is actively

126-127

considered as a diagnostic and/or therapeutic target. Several approaches have been
utilized to reduce/target tumor hypoxia including the administration of erythropoietin
(EPO) to improve blood flow, RAS inhibitor to reduce local oxygen consumption in
tumors, hypoxia inducible factor (HIF) pathway inhibitors to block hypoxia-induced
downstream oncogenic pathways and the utilization of tumor-selective hypoxiaactivated prodrugs

128

. Multiple classes of hypoxia-selective bioreductive drugs (e.g.

nitroimidazole, aromatic N-oxides and quinones) have been synthesized and explored

19

preclinically and clinically and some examples are presented in Figure 1.5

.

129-134

Generally, these prodrugs can be selectively reduced under a hypoxic environment
thereby generating reactive radicals and electrophiles. For example, the aromatic Noxide tirapazamine (TPZ) can produce a DNA-reactive free radical; aliphatic N-oxides
banozantrone (AQ4N) can transform into an aliphatic N-oxide DNA intercalator and
nitrogen mustard prodrug PR-104 and TH-302 can generate activated nitrogen mustard
as a cytotoxin

. To date, one of the most promising hypoxia selective prodrugs is TH-

135

302, which employs 2-nitroimidazole as the hypoxia-selective group and is the bromo
analogue of the FDA approved DNA-alkylating agent, Ifosfamide

133-134, 136-137

. After

reduction (triggered) in hypoxic cells, it will form a mustard moiety fragment serving as
a DNA cross-linking agent 138. Additionally, the development of other hypoxia-triggered
agents

utilizing

2-nitroimidazole derivatives

have been actively

investigated.

Pimonidazole HCl, a 2-nitroimidazole derivatives, is a hypoxia probe approved for
intravenous use in the clinic since 1993. In radiopharmaceuticals, imaging agents
employing 2-nitroimidazole derivatives as hypoxia-targeting agents have been actively
explored

139-141

. For example,

F-fluoromisonidazole (18F-FMISO), a conjugated-2-

18

nitroimidazole derivative, is widely investigated under clinical trials to assess hypoxia
levels by PET in various cancers 142-144.
Clinical studies have shown TH-302 has enhanced hypoxia selectivity, which makes
it an ideal candidate for our studies as a hypoxia-selective trapping agent (HSTA)
prodrug for conjugation with cellular nucleophiles upon hypoxia activation inside of
cells

145

. In detail, 2-nitroimidazole derivatives can be selectively reduced under hypoxic

20

conditions to form potent electrophiles. Once inside a hypoxic cell, these agent can be
reduced and irreversibly bind to nucleophilic macromolecules, which leads to the agent
being trapped and retained

. Nitrogen mustard derivatives of 2-nitroimidazole have

146

substantially longer lifetimes in biological solutions after activation than other 2nitroimidazole derivative

. Thus, we propose to design and develop radiolabeled

147

BB2r-targted peptides conjugated with 2-nitroimidazole phosphoramide nitrogen
mustard for cancer diagnosis/therapy. The rationale behind this approach is depicted in
Figure 1.6.
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Figure 1.5 Representative structures of hypoxia-selective bioreductive prodrugs.
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Radiolabeled cycloaddition conjugates
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Figure 1.6 Proposed mechanism of 2-NIPAM incorporated BB2r-targeted analogues in
hypoxic BB2r-positive tumor cells.
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1.6 Animal Models Used in Prostate Cancer Research
In the history of anticancer drug discovery, a critical component of preclinical stage
research is the assessment of drug efficacy in clinically relevant tumor models. As the
most widely utilized animal models, mouse models have been developed and evaluated
in human cancer research, including prostate cancer, for many years
models

provide

valuable

information

concerning

pharmacodynamics and the mechanisms of drug action

in

vivo

148-150

. Mouse

pharmacokinetics,

. Additionally, the closer the

151

models can resemble the human tumor pathologically, the greater chance the preclinical
data collected from those models can predicate the clinical outcomes and potentially
guide clinical trials designs

. To date, there are a variety of mouse models that are

152

commonly used in preclinical cancer research, such as subcutaneous and orthotopic
xenografts, genetically engineered mice (GEM) models and patient-derived xenograft
(PDX) models. To summarize, highlighted features and comparisons for each mouse
model are listed in Table 1.2.
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Table 1.2 Comparison of animal models for the assessment of prostate cancers.
Animal model

Advantages

• Low cost

Subcutaneous

• Lower skills required
• Short establish time
• Commonly used

Limitation
• Mice are immunodeficient,
lacking realistic tumor
microenvironment information
• Hard to metastasis
• Different progress to human
cancer
• Higher cost and Higher skill

• Have some similar human tumor
Orthotopic

microenvironment
• Possible to metastasis

required
• Long establish time (weeks)
• Longer time to metastasis
• Mice still are immunodeficient

• Tumor progress in a competent
immune system with natural
Genetical
engineered mice
(GEM)

microenvironment
• The mutations identified in human
can directly induced in mice
• The early stage of tumor
development can be monitored

• Only limited number of genes
can be targeted so far
• High cost and time consuming
(months)
• Require lots of validation
before successful
• High cost

• Have high human cancer relevance
Patient cancerDerived
Xenografts (PDX)

• Have high experimental robustness
• Have preserved tumor histological
and biological information

• Need to confirm the exist of
target biomarker in each
patient samples
• Various tumor development
time
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For the past three decades, the human cancer cell line xenograft model has been the
most common used mouse model. In this model, the human cancer cells lines are
inoculated, either under the skin or directly into the organs, into immunodeficient mice
to produce the subcutaneous or orthotopic xenograft mouse model, respectively. Studies
have demonstrated that depending on the tumor cell types, the development of tumor
ranges from days to weeks. Unfortunately, both subcutaneous and orthotopic cancer cell
line generated mouse models rarely predict efficacy in human. Their rapid growth rate,
opposite to the slowly progression of human cancers, exhibit a dramatically altered
tumor microenvironment and are unable to reflect genetic changes during long-term
tumor progression in patients 153. Specifically, the subcutaneous tumors lack an adequate
representation for the primary tumor in patients due to lack of those local tumor
microenvironment, which has a significant influence with regard to a patient’s response
of chemotherapy

. Based on the above reasons, biological variables, such as the

154-155

degree of angiogenesis, found in patients are certainly better reflected in orthotopic
models relative to subcutaneous models. Also, between those two models, it has been
demonstrated that orthotopic models more commonly mimic the metastatic spread (e.g.
lymph nodes) found in the clinic156. With that said, due to the fast growth rate and low
technical barrier in subcutaneous models, the subcutaneous model is still the
predominate choice for the first-step screen and in vivo evaluation of cytotoxic agents 149,
. This model is an expedient choice for the first-time investigation of biological

157

performance parameters, such as pharmacokinetic/pharmacodynamic, toxicity and drug
resistance, for targeted drugs.
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Another mouse model considered to be more advance is the genetically engineered
mouse (GEM) model 158-161. In this model, one or more genes related to carcinogenesis are
modified to promote tumor initiation and progression. One major advantage of this
model is that the mice have a competent immune system and thus the mouse’s immune
response to tumor development can be examined. For example, mice that are geneengineered to express the simian virus 40 large tumor antigen-coding region, can
progressively form prostatic disease that histologically resembles human prostate cancer
. In this case, the prostate tumors can be detected in the mice as early as 10-weeks-of

162

age. Despite GEM models having the ability to mimic molecular and histopathological
of human tumors and to predict drug response and resistance, this model has major
disadvantages, include having reduced clonal heterogeneity of human tumors, hard to
generate tumor metastasis and the cost/time required to generate this model 152-153, 163-164.
Recently, another mouse model that has drawn considerable attention is the patientderived xenograft (PDX) models

. In this model, primary tumor tissues from

165-167

patients are implanted into immunocompromised mice, which are considered to
preserve the patient cancer biology in vivo. As consequence, it can provide valuable
information regarding tumor histological and biological assessment, screening of tumor
target and therapeutic response

. Studies has demonstrated a reliable correlation

161, 168-170

between the chemo-drug response in the PDX model and what is found for clinical
outcomes in terms of tumor drug resistance (97%) and sensitivity (90%). As with all
mouse models, PDX model also have their limitations. The successful engraftment rate
varies depending on types/quality of human tumor samples and mouse strains.
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Moreover, the initial presented human tumor stroma can be gradually replaced with
mouse ones, causing the loss of the human-specific microenvironment. Most
importantly, the generation of PDX models use immunodeficient mice, which limits the
exploration of immune cell function in the tumor model.
For the development of new radiopharmaceuticals agents, xenograft mouse models
(subcutaneous and orthotopic) using human cancer cell line are still the first choice,
especially compared to PDX and GEM models, due to the relative ease of generation and
availability. Furthermore, the fast growth rate and the standardized easy manipulated
culture condition of immortalized cancer cell lines, compared to tumor cells from
patients, make it more convenient to validation the in vitro pharmakinetic properties of
the agents. Between these two models, the subcutaneous mouse model typically is more
commonly utilized to evaluate the first-time pharmacokinetic profiles of agents due to
its lower technical barriers. In reality, since there are no perfect animal models that 100%
mimic human cancers, the choice of mouse models is generally dependent on the
scientific purpose of the experiment, the technical difficulties, the time required to
generate the model and the cost. The summary of mouse models commonly used to
evaluate radiopharmaceuticals in prostate cancer research are shown in Table 1.3.
Lastly, the tumor blood vessels are generally abnormal in functionality with such
properties as the lacking smooth-muscle layer, malfunctioning vascular architecture,
inefficient lymphatic drainage and high interstitial fluid pressure (IFP), etc. Those factors
cause variance in the distribution of blood throughout the tumor leading to a disparity
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in tumor perfusion, eventually impacting the delivery of nutrients (e.g. oxygen) and
drugs. Specifically, the differences in the tumor microenvironment (TEM) between
subcutaneous and orthotopic xenograft models, such as blood vasculature density,
perfusion efficiency, oxygenation and interstitial fluid pressure (IFP) result in having a
significant impact on the delivery of intravenously distributed radiopharmaceuticals
agents and need to be taken into consideration when choosing a suitable model for
pharmaceutical evaluation. Studies have demonstrated that angiogenesis was generally
more extensive and overall perfusion was higher in the orthotopic relative to the
subcutaneous mouse model

171-174

. Combining with the fact that the orthotopic tumors

generally show lower IFP and have more spatially distributed functional vasculature
than subcutaneous tumors, it is anticipated that the overall hypoxia burden is lower, and
the tumor uptake of agents is higher in orthotopic than subcutaneous tumors 175-178.
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Table 1.3 Animal models for the investigation of radiopharmaceuticals in prostate
cancer.
Animal

Cancer cell lines

Type of tumor cells
inoculations

Refs

Severe combined
immunodeficient

LNCa-P

Subcutaneous

179

PC-3

Subcutaneous

179-182

PC-3

Subcutaneous

92, 183-184

LNCa-P

Subcutaneous

185-186

PC-3

Orthotopic

187

CWR22rv

Subcutaneous

188-189

LNCa-P

Subcutaneous

190

mice (SCID)
SCID
Athymic nu/nu
mice
Athymic nu/nu
mice
Athymic nu/nu
mice
Athymic nu/nu
mice
nu/nu Balb C
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1.7 Conclusion
For the past five years, the field of peptide-based radiopharmaceuticals targeting the
BB2r has thrived, resulting in several promising agents that have been actively evaluated
in clinical studies so far. In order to enhance the tumor retention of low molecule-weigh
radio-peptides,

new

concepts

(e.g.

utilizing

enzyme

inhibitors

and

homodimers/heterodimers) have been brought up and have shown to exhibit the
potential to improve diagnosis and therapy. To better understand how the variance of
biology in different mouse models impact BB2r-targeted agent delivery, we intend to
first perform a direct comparison of perfusion and vascular density between
subcutaneous and orthotopic tumors. As discussed in Chapter 2, the study will provide
insight regarding the cause-effect relationship between these biological parameters and
its impacts on drug delivery. By examining this, we hope to give researchers an
informed choice when deciding the best in vivo model for their studies in prostate
cancer. Moreover, the BB2r-targeted agents, like any other small molecule weight
radiopharmaceuticals, demonstrates rapid targeting and uptake in receptor-positive
tumors, yet relatively swift clearance from tumors due to intrinsically high diffusion and
efflux rates leading to lower retention at the tumor site. Consequently, the diagnostic
and therapeutic efficacy of the agent is reduced. Thus, in this dissertation, we propose to
incorporate two different trapping agents in our tumor-targeted peptide backbone to
address this issue. The comprehensive in vitro and in vivo evaluation of CC inhibitor
incorporated BB2r-targeted agents was examined and discussed in Chapter 3. Moreover,
the development and examination of hypoxia-selective 2-NIPAM for BB2r conjugation
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was documented in Chapter 4. After receptor-mediated endocytosis in tumors, the
modified agents can irreversibly bind to intracellular macromolecules and substantially
elongate retention to further improve T/NT ratios. If successful, our strategies can
potentially increase the clinical translational opportunities for BB2r-targeted agents and
these outlined

approaches

may

radiopharmaceuticals in general.

even

be

applied

to

other

peptide-targeted
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Chapter 2. Comparative Study of Subcutaneous and Orthotopic Mouse Model
of Prostate Cancer: Vascular Perfusion Efficiency, Vasculature Density,
Hypoxic burden and BB2r-Targeting Evaluation.
2.1 INTRODUCTION
The gastrin-releasing peptide receptor (BB2r) is a G-protein coupled receptor that
has been of significant interest to the field of cancer drug development due to its
overexpression in a variety of cancers, including prostate cancer

. Accordingly,

22

numerous theranostic BB2r-targeted agents have been developed over the years with
several agents going on to clinical trials

. Generally, these agents have been

60, 67, 72, 85, 191

based on synthetic derivatives of the C-terminal portions of the Bombesin (BBN) peptide,
which retain nanomolar affinities for the BB2r. To evaluate newly developed BB2rtargeted agents, researchers have numerous tumor models (e.g., subcutaneous,
orthotopic and genetically engineered mouse models) to choose

192

. However, in many

cases, how well these models mirror the pathology and clinical chemotherapeutic
response of human cancers is roughly inversely related to the technical difficulties in
generating the model. As such, researchers typically rely on relatively simple
subcutaneous tumor xenografts to first study the biological performance of new agents.
These models are invaluable for examining the pharmacokinetic profiles of agents,
verifying in vivo BB2r-targeting and identifying lead compounds. Yet, it is well-known
that the tumor biology of subcutaneous xenografts are not as reflective as other models
(e.g., orthotopic) of human tumors. Arguably the most common xenograft model to

33

evaluate BB2r-targeted agents is the murine xenograft model utilizing the human
prostate cancer PC-3 cell line, which has been shown to highly overexpress the BB2r 32, 87,
193-194

.

The tumor microenvironment (TME) is a wide-ranging term utilized to describe the
complex environment in which tumor exist. In regard to drug delivery, perhaps the
most important TME variable is the density and functionality of the tumor vasculature.
Tumor perfusion, essentially how well the tumor vasculature distributes blood
throughout the tumor, directly influences the delivery of drugs and biologically
important nutrients (e.g., oxygen). As a consequence, many solid tumor, including
prostate cancer, contain significant regions of hypoxia due to their distorted and
insufficiently developed vasculature

. Hypoxia is also recognized as a crucial stimuli

195

for tumor angiogenesis, metastasis and, in many cases, aggressiveness 196.
The purpose of this study is to elucidate the impact of tumor perfusion and vascular
density on BB2r-targeted drug delivery and tumor hypoxia. Specifically, we undertake
this investigation in subcutaneous and orthotopic PC-3 xenograft mouse models over a
spectrum of tumor volumes to explore similarities and differences between the two
models. By this study, we hope to give the research community utilizing these models a
better understanding of the cause-effect relationship between these variables and their
potential impact on drug delivery. To this end, sodium pertechnetate (Na99mTcO4), a
freely diffusible blood perfusion agent, was employed to evaluate the PC-3 tumor
perfusion efficiency

. The functional vasculature density of the tumors was measured

197
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using Hoechst staining

198

. A novel BB2r-targeted analog, DOTA-(D)S-(D)S-(D)S-(D)S-

(D)S-PEG3–BBN(7-14)NH2 (DOTA-SP714), was utilized to examine in vivo BB2r uptake
and tumor distribution, as showed in Figure 2.1A. Lastly, the hypoxic burden of the PC3 tumors was measured by pimonidazole staining 199.
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Figure 2.1 A) Structure of 177Lu-DOTA-SP714. B) Experimental design and timeline.
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2.2 MATERIALS AND METHODS
2.2.1 Reagents and Instruments
All solvents utilized for synthesis were ACS grade, purchased from Fisher Scientific
and used without further purification, unless otherwise stated. Acetonitrile utilized for
HPLC analysis and purification was HPLC grade and purchased from Fisher Scientific.
Formic acid, N,N-diisopropylethylamine (DIEA), N,N-dimethylformamide (DMF),
dichloromethane (DCM), N,N'-dicyclohexylcarbodiimide (DCC), N-methylpyrrolidone
(NMP),

thioanisol,

sodium

hydroxide,

L-ascorbic

acid,

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES), bovine serum albumin (BSA), Hoechst 33342
and O.C.T. Compound were purchased from Fisher Scientific (U.S.). Water was
deionized by Millipore® Milli Q Biocell Ultrapure Water System before use. D-Luciferin,
O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU), Fmocprotected natural amino acids and the appropriate Rink Amide resins were purchased
from Nova Biochem (U.S.). Ham's F-12K (Kaighn's) medium, phosphate buffered saline
(PBS), and mammalian protein extraction reagent (M-PER) were purchased from
Thermo Scientific (U.S.). Naturally abundant lutetium chloride (natLuCl3), triisopropyl
silane, trimethylsilyl chloride, hydrochloric acid (HCl) and 3,6-dioxa-1,8-octanedithiol
were purchased from Sigma-Aldrich (U.S.). Radioactive lutetium chloride (177LuCl3) was
purchased from the National Isotope Development Center operated by the United States
Department of Energy, Office of Science. Sodium Pertechnetate (Na99mTcO4) was
purchased from Cardinal HealthTM. The human prostate cancer PC-3 cell line was
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obtained from American Type Culture Collection (U.S.) and cultured under vendor
recommended conditions. TrypLETM Express was purchased from Invitrogen (U.S.).
TransduxTM was purchased from System Biosciences. Pre-made lentiviral expression
particles was purchased from AMS Biotechnology Limited. Pimonidazole hydrochloride
and FITC Mab were purchased from HypoxyprobeTM.
Four weeks-old NOD SCID (NOD.CB17-Prkdcscid/NCrCrl) mice were obtained
from Charles River Laboratories (Wilmington, MA). Food and water were given ad
libitum. Five mice per group were kept in the same cage with an air filter cover and a
light- (12 h light/dark cycle) and temperature-controlled (22 ± 1°C) environment prior to
experiments. On the day of the experiment, each animal was isolated under the same
housing conditions. The animals were treated in accordance to the Principles of Animal
Care outlined by the National Institutes of Health and approved by the Institutional
Animal Care and Use Committee of the University of Nebraska Medical Center.
Peptide synthesis was performed using an automated solid-phase peptide
synthesizer employing traditional Fmoc chemistry and using a Rink Amide resin. Briefly,
the resin (100 µmol of the resin substituted peptide anchors) was deprotected using
piperidine, resulting in the formation of a primary amine from which the C-terminus of
the growing peptide was anchored. microwave peptide synthesizer from CEM (U.S.). A
Waters e2695 system equipped with a Waters 2489 absorption detector and a Waters Qtof Micro electrospray ionization mass spectrometer was used to perform high
performance liquid chromatography/mass spectrometry analyses. A Phenomenex
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Jupiter C12 Proteo 250×10 mm semiprep column was used for the purification of bulk
amounts of the BB2r-targeted peptide. The peptide was concentrated on a Centrivap
(U.S.) Centrifugal Concentrator. Evaluation and purification of the radiolabeled
conjugate was performed on a Waters 1515 binary pump equipped with a Waters 2489
absorption detector and a Bioscan (U.S.) Flow Count radiometric detector system, using
a Phenomenex Jupiter C12 Proteo 250×4.6 mm column. Solid phase extraction was
performed using Empore (U.S.) C18 10 mm high performance extraction disks. Gas
anesthesia was administered at a vaporizer setting of 5% isoflurane (Halocarbon Corp,
River Edge, NJ) with 0.5 L/min oxygen using an E-ZAnesthesia apparatus (EUTHANEX
Corp, Palmer, PA). Cell sorting was accomplished by fluorescence activated cell sorting
of living cells (FACS) using FACSAria. Biodistribution radiation measurements were
made with a NaI (Tl) well detector constructed by AlphaSpectra, Inc. (U.S.).
Bioluminescence images were acquired by IVIS® Spectrum. Animal tissue slides were
generated by microtome cryostat HM 500 OM from MICROM. Confocal microscopy
images were taken on a Leica LSM 510 META Microscope equipped with an argon laser
and processed by ZEN blue software. The autoradiography studies were accomplished
by GE Lifesciences Typhoon FLA 9500 laser scanner.

2.2.2 Solid-Phase Peptide Synthesis (SPPS)
Peptide synthesis was performed using an automated solid-phase peptide
synthesizer employing traditional Fmoc chemistry and using a Rink Amide resin. Briefly,
the resin (100 µmol of the resin substituted peptide anchors) was deprotected using
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piperidine, resulting in the formation of a primary amine from which the C-terminus of
the growing peptide was anchored. The Fmoc protected amino acids (300 µmol) with
appropriate orthogonal protection were activated with HBTU and sequentially added to
the resin. The resulting peptide was orthogonally deprotected and cleaved from the
resin using a cocktail consisting of triisopropyl silane (0.1 mL), water (0.1 mL), 3,6-dioxa1,8-octanedithiol (0.1 mL), trifluoroacetic acid (4.625 mL) and thioanisole (0.075 mL),
respectively. The cleaved peptide was subsequently precipitated and washed using cold
(0 °C) methyl-tert-butyl ether (10 mL×3). The crude conjugate was dried by a centrivap
concentrator and weighed. ES-MS was used to determine the molecular mass of the
prepared peptides. All conjugates were peak purified to

95% purity and quantified by

RP-HPLC prior to in vitro/in vivo investigations.

2.2.3 HPLC Purification and Analysis Methodology
Sample analysis and radioconjugate purification was performed on an analytical
Proteo column with a flow rate of 1.5 mL/min. HPLC solvents consisted of H2O
containing 0.1% formic acid (solvent A) and acetonitrile containing 0.1% formic acid
(solvent B). Bulk peptide purification was performed using a semi-preparative Proteo
column with a flow rate of 5.0 mL/min. For all unlabeled and 177/natLu-labeled conjugates,
purification was achieved using an initial gradient of 80 % A : 20 % B which linearly
decreased to 70 % A : 30 % B over a 15 minute time period. At the end of the run time,
the column was flushed with the gradient 5 % A : 95 % B and re-equilibrated to the
starting gradient.
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2.2.4 Labeling with natLuCl3
For the convenient characterization of the Lu-labeled peptide, naturally abundant
natLu was used to substitute for

177

Lu in the ES-MS and in vitro binding studies. A

sample of conjugate (1 mg) was dissolved in ammonium acetate buffer (1 M, 200 µL, pH
5.5) and mixed with a solution of natLuCl3 (5.5 mg). The solution was heated for 60 min
at 50 °C. After cooling to room temperature, the
RP-HPLC.

Lu

nat

conjugates

were

95%

Lu-conjugate was peak purified by

nat

purity

before

mass

spectrometric

characterization and in vitro binding studies were performed.

2.2.5 Radiolabeling BBN-analogs with 177LuCl3
Radiolabeling was performed on BBN-analogs by mixing 100 µg samples with 37
MBq

177

LuCl3 in ammonium acetate buffer (1 M, 200 µL, pH 5.5). The solution was

heated for 60 min at 90 °C. In order to separate radiolabeled peptides from unlabeled
peptides on HPLC, 4-5 mg CoCl2 was added to the crude peptide mixture and incubated
for 5 min at 90 °C to increase the hydrophobicity of unlabeled conjugates. The resulting
radioconjugate was allowed to cool to room temperature, peak purified using RP-HPLC
( 95%) and concentrated using a C18 extraction disk. Elution of the extraction disk with
ethanol/sterile saline solution (6 : 4, 150 µL × 2). The ethanol eluent was evaporated by
purging with nitrogen gas.

2.2.6 Distribution Coefficient Studies
The partition coefficients were determined for the

177

Lu-labeled conjugate. In a

microcentrifuge tube, 0.5mL of 1-octanol was added to 0.5 mL phosphate-buffered saline
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(pH 7.4) containing the radiolabeled peptide (100,000 cpm). The solution was vigorously
stirred for 2 min at room temperature and subsequently centrifuged (100g, 5 min) to
yield two immiscible layers. Aliquots of 100 µL were taken from each layer and the
radioactivity of each was quantified by a

-counter. Statistical analysis using the

unpaired two-tailed Student’s t-test was performed in order to compare the logD values
and p values < 0.05 were considered statistically signi cant.

2.2.7 Radiochemical Stability Studies
In a vial, 25 µg samples of 177Lu-conjugate were mixed with 74 MBq of

177

LuCl3 in an

ammonium acetate buffer (0.5 M, 120 µL, pH 5.5). The mixture was heated at 90 °C for
40 min and subsequently heated for an additional 5 min in the presence of 4-5 mg CoCl2.
The resulting radioconjugates were peak purified using RP-HPLC and concentrated
using C18 extraction disks with ethanol/sterile PBS (6:4, 200 µL). The ethanol was
evaporated using nitrogen gas and the resulting solutions were diluted with either 1 mL
A: PBS, B: Ascorbic acid in 0.9% sodium chloride solution (final ascorbic acid
concentration, 40mg/ml), or C: Selenomethionine (Se-Met) in buffer B (final Se-Met
concentration, 0.2mg/ml). The purity of the radioconjugate solution was determined by
HPLC at 24, 48 and 72 h.

2.2.8 In Vitro Competitive Cell-Binding Studies
The half maximum inhibitory concentration (IC50) of the natLu conjugate was
determined by competitive displacement cell-binding assays using PC-3 cells. The
natLu-conjugate was used as substitutes for the corresponding

177

Lu-radioconjugate.
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Briefly, PC-3 cells (~3×104) were suspended in RPMI 1640 media (pH 7.4, 4.8 mg/mL
HEPES, and 2 mg/mL BSA) and incubated at 4°C for 40 min in the presence of
radiolabeled [125I-Tyr4]-Bombesin and various concentrations of the

Lu-conjugate. At

nat

the end of the incubation period, the cells were centrifuged, aspirated and washed with
media a total of three times. The cell associated activity was measured using a -counter
and the IC50 values determined by nonlinear regression using the one-binding site model
of Graphpad PRISM 5 (U.S.).

2.2.9 Establishment of Stably Transfected PC-3-Luc Cells
To generate the PC-3-Luc cells, we utilized pre-made lentivirus particles encoding
luciferase and GFP (EF1a-Luciferase (firefly)-2A-GFP (Puro), AMSBIO) for transfection.
Briefly, normal PC-3 cells were seeded in a 24-well plate using 0.5 mL of medium
containing 0.5 × 105 cells/mL and incubated overnight. The medium was removed and
replaced with 0.5 mL of fresh medium pre-mixed with 2.5 µL TransduxTM. To each well
was added 2 µL of the lentivirus particle solution and swirled to mix. The plate was
returned to the incubator and cultured for 3 days. Once the cells grew to confluence,
they were harvested and transferred to larger plates (from 6-well plates to 60 mm
dishes). 1.5 mL of suspended cells in PBS at a concentration of 5 × 106/mL was sorted by
the FACS method to give the GFP positive (PC-3-Luc) cells that were returned to culture
for in vitro and in vivo studies.

2.2.10 Cell Culture
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The normal PC-3 cells and PC-3-Luc were cultured in our laboratory, as per ATCC
protocols, in Ham’s F-12K medium containing 10% FBS, 2.5 mM L-glutamine, 15 mM
HEPES and 0.5 mM sodium pyruvate. Cells were incubated at 37 °C at 5% CO2.

2.2.11 Animal Studies
All animal experiments were performed in accordance with the NIH animal use
guideline and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Nebraska Medical Center (Omaha, NE).

2.2.11.1 Development of PC-3 Xenograft SCID Mice
All animal experiments were performed in accordance with the NIH animal use
guideline and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the UNMC. NOD.CB17-PrkdcsicdIJ (NOD SCID) mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). The mice were housed in groups of five in
UNMC animal facility for the entire tumor generation period. All mice were under
constant temperature (set up at 21 oC) and humidity on a 12-hour light/dark cycle, which
lights on at 7:00 am. Standard food and filtered water were available ad libitum.
For the subcutaneous model

, 5-week old female SCID mice were inoculated in the

200

flanks with 5 × 106 PC-3 cells in Matrigel®. The tumor size was monitored by caliper. For
generation of the orthotopic model (31), the PC-3-Luc cells was selected by 0.5 µg/mL
puromycin twice before inoculation. The male 6-weeks SCID mice were anesthetized,
the muscles of abdomen area were cut after retracting the skin, and the prostate gland
exposed. 50 µL of PC-3-Luc cell suspension at 0.5 × 106/mL in Matrigel® was injected
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into a dorsal prostatic lobe. The wound was closed in two layers and the skin was
clipped. Animals were given analgesic drugs for 3 days and the tumors were monitored
by an IVIS optical imaging system.

2.2.11.2 In Vivo Biodistribution Studies
The body weight, tumor volume and tumor luminescence of the mice were recorded
every three days. The mice were divided into three groups based on tumor volume (<300,
300-700 and >700 mm3). Each mouse (average weight: 20 g for female mice and 25g for
male mice) was treated with pimonidazole solution (80mg/kg in PBS) via intraperitoneal
injection. After 1h, the mice received an intravenously injection of 10 µCi (370 kBq) of
the radio-RP-HPLC peak purified

177

Lu-labeled conjugate (177Lu-C1) in 100 µL of PBS.

After an additional 1h, the mice were injected intravenously with a PBS solution
containing 10 µCi (370 kBq) of Na99mTcO4 and 15mg/kg Hoechst 33342. The animals
were sacrificed 5 minutes later, and their tissues collected. The excised tissues were
weighed, the radioactivity in each tissue was measured, and the %ID/g was calculated
for each tissue. Due to the overlap of the energy spectra of Tc-99m and Lu-177, we first
measured the total radioactivity in each organ at day 1 (A) and measured again at day 4
(B). Since the Tc-99m had completely decayed by day 4, the radioactivity observed at
timepoint B was Lu-177. A decay correction was performed to calculate the amount of
radioactivity associated with the Lu-177 component at day 1 (C). The difference of value
between A and C was the radioactivity of Tc-99m at day 1.

2.2.12 Bioluminescent Imaging
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Bioluminescent imaging was acquired according to standard protocol from the
UNMC Small Animal Imaging Core Facility. Imaging and quantification of the signals
were performed by Living Image® 4.5 software (PerkinElmer® Health Sciences). For in
vitro imaging, PC-3-Luc cells were diluted and plated in a black, clear bottom 96-well
plate. 50 µL D-luciferin (150 µg/mL) in media was added to each well 5 min prior to
imaging (Figure 2.2). For in vivo imaging, mice were given 100 µL D-luciferin (150
mg/kg) 15-20 min prior to imaging and anesthetized by isoflurane. Mice were
transferred to the imaging box and anesthesia nose cones attached. Images were
acquired with auto exposure. Regions of interest from each image were selected and
quanti ed.
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Figure 2.2 (A) Representative images of in vitro bioluminescence of human prostate
cancer cell line with or without luciferase expression gene (PC-3-Luc and PC-3). (B)
2

Correlation between cell number and mean radiance (photons/sec) per well (R =0.9992).
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2.2.13 Microscopy and Autoradiography
The tumors from mice were washed by deionized water, dried and embedded by
O.C.T compound on dry ice. The frozen tumor sections were cut at 10 µm and stored at 80 °C for the following studies. The adjacent tumor slides were scanned for Hoechst
33342 and pimonidazole by a confocal microscopy and exposed to storage phosphor
screens (BAS-IP SR 2025 E, GE Healthcare) for 3 days. The phosphor screens were
subsequently scanned by Typhoon FLA 9500 (GE Healthcare) with 25 µm pixel size. The
range of interest (ROI) was drawn to exclude the edge of each tumor slide. The
fluorescent arithmetic mean intensity of images were measured by Zeiss ZEN (blue
edition) software.

2.2.14 Statistical Analysis
Data was presented as Mean ± SD/SEM as noted. IC50 values were determined by
nonlinear regression using the one-binding-site model of GraphPad PRISM 5. Pearson
correlation coefficients (r) were calculated to assess the relationship between tumor
volume and tumor uptake of the radiotracer (177Lu-DOTA-SP714 and Na99mTcO4). In
vitro stability studies of the radioconjugates in various buffers were analyzed by the
two-tailed Student’s t-test. For comparison between the two models, analysis of the
biodistribution studies, hypoxic burden and blood vessel density of tumor was carried
out by a two-tailed Student’s t-test. Comparisons of the means of the BB2r-uptake, blood
perfusion, hypoxic burden and blood vessel density of the tumors among the three
tumor volume groups for each animal model were analyzed by one-way ANOVA. If the
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overall p-value was statistically significant, pairwise comparisons were adjusted using
Tukey’s method. A p-value < 0.05 was considered statistically significant.

2.3 RESULTS
2.3.1 Synthesis and Radiolabeling of nat/177Lu-DOTA-SP714
DOTA-SP714 was synthesized with a yield of 26.6% as determined by HPLC-MS.
The peptides were labeled with nat/177LuCl3 and subsequently purified by radio-RP-HPLC.
Analysis of the chromatograms revealed the purity of the radiolabeled peptide was
95% with a radiolabeling yield of 90.5% (Table 2.1).

2.3.2 Distribution Coefficient and Competitive Binding Studies
The distribution coefficient (mean ± SD) at pH = 7.4 (LogD7.4) for 177Lu-DOTA-SP714
was determined to be -2.2 ± 0.1 by radiometric analysis. The hydrophilic nature of the
radioconjugate suggests that cellular internalization should occur only through BB2rmediated endocytosis. Subsequently, competitive binding studies demonstrated that
both peptides demonstrated low nanomolar binding affinity, with

Lu-DOTA-SP714

nat

(1.0 ± 1.7 nM) giving a significantly higher affinity relative to the unlabeled conjugate
(9.8 ± 1.7 nM). Both the IC50 and the LogD7.4 values are provided in Table 2.1.
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Table 2.1. Characterization of conjugates.

Analogue

Retention IC50/nM†

LogD

Formula

Calcd

Found

C85H137N23O31S

2008.0

2008.6

8.67

9.8 ± 1.7

Lu-DOTAC85H134177LuN23O31S 2179.9
SP714

2179.9

8.65

1.0 ± 1.7 -2.2 ± 0.1

DOTA-SP714
nat/177

Molecular

MW (m/z, [M+H]+) RP-HPLC

† Values represent mean ± SEM (n=6)
‡ Values represent mean ± SD (n=3)

Time/min

(pH7.4)‡
-
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2.3.3 Radiochemical Stability Studies
To investigate the susceptibility of

177

Lu-DOTA-SP714 to radiolytic degradation and

examine the efficacy of stabilizers, two stabilizing buffers formulated using ascorbic acid
with/without selenomethionine were tested and compared to a control PBS buffer. The
results from these studies are depicted in Figure 2.3. In PBS alone, 39.9% of a 0.37
MBq/mL (100µCi/mL) solution of

177

Lu-DOTA-SP714 degraded over the course of 72 h.

As expected, the addition of ascorbic acid (40 mg/mL) demonstrated substantial
improvements in stability with only 17.3% radiolytic breakdown. However, the
combination of ascorbic acid (40 mg/mL) and selenomethionine (0.2 mg/mL) gave
superior results with only 5.3% breakdown observed by the 72 h timepoint.
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***
***
***

***
***
***

***
**
ns

100

PBS
Ascorbic acid
Ascorbic acid + Selenomethionine

80
60

Time (h)

0
24
48
72

0
24
48
72

40
0
24
48
72

Percentage of desired
radioconjugates (%)

120
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2.3.4 Animal Model Establishment
In this study, subcutaneous and orthotopic xenograft models were generated. For
the subcutaneous model, the diameters of tumor were determined by caliper
measurements, while tumor growth in the orthotopic model was monitored weekly after
implantation surgery using bioluminescence imaging (Figure 2.4A-B). The orthotopic
model gave a gradual increase in estimated tumor volumes over the 6-weeks, while the
subcutaneous model showed a sharp and rapid increase in tumor size starting at 4thweek (Figure 2.4C). While above measurements were used to non-invasively monitor
tumor growth, the assignment of the tumor volume in our subsequent studies are based
on caliper measurements of the excised tumors. For both measurements, tumor volumes
were calculated by using the following formula: Volume=(Length×Width2)/2.
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2.3.5 BB2r-Targeted Peptide Uptake and Perfusion in PC-3 Tumor Xenograft
Models
To examine the in vivo BB2r-targeting efficacy and tumor perfusion of the two
mouse models, we performed dual, simultaneous biodistribution studies utilizing the
177

Lu-DOTA-SP714 and Na99mTcO4. The %ID/g in each organ and the total excretion (%ID)

of the radioactivity from the mice are presented in Table 2.2. Overall, the scatter plots of
the tumor uptake of

177

Lu-DOTA-SP714 and

TcO4- against tumor volume in both

99m

animal models are depicted in Figure 2.5A-2.5D. There was a significant moderate to
strong positive correlation (Table 2.3), observed between tumor volume and BB2ruptake (%ID/g) of the

177

Lu-DOTA-SP714 (r=0.55, p=0.0049 and r=0.73, p=0.0001) as well

as tumor perfusion (99mTcO4-) (r=0.47, p=0.021 and r=0.49, p=0.017) in subcutaneous and
orthotopic mice models, respectively. Interestingly, the correlation (Figure 2.6) between
tumor perfusion (Na99mTcO4) and BB2r-uptake (177Lu-DOTA-SP714) was weak to
moderate for the subcutaneous (r=0.28, p=0.19) and orthotopic (r=0.66, p=0.0006) models,
respectively, suggesting tumor size is a better indicator of BB2r-uptake in both models.
Grouping tumor volumes categorically, <300, 300-700 and >700 mm3, revealed some
interesting trends (Figure 2.5E&F). For the orthotopic model, the mean (mean ± SD)
categorical tumor volumes were 215.62 ± 103.90, 574.14 ± 73.89 and 1052.78 ± 256.12 mm3
for <300, 300-700 and >700 mm3 groups respectively. With respect to the subcutaneous
model, the corresponding mean categorical tumor volumes for <300, 300-700 and >700
mm3 groups were 169.06 ± 74.94, 491.69 ± 114.89 and 1139.25 ± 378.68 mm3. In the
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orthotopic model, the average uptake (mean ± SD) of the

177

Lu-DOTA-SP714 was 8.07 ±

3.23, 8.55 ± 2.65 and 11.13 ± 2.88 %ID/g for the <300, 300-700 and >700 mm3 groups,
respectively. By ANOVA test, while close (p=0.061), this trend of increased BB2r-uptake
with increasing tumor volume did not meet statistical significance given our study size.
For the subcutaneous model, the mean uptake of the radioconjugate increased
significantly (p=0.0014) with increasing tumor size from 4.16 ± 1.74 (<300 mm3) to 5.35 ±
1.75 (300-700 mm3) to 9.44 ± 3.66 (>700 mm3) %ID/g. Uptake of the perfusion agent in
subcutaneous tumors increased from 0.54 ± 0.32 (<300 mm3) to 0.68 ± 0.49 (300-700 mm3)
to 0.86 ± 0.37 (>700 mm3) %ID/g as tumor volume increased (p=0.15). Likewise, the
average tumor uptake of the

99m

TcO4- for the orthotopic model increased when

comparing the <300 mm3 (2.23 ± 1.09 %ID/g), 300-700 mm3 (2.94 ± 0.76 %ID/g) and >700
mm3 (3.19 ± 0.66 %ID/g) groups (p=0.078).
The most striking differences were observed when comparing the BB2r-mediated
uptake and perfusion between models at each tumor volume category. The average
uptake of the

177

Lu-DOTA-SP714 for the orthotopic model was 1.9, 1.6 and 1.2-fold

higher compared to the respective tumor volumes of the subcutaneous model (<300 mm3,
p=0.0055; 300-700 mm3, p=0.011; and >700 mm3 group, p=0.34). Similarly, a substantial
and statistically significant increase in tumor perfusion was observed for the orthotopic
versus the subcutaneous model for each tumor volume category. The average uptake of
perfusion tracer in orthotopic model was 4.1, 4.3 and 3.7-fold higher compared to the
respective subcutaneous model (<300 mm3, p=0.0008; 300-700 mm3, p=0.0001; and >700
mm3,p=0.0001).
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Table 2.2. Biodistribution studies in tumor–bearing scid mice.
Lu-BB2r conjugates uptake

Perfusion (99mTcO4-)

177

Tissue (%ID/g) *

Tumor volume (mm3)
<300

300-700

>700

<300

300-700

>700

Subcutaneous
blood

0.49 ± 0.40

0.78 ± 0.81

2.27 ± 0.60

1.01 ± 0.06

0.88 ± 0.34

2.61 ± 1.54

heart

0.16 ± 0.05

0.16 ± 0.03

0.68 ± 0.48

0.40 ± 0.24

0.22 ± 0.11

0.43 ± 0.38

lung

1.08 ± 1.55

0.64 ± 0.39

1.39 ± 0.67

0.74 ± 0.27

0.49 ± 0.21

1.24 ± 1.00

liver

0.29 ± 0.12

0.31 ± 0.06

0.90 ± 0.49

0.67 ± 0.43

0.41 ± 0.19

0.85 ± 0.77

pancreas

19.38 ± 12.99

23.82 ± 8.43

22.64 ± 7.83

2.26 ± 1.95

3.30 ± 2.30

6.22 ± 6.53

stomach

0.94 ± 0.53

1.68 ± 0.85

4.89 ± 3.52

2.26 ± 1.06

2.41 ± 1.25

3.03 ± 2.52

spleen

1.46 ± 1.32

2.53 ± 1.31

3.02 ± 0.63

1.35 ± 1.21

0.87 ± 0.74

0.43 ± 0.51

small intestine

2.53 ± 1.39

2.82 ± 1.14

4.21 ± 1.92

0.52 ± 0.38

0.61 ± 0.43

0.53 ± 0.43

large intestine

1.38 ± 0.75

2.63 ± 2.12

3.75 ± 2.89

0.44 ± 0.35

0.43 ± 0.47

0.53 ± 0.53

kidney

2.75± 1.29

2.59 ± 1.02

6.64 ± 2.83

0.66 ± 0.33

0.53 ± 0.19

1.11 ± 0.92
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Lu-BB2r conjugates uptake

Perfusion (99mTcO4-)

177

Tissue (%ID/g)

Tumor volume (mm3)
*

<300

300-700

>700

<300

300-700

>700

tumor

4.16 ± 1.74

5.35 ± 1.75

9.44 ± 3.66

0.51 ± 0.31

0.68 ± 0.49

0.86 ± 0.35

muscle

0.17 ± 0.12

0.15 ± 0.07

0.46 ± 0.24

0.19 ± 0.11

0.11 ± 0.04

0.21 ± 0.20

bone

0.20 ± 0.12

0.26 ± 0.19

0.67 ± 0.07

0.34 ± 0.27

0.16 ± 0.06

0.34 ± 0.31

brain

0.03 ± 0.02

0.03 ± 0.01

0.09 ± 0.05

0.06 ± 0.04

0.03 ± 0.02

0.06 ± 0.05

68.51 ± 23.40

73.16 ± 7.00

59.05 ± 12.41

83.64 ± 9.63

85.78 ± 9.65

82.76 ± 12.78

excretion† (%ID)

Orthotopic
blood

0.27 ± 0.19

0.33 ± 0.14

0.57 ± 0.12

3.13 ± 1.02

3.51 ± 1.28

3.96 ± 0.90

heart

0.13 ± 0.09

0.39 ± 0.49

0.30 ± 0.17

1.29 ± 0.61

1.20 ± 0.63

1.79 ± 0.87

lung

0.82 ± 0.50

0.92 ± 0.41

1.28 ± 0.47

2.86 ± 1.06

2.78 ± 1.27

3.34 ± 0.84

liver

0.26 ± 0.07

0.40 ± 0.18

0.52 ± 0.19

2.51 ± 0.73

2.92 ± 0.95

3.02 ± 0.77

pancreas

30.01 ± 12.48

40.12 ± 11.47

37.24 ± 7.29

4.94 ± 4.84

5.17 ± 5.32

4.03 ± 3.24

stomach

1.07 ± 0.53

1.59 ± 0.90

1.46 ± 0.62

16.33 ± 4.08

19.15 ± 6.40

15.44 ± 3.98
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Lu-BB2r conjugates uptake

Perfusion (99mTcO4-)

177

Tissue (%ID/g)

Tumor volume (mm3)
*

<300

300-700

>700

<300

300-700

>700

spleen

1.77 ± 1.19

2.02 ± 3.14

2.91 ± 4.89

2.84 ± 1.87

1.70 ± 1.20

1.80 ± 1.37

small intestine

2.97 ± 0.66

3.74 ± 1.15

3.80 ± 1.46

1.31 ± 0.31

1.36 ± 0.45

1.32 ± 0.78

large intestine

2.06 ± 1.02

4.52 ± 1.31

4.07 ± 1.91

1.52 ± 0.36

2.24 ± 0.57

2.14 ± 0.55

kidney

3.40 ± 0.92

4.80 ± 4.92

5.98 ± 3.08

1.85 ± 0.91

2.25 ± 2.25

1.45 ± 0.64

tumor

8.07 ± 3.23

8.55 ± 2.65

11.13 ± 2.88

2.23 ± 1.09

2.94 ± 0.76

3.19 ± 0.66

muscle

0.23 ± 0.12

0.22 ± 0.10

0.48 ± 0.34

0.47 ± 0.20

0.59 ± 0.18

0.63 ± 0.24

bone

0.29 ± 0.22

0.46 ± 0.22

0.53 ± 0.24

1.10 ± 0.73

1.27 ± 0.68

0.85 ± 0.49

brain

0.03 ± 0.01

0.06 ± 0.03

0.06 ± 0.02

0.14 ± 0.04

0.18 ± 0.18

0.16 ± 0.07

60.77 ± 29.28

67.22 ± 8.53

60.18 ± 10.77

39.51 ± 22.40

37.55 ± 14.08

46.43 ± 13.26

excretion† (%ID)

*. Organ uptake values expressed as %ID/g and values are n

8 unless otherwise noted.

†. Excretion values (%ID) were calculated using the activity values associated with the excreted urine and fecal material contents
at the time of sacrifice.
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Animal Model
177

Lu-DOTA-SP714 (A&C) and of

99m

TcO4-

(B&D) in orthotopic (n=23) and subcutaneous (n=24) model respectively. E&F).
Grouped box-whisker plot of tumor uptake of 177Lu-DOTA-SP714 and 99mTcO4 in two

animal models. (*p<0.05, **p<0.01, ***p<0.001, ns=no significance, +: mean, line at
median.)
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Table 2.3 Pearson correlation coefficient and p-value of tumor volume with uptake of
radiotracer in mice models.
Tumor uptake (%ID/g)
Lu-DOTA-SP714

177

Orthotopic

99m

TcO4

-

Lu-DOTA-SP714

177

Subcutaneous

99m

TcO4

-

Tumor volume (mm3)
Pearson r
p-value
0.73
0.0001
0.49

0.017

0.55

0.0049

0.47

0.021
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2.3.6 Quantification of Hypoxic Burden and Blood Vessel Density in PC-3
Tumors
Prior to sacrifice of the mice, pimonidazole (hypoxia marker) and Hoechst
(functional vasculature marker), were administered to examine the hypoxia burden and
vascular density of the human PC-3 tumor xenografts. The excised human PC-3 tumors
were sectioned and histologically evaluated for fluorescence signal using adjacent tumor
slices. Both signals were calculated by mean intensity per µm2 and grouped by tumor
volume groups for each mouse model (Table 2.4).
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Table 2.4. Mean intensity/µm2 of hypoxic burden and blood vessel density in tumor
xenograft.
Mean Intensity/µm2 (mean ± SEM)*
Tumor
volume
(mm3)

*.

Subcutaneous

Orthotopic

Hypoxic

Vasculature

Hypoxic

Vasculature

burden

Density

burden

Density

<300

9.47e-6 ± 1.74e-6

4.06e-6 ± 8.54e-7

4.33e-6 ± 1.41e-6

8.33e-6 ± 1.42e-6

300-700

3.84e-5 ± 6.98e-6

9.90e-6 ± 1.88e-6

1.18e-5 ± 2.64e-6

8.67e-6 ± 6.44e-7

>700

2.69e-5 ± 2.98e-6

2.11e-5 ± 4.30e-6

5.75e-6 ± 1.45e-6

1.39e-5 ± 1.81e-6

Values represent mean ± SEM (n 6).
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On average, subcutaneous tumors exhibited a 3.4-fold higher level of hypoxia
burden (signal) than the orthotopic tumors (Figure 2.7A). For both xenograft models, the
tumors demonstrated a trend toward maximal hypoxia burden for the 300-700 mm3
group (Figure 2.7C). Overall, there was no significant difference (p=0.13) in hypoxia
burden among the tumor volume groups in the orthotopic model (one-way ANOVA).
However, a significant difference in hypoxia levels was observed within the tumor
volume groups of the subcutaneous mouse model (p<0.001). Comparison of hypoxia
burden for the <300 mm3 tumor groups revealed no significant difference (p=0.053)
between

models.

In

contrast,

significant

differences

(p=0.002

and

p<0.0001,

correspondingly) between xenograft models were observed for the 300-700 and >700
mm3 groups, largely due to the substantial increase in hypoxia levels in the
subcutaneous models for tumor volumes exceeding 300 mm3. Specifically, the hypoxia
burden increased 4.0-fold in the subcutaneous model for the 300-700 mm3 group
compared to the <300 mm3 group (p<0.001). In both tumor models, the hypoxia levels
decreased on average by 30-50% when the tumor size exceeded 700 mm3 compared to
the respective 300-700 mm3 group (p>0.05).
The functional tumor blood vessel density of the excised PC-3 tumors are depicted in
Figure 2.7B. On average, the subcutaneous tumors had a slightly higher functional
vascular density compared to the orthotopic tumors. For both xenograft models, there
was a trend toward higher vascular density as tumor volume increased (Figure 2.7D).
For the subcutaneous model, there was a 2.4 and 5.2-fold increase of functional vascular
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density in the 300-700 (p=0.013) and >700 mm3 groups (p=0.0041) relative to the <300
mm3 group. With respect to the orthotopic tumors, no increase in vascular density was
observed for the 300-700 mm3 (p=0.82) group compared to the <300 mm3 group.
Although, a 1.7-fold increase in vessel density was observed for the >700 mm3 (p=0.084)
tumor volume group relative to the smaller groups. For tumor group comparisons
between models, the orthotopic tumors of the <300 mm3 group had a significantly
(p=0.0021) higher vascular density compared to the subcutaneous model, but no
statistically significant differences were found between the 300-700 and >700 mm3
groups (p=0.55 and p=0.11, correspondingly).
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Figure 2.4 Summary of quantification of A) hypoxia burden B) blood vessel density of

tumor slides in two mouse models. Line at grand mean. Box-whisker plots are indicating
the variance of C) hypoxia burden and D) blood vessel density between different tumor
volume groups in two animal models. (+: mean, line at median)
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2.3.7 Qualitative Examination of the Distribution of the BB2r-Targeted Peptide in
Tumor Xenografts
To better examine the distribution of

177

Lu-DOTA-SP714 in the two xenografts

models in relation to the hypoxic fractions and functional vasculature of tumors,
sections of tumors were examined by autoradiography (BB2r-targeted peptide) and
confocal microscopy to determine the hypoxic areas (Green) and functional vasculature
(Blue). The representative images from the <300, 300-700 and >700 mm3 group in
subcutaneous and orthotopic mouse model are shown in Figure 2.8 and Figure 2.9. As
expected, the predominate localization of the

177

Lu-DOTA-SP714 was in areas that had

significant functional vasculature. While in some areas that lacked vasculature were
hypoxic and exhibited a significantly lower concentration of 177Lu-DOTA-SP714.
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0.5 mm

1 mm

1.5 mm

Figure 2.5 Representative confocal microscopy images of adjacent subcutaneous tumor
sections in different tumor volume group. The sections were scanned for Hoechst 33342
(blue), the fluorescent antibody of pimonidazole (green) and underwent
autoradiography. The contrast of each image was optimized for clarity.
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0.5 mm

1 mm

1.5 mm

Figure 2.6 Representative confocal microscopy images of adjacent orthotopic tumor
sections in different tumor volume group. The sections were scanned for Hoechst 33342
(blue), the fluorescent antibody of pimonidazole (green) and underwent
autoradiography. The contrast of each image was optimized for clarity.
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2.3.8 H&E Staining of Non-target Tissues
Upon dissection of the mice from the orthotopic mouse model with tumors
exceeding 700 mm3, gross anatomy abnormalities of the kidneys, pancreas and liver
were perceived. The kidneys were often found to be pale and enlarged and the
formation of fluid-filled cysts on the surface of the kidneys were observed, likely due to
hydronephrosis. In several cases, enlargement and/or discoloration of the liver and
pancreas were also noted. The tissues taken from orthotopic models along with
analogous subcutaneous model (>700 mm3 group) and normal control mouse were
sectioned and underwent H&E staining, see Figure 2.10. All of the sectioned tissues
associated with the orthotopic model were more diffuse than subcutaneous and normal
controls probably due to the increased interstitial volume resulting from reduced urine
output. For the orthotopic tumor group, micrometastasis were observed in the pancreas,
but, surprisingly, were not found in the liver or kidney sections. No micrometastasis
were observed in the sections obtained from the subcutaneous model.
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Liver

Pancreas

Kidney

Control

Subcutaneous

Orthotropic

Figure 2.7 Representative H&E image of the liver, pancreas and kidney tissue sections (10
) of non-tumor bearing, subcutaneous and orthotopic xenograft mouse respectively.
Scale bar: 100 µm.
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2.4 DISSCUSSION
The purpose of this work is to investigate how the vascular density and perfusion of
tumors impact the hypoxia burden and drug delivery of BB2r-targeted agents.
Specifically, we investigated these factors in subcutaneous and orthoptopic xenografts
across a range of tumor volumes. By understanding this, we hope to provide researchers
a better understanding of these biological variables as well as the advantages and
limitations of both subcutaneous and orthotopic models for BB2r-targeted agent
development.
We first synthesized and characterized a new hydrophilic, BB2r-targeted
radioconjugate (177Lu-DOTA-SP714). In addition to examining it’s chemical and in vitro
properties, we also accessed the solution stability of the radiocojugate. This investigation
was prompted out of the need to perform in vivo experiments with large numbers of
mice and the desire to reduce the need for constant synthesis of the radioconjugate. It is
well established that ionizing radiation (e.g.,

2+ and

- particles) can directly or

indirectly, through the generation of solvated electrons and free radicals species,
degrade peptides and proteins

201

. Ascorbic acid and selenomethionine have been

demonstrated to have a protective effect against radiolytic degradation in both
preclinical and clinical studies

. Indeed, Chen and co-workers examined these

202-204

radioprotectants among others with Lu-AMBA, a clinically investigated BB2r-targeted
agent

205

. Similar to their findings, our studies revealed that the combination of the two
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radioprotectants, ascorbic acid (40mg/mL) and selenomethionine (0.2mg/mL), was better
than ascorbic acid alone with approximately 95% of the radioconjugate intact by 72h.
The establishment of the subcutaneous and orthotopic PC-3 xenograft model was
carried out over a four-eight week period depending on the model and the desired
tumor size. The measured tumor size for orthotopic tumors initially outpaced
subcutaneous, but the subcutaneous tumors demonstrated a more rapid growth at
approximately 4-weeks post-inoculation. The disparity of growth rates between two
models likely stem from the different measurement techniques employed and the initial
cell numbers administered. Based on body weight measurements, the overall health of
the mice appeared good across models and tumor size ranges investigated (Figure 2.11).
However, for the largest orthotopic tumor volume group (>700 mm3), abnormalities
were found upon gross examination of the kidneys, liver and pancreas. This prompted
the histological examination of these tissues for both models. The tissues obtained from
the orthotopic model were more diffuse and were consistent with a larger interstitial
water content, likely due to urinary obstruction resulting from the PC-3 tumor in the
prostate. This observed condition has been noted for other orthotopic prostate cancer
mouse models 206.
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Figure 2.8 Body weight changes of mice after the orthotopic (blue) and subcutaneous
(red) xenograft implantation.).
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Examination of the perfusion characteristics of two models revealed some interesting
findings. The average perfusion of the tumors increased as tumor size increased.
However, orthotopic model showed the substantially higher perfusion (>3-fold)
compared to subcutaneous ones for the smallest tumor group (<300 mm3). This is
interesting given the similar amount of functional vasculature in both models based on
Hoechst staining. This comparably higher perfusion rate has also been observed in other
orthotopic/subcutaneous models

172-174

. The most likely reason is that the subcutaneous

tumors exhibit higher interstitial fluid pressure (IFP). In general, the functional
vasculature of the orthotopic tumors are more spatially distributed throughout the
tumors and have larger vessel diameters

. This has been shown to reduce IFP in

175-176

orthotopic over subcutaneous tumors, with the latter having a higher vasculature
density on the periphery of the tumor. Another factor that might contribute to the
observed perfusion differences is the efficacy of the lymphatic drainage of the tumors. If
the lymphatic system present in the orthotopic tumors are more efficient thereby
lowering IFP, this would lead to an enhancement in perfusion efficacy 177-178.
The BB2r-targeting efficacy of the

177

Lu-DOTA-SP714 was examined in both PC-3

xenograft models. Generally, the average %ID/g uptake of the radioconjugate increased
as the tumor size increased. Specifically, orthotopic tumors exhibited significantly higher
uptake compared to subcutaneous tumors across tumor groups. This is almost certainly
due to the increased perfusion of orthotopic over subcutaneous tumors. Thus, the
substantial higher perfusion for PC-3 orthotopic tumors should be considered carefully
when evaluating the targeting efficacy of BB2r- and other targeted agents.
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Using pimonidazole, the hypoxia burden of the tumors was evaluated for both
models. For the orthotopic tumors, no significant differences in hypoxia levels were
observed across the tumor volume ranges. However, the subcutaneous tumors exhibited
significant increases in hypoxia with tumor sizes that exceeded 300 mm3. The increased
hypoxia levels for the 300-700 and >700 mm3 tumor groups may be attributable to the
spatial distribution of the functional vascular on the periphery of tumors. For small
tumors, the peripheral vasculature can adequately perfuse the whole tumor. Yet, as the
tumor grows the vasculature becomes unable to perfuse/supply large segments of the
tumor at the core thus resulting in significant increases in hypoxia burden

207

. While

hypoxia was observed for both models, medium to large subcutaneous tumors more
reliably gave tumors with significant fractions of hypoxia, perhaps making this a more
convenient model to investigate the efficacy of hypoxia-targeted or hypoxia-selective
agents.

2.5 CONCLUSION
Orthotopic models are known to better simulate clinical prostate cancer, particularly
with respect to the tumor microenvironment, compared to subcutaneous models. To
better understand the how the biology of these tumor models impact BB2r-targeted
agent delivery, we examined the tumor vascular perfusion, microvasculature density
and hypoxia burden of orthotopic and subcutaneous PC-3 xenograft mouse models.
Compared to the subcutaneous model, the results demonstrate that the orthotopic PC-3
tumors have a higher vascular perfusion that leads to higher BB2r targeting as well as
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lower hypoxic burden. While the vessel density was slightly lower in orthotopic model
compared to subcutaneous ones, no statistical significance was observed. In general, for
both models, BB2r-targeting, perfusion and vascular density increased with increasing
tumor

volume.

Immunofluorescence

and

autoradiography

illustrated

the

microbiodistribution pattern of BB2r-targeted conjugate relative to functional
vasculature and hypoxic regions. As expected, higher concentrations of the radiolabeled
conjugate were observed near functional vasculature compared to hypoxic regions that
were devoid of functional vasculature. Overall, this work demonstrates that the tumor
microenvironments of orthotopic and subcutaneous PC-3 tumors are impactfully
different in terms of drug delivery. Careful consideration should be taken when
comparing the data of BB2r-targeted agents, as well as other targeted agents, in
orthotopic and subcutaneous tumor models.

78

Chapter 3. Enhanced tumor retention of receptor-targeted agonist and
antagonist: a comprehensive study of hydrophilic cysteine cathepsins
inhibitor incorporated analogues in prostate cancer imaging
3.1 INTRODUCTION
Due to the elevated expression of the gastrin-releasing peptide receptor (BB2r) in
numerous cancers (e.g., prostate, breast and lung), a number of BB2r-targeted diagnostic
and therapeutic agents have undergone and continues to undergo clinical investigations
. The vast majority of these agents are based on bombesin (BBN), a 14 amino

67-69, 208-210

acid amphibian peptide. In most instances, only the C-terminal fragment of the BBN
peptide (e.g., BBN(7-14)NH2: Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) is employed in
BB2r-targeted agent design due to its ability to achieve nanomolar affinity for the
targeted receptor

. Over the years, examination of the structure-activity profile of

74, 211

this fragment has revealed numerous high BB2r-binding derivatives with different
pharmacological profiles in terms of agonistic vs antagonistic character

.

23, 63-64, 74-77, 84

However, despite the encouraging clinical and preclinical results of many of these
studies, the relatively short tumor residence time of BB2r-targeted peptides still
represents a translational hurdle, particularly with regard to radiotherapeutic
approaches.
Cysteine cathepsins (CCs), a family of endolysosomal proteases, play key roles in
numerous biological functions, but are primarily associated with intracellular protein
turnover

106, 212

. In cancers, it has been demonstrated that these proteases contribute to

79

tumor progression. CCs become increasingly localized extracellularly in many cancers 104,
; though it is important to recognize that the extracellular CC concentrations and

213

activities in cancer are well below endolysosomal levels

. Due to its oncogenic role,

105, 214

over the years a variety of reversible and irreversible (e.g., E-64) CC inhibitors have been
developed for therapeutic purposes

22-23

. Specifically, several groups have reported

efforts to develop fluorescent 24-25 and nuclear medicine 26 diagnostic probes targeting the
upregulation of CCs in cancer cells.
The utilization of low-molecular weight targeted agents as diagnostics and
therapeutics offer several advantages in terms of pharmacokinetic profile and clinical
utility when compared to longer circulating macromolecules. However, one significant
detriment to the use of low-molecular weight carriers is the relatively limited residence
time at target (e.g., tumors) sites. This situation is particularly problematic for targeted
radiotherapeutic applications in cancer where short residence times, in many cases,
limits deliverable therapeutic doses. Our laboratory has recently begun exploring
chemical approaches to enhance the retention (i.e., residualization) of low-molecular
weight, receptor targeted agents

115

. One of these approach uses irreversible CC

inhibitors (i.e., CC trapping agents) to form high molecular weight adducts within the
endolysosomal compartments of targeted cancer cells. These adducts have been shown,
both in vitro and in vivo, to provide substantial enhancements in the retention of
receptor-targeted drugs.
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Here, for the first time, we explore our CC residualization approach using the wellvalidated, BB2r-targeted agonistic and antagonistic constructs BBN(7-14)NH2 and RM2
(D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2).

Our

impetus

for

this

line

of

investigation was to examine the efficacy of our methodology with two clinically
validated pharmacophores. Additionally, by examining this agonistic and antagonistic
pair, we hope to confirm mechanistically if, as we suspect, internalization is key to the
efficient formation of highly retained adducts thereby resulting in increased tumor
retention. Specifically, we synthesized an analog of E-64, a well-known CC inhibitor, and
incorporated this into the structure of the agonist and antagonist BB2r-targeted
constructs. The biological performance of these analogs was examined using in vitro and
in vivo human prostate cancer PC-3 cell models. The results obtained herein reveal
interesting mechanistic insights concerning the generality of our CC/endolysosomal
trapping and leads us to question the extent of the antagonistic character of the RM2,
and perhaps other, BB2r-targeted antagonists.

3.2 MATERIALS AND METHODS
3.2.1 Reagents and Instruments
All solvents used for reactions and silica gel purification were ACS grade and
purchased from Fisher Scientific, unless otherwise stated. Acetonitrile utilized for HPLC
analysis and purification was HPLC grade and purchased from Fisher Scientific. Water
was deionized by Millipore® Milli Q Biocell Ultrapure Water Systembefore use.
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CDCl3 was obtained from ACROS Organics™. Dimethyl sulfoxide was obtained
from Cambridge Isotope Laboratories. Ethylenediaminetetraacetic acid (EDTA), Brij®35
Cu (II) chloride were obtained from Sigma-Aldrich (St Louis, MO). Fmoc-protected
natural amino acids were purchased from Nova Biochem (Waltham, MA). Fmoc-NH(PEG) -COOH were purchased from MilliporeSigma (St. Louis, MO). Fmoc-Lpropargylglycine and N,N-diisopropylethylamine (DIEA) was obtained from ChemImpex International (Wood Dale, IL). Sieber Resin (100-200 mesh)were purchased from
ChemPep Inc (Wellington, FL). Deuterium oxide were purchased from Alfa Aesar®
(Haverhill, MA). CA-074 was purchased from ApexBio (Houston, TX). (1-Cyano-2ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium
hexafluorophosphate (COMU) was purchased from AK Scientific (Union City, CA).
Bovine serum albumin (BSA) was purchased from Atlas Biologicals, Inc. Human serum
was obtained from MP Biomedicals (Santa Ana, CA). TrypLE Express was obtained from
Invitrogen (Grand Island, NY). N,N-dimethylformamide (DMF), dichloromethane
(DCM), petroleum ether (PE), methanol, ethyl acetate, acetonitrile, formic acid,
trifluoroacetic acid (TFA), pyridine, piperidine and N-methylpyrrolidone (NMP),
hydrochloric acid and L-glutamine were obtained from Fisher Scientific (Fair Lawn, NJ).
Kaighn's Modification of Ham's F-12 Medium (F-12K Medium), 4-(2-hydroxyethyl)-1piperazineethanesulfonic

acid

(HEPES),

Penicillin-Streptomycin,

and

phosphate

buffered saline (PBS) were purchased from HyClone Laboratories, Inc. (Logan, UT).
Cytofix Fixation buffer was obtained from BD Biosciences (San Jose, CA). Novex™ TrisGlycine SDS sample buffer, Pierce™ RIPA buffer, PageRuler™ Prestained protein ladder,
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HaltTM Protease inhibitor cocktail, LysoTracker® Green DND-26 and NuPAGE® sample
reducing reagent (10×) were purchased from Thermo Fisher Scientific (Waltham, MA).
Amicon Ultra-4 centrifugal filter (10 kDa) was purchased from Merck Millipore
(Burlington, MA). [177Lu] LuCl3 was purchased from Oak Ridge National Laboratory
(Oak Ridge, TN). The human prostate cancer PC-3 (CRL-1435™) was purchased from
American Type Culture Collection.
Peptides were synthesized by solid phase peptide synthesis (SPPS) on a Liberty
microwave peptide synthesizer from CEM Corperation (Matthews, NC). A Waters e2695
system equipped with a Waters 2489 absorption detector and a Waters Qtof Micro
electrospray ionization mass spectrometer was used to perform high performance liquid
chromatography/mass spectrometry (HPLC-MS) analyses. A Phenomenex Jupiter C12
Proteo 250×10 mm semiprep column was used for the purification of peptides. 1H and
13

C NMR spectrums were recorded on a Bruker Avance-III HD 500 MHz instrument.

Residual protio-solvent signals (1H NMR, CDCl3 7.26, DMSO-d6 2.50, 13C NMR, CDCl3
77.00, DMSO-d6 39.51) were used as internal references. Evaluation and purification of
radiolabeled conjugates was performed on a Waters 1515 binary pump equipped with a
Waters 2489 absorption detector and a Bioscan Flow Count radiometric detector system,
using a Phenomenex Jupiter C12 Proteo 250×4.6 mm column. Solid phase extraction was
performed using Empore (U.S.) C18 10 mm high performance extraction disks. Costar®
Polystyrene TC-Treated Microplates (96-well plate and 6-well plate) were used for
Cathepsin B inhibition kinetic studies and in vitro internalization-efflux study separately.
Gas anesthesia was administered at a vaporizer setting of 5% isoflurane (Halocarbon
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Corp, River Edge, NJ) with 0.5 L/min oxygen using an E-Z Anesthesia apparatus
(EUTHANEX Corp, Palmer, PA). Gamma decay detection of

177

Lu for the in vitro cell

studies and tissue homogenates was accomplished using an LTI (U.S.) Multi-Wiper™
nuclear medicine gamma counter. Gamma decay detection of

177

Lu-labeled conjugates

for biodistribution studies was accomplished using a NaI (Tl) well detector constructed
by AlphaSpectra, Inc (U.S.). Fluorescence intensities were measured by a SpectraMax®
M5 multimode plate reader. Lab-Tek™ chambered borosilicate coverglass disks (8 well)
were used for confocal cell imaging. Confocal microscopy images were taken on a Leica
LSM710 META Microscope equipped with an argon laser. The fluorescent images were
analyzed by the ZEISS ZEN blue software. Autoradiography was recorded via BAS
storage phosphor screens and scanned by GE Lifesciences Typhoon FLA 9500
biomolecular imager. A hybrid single photon emission computed tomography system
and x-ray computed tomography (SPECT/CT) (Flex Triumph, TriFoil Imaging,
Northridge, CA, USA) fitted with a five pinhole (1.0 mm per pinhole) collimator was
used for in vivo imaging study.

3.2.2 Animals
Four weeks-old NOD SCID (NOD.CB17-Prkdcscid/NCrCrl) mice were obtained
from The Jackson Laboratory (Bar Harbor, ME). Food and water were given ad libitum.
Five mice per group were kept in the same cage with an air filter cover under light- (12 h
light/dark cycle) and temperature-controlled (22 ± 1°C) environment before experiment.
At the day of experiment, each animal was kept in individual cage with same housing
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condition. The animals were treated in accordance to the Principles of Animal Care
outlined by National Institutes of Health and approved by the Institutional Animal Care
and Use Committee of the University of Nebraska Medical Center.

3.2.3 Chemistry
3.2.3.1 Synthesis of Intermediate Compound of Cystine Cathepsin Inhibitor and
Its Control
(9H-fluoren-9-yl)methyl (S)-(1-((2-azidoethyl)amino)-1-oxo5-(3-((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)carbamate

(1):

To

a

solution of Fmoc-Arg(Pbf)-OH (500 mg, 0.77 mmol) in DMF (5 mL), EDCI (162 mg, 0.85
mmol) and NHS (116 mg, 1.00 mmol) were added dropwise at 0 °C. The solution was
stirred at room temperature for 2h before adding to the solution containing 2azidoethanamine (132 mg, 1.54 mmol) and (405 µL, 2.31 mmol) in DMF (3 mL). The
mixture was kept stirring for overnight and partitioned in ethyl acetate (30 mL ×3) and
brine (20 mL). The combined organic phase was washed with water and concentrated by
rotary evaporation to yield a white foam (508 mg, 92%).
1

H-NMR (500 MHz, CDCl3):

7.73 (d, J = 7.5 Hz, 2H), 7.55 (d, J = 7.0 Hz, 2H), 7.45 (br,

1H), 7.37 (d, J = 7.5 Hz, 2H), 7.24-7.22 (m, 2H), 6.27 (s, 2H), 6.05 (d, J = 7.0 Hz, 1H), 4.334.31 (m, 3H), 4.14 (m, 1H), 3.43-3.27 (m, 6H), 2.90 (s, 2H), 2.58 (s, 3H), 2.50 (s, 3H), 2.07 (s,
3H), 1.86-1.55 (m, 5H), 1.42 (s, 6H).
MS (m/z): [M+H]+ calcd. for C36H44N8O6S H+: 717.3, found: 717.3.

85

(9H-fluoren-9-yl)methyl

((S)-1-(((S)-1-((2-

azidoethyl)amino)-1-oxo-5-(3-((2,2,4,6,7-pentamethyl2,3-dihydrobenzofuran-5-yl)sulfonyl)guanidino)pentan2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (2): Compound 1 (500 mg, 0.70
mmol) was dissolved in 20% piperidine in DMF (10 mL) and stirred for 30 min. The
solution was extracted with ethyl acetate (30 mL ×3) and the organic phase was
concentrated by rotary evaporation. The residue was re-dissolved in DMF (5 mL) and
added to the mixture of COMU (342 mg, 0.80 mmol) and Fmoc-Leu-OH (247mg, 0.70
mmol) in DMF (10 mL). The solution was stirred for 5 min before DIEA (250 µL, 1.4
mmol) was added in. The mixture was kept for stirring for another 2 h. Brine (100 ml)
and ethyl acetate (30 mL ×3) were poured into the flask and the organic phase was
separated, washed twice with aq. HCl (100 mL, 0.5N) saturated NaHCO3 (100 mL),
water (100 mL) and dried over Na2SO4. The organic layer was evaporated to dryness and
was purified by flash column chromatography (silica gel, DCM/methanol = 15:1) to
afford as a pale foam (424 g, 73%).
1

H-NMR (500 MHz, CDCl3):

7.75 (d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.46 (br,

1H), 7.38 (t, J = 7.5 Hz, 2H), 7.8 (m, 2H), 6.08 (s, 2H), 5.47 (br, 1H), 4.72-4.33 (m, 5H), 4.14
(m, 1H), 3.46-3.21 (m, 6H), 2.92 (s, 2H), 2.57 (s, 3H), 2.50 (s, 3H), 2.01 (s, 3H), 1.65 (m, 2H),
1.43 (s, 6H), 1.26 (m, 2H), 1.11 (s, 2H), 0.96-0.92 (m, 8H).
MS (m/z): [M+H]+ calcd. for C42H55N9O7S H+: 830.4, found: 830.2.
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(2R,3S)-3-((1-((1-((2-azidoethyl)amino)-1-oxo-5-(3((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-4-methyl1-oxopentan-2-yl)carbamoyl)oxirane-2-carboxylic acid (3). Compound 2 (200 mg, 0.24
mmol) was dissolved in 20% piperidine in DMF (5 mL) and stirred for 30 min. The
solution was extracted with ethyl acetate (20 mL ×3) and the organic phase was
concentrated by rotary evaporation. To the solution of the residue in DMF (5 mL), was
added in the mixture of COMU (171 mg, 0.40 mmol) and (+/-)-trans-oxirane-2,3dicarboxylic acid (158mg, 1.20 mmol) in DMF (10 mL) and was stirred for 5 min before
DIEA (500 µL, 2.8 mmol) was added in. The mixture was kept for stirring for another 2 h.
Brine (100 ml) and ethyl acetate (30 mL ×3) were poured into the flask and the organic
phase was separated, washed twice with aq. HCl (100 mL, 0.5N) and water (100 mL ×3),
and dried over Na2SO4. The organic layer was evaporated to dryness and was purified
by a semi-preparative Proteo C12 HPLC column with a 15 min gradient and a flow rate
of 5.0 mL/min (40% - 90% ACN in water containing 0.1% formic acid) to give compound
5 as a yellow powder (99 mg, 57%).
1

H-NMR (500 MHz, DMSO-d6):

8.59 (dd, J = 29.5, 8.0 Hz, 2H), 8.13 (m, 1H), 8.08 (m,

1H), 6.64 (br, 1H), 6.38 (br, 1H), 4.39 (m, 1H), 4.19 (m, 1H), 3.66 (s, 1H), 3.48 (d, J = 9.0 Hz,
1H), 3.26-3.16 (m, 4H), 3.02 (s, 2H), 2.96 (s, 2H), 2.54 (s, 1H), 2.47 (s, 3H), 2.42 (s, 3H), 2.01
(s, 3H), 1.59-1.23 (m, 13H), 0.88-0.84 (m, 6H).
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13

C-NMR (125 MHz; DMSO-d6):

172.0, 169.2, 163.5, 157.9, 156.5, 131.9, 124.8, 86.8, 53.1,

52.8, 51.9, 51.8, 51.7, 50.4, 42.9, 41.3, 28.8, 24.7, 23.5, 23.4, 22.0, 19.4, 18.1, 12.7.
MS (m/z): [M+H]+ calcd. for C31H47N9O9S H+: 722.3, found:722.2.
4-((1-((1-((2-azidoethyl)amino)-1-oxo-5-(3((2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5yl)sulfonyl)guanidino)pentan-2-yl)amino)-4methyl-1-oxopentan-2-yl)amino)-4-oxobutanoic

acid

(4).

This

compound

was

synthesized by the similar method for compound 3, succinic acid was used instead of
(+/-)-trans-oxirane-2,3-dicarboxylic acid. The compound was purified by a semipreparative Proteo C12 HPLC column with a 15 min gradient and a flow rate of 5.0
mL/min (40% - 90% ACN in water containing 0.1% formic acid) to give a white powder
(87 mg, 49%).
1

H-NMR (500 MHz, DMSO-d6):

8.55-7.98 (m, 4H), 7.40 (br, 3H), 4.43 (dq, J = 51.5, 6.0

Hz, 1H), 4.24 (m, 1H), 3.51 (s, 1H), 3.26-3.17 (m, 4H), 3.10-3.06 (m, 3H), 1.66 (m, 1H), 1.541.44 (m, 6H), 0.88-0.83 (m, 6H).
13

C-NMR (125 MHz; DMSO-d6):

171.8, 171.7, 171.1, 170.7, 167.6, 167.2, 164.2, 157.4,

157.3, 54.3, 54.2, 52.7, 52.4, 52.2, 52.1, 51.4, 51.1, 50.1, 48.8, 40.9, 38.3, 29.2, 29.1, 25.1, 25.0,
24.4, 24.3, 23.2, 21.9, 21.7.
MS (m/z): [M+H]+ calcd. for C31H49N9O8S H+:708.4, found: 708.2.
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3.2.3.2 Synthesis of Cystine Cathepsin Inhibitor-BB2r Peptide Conjugates with
Matching Controls
General procedure for synthesis of compound 7-10. To the mixture of compound 5
(2 µmol) and compound 3 (5 µmol) in water/n-butanol/DMF (200 µL, v/v/v=1:1:2) was
added CuSO4 (200 µg, 1.25 µmol) in water (50 µL). After stirring for 5 min at room
temperature, a solution of ascorbic acid (6 µmol) in water (50 µL) was added to the
mixture. The reaction mixture was continuously stirred for 1 h under nitrogen. The
product was obtained by the purification via a semi-preparative Proteo C12 HPLC
column with a 15 min gradient and a flow rate of 5.0 mL/min to give the product.
Compound 4 was clicked to BBN peptide in the similar way to yield control conjugates.
General procedure for synthesis of compounds 11-14 (E-AG, C-AG, E-AN and CAN, respectively). Take E-AG for example, compound 3 clicked BB2r-targeted agonist
peptide (compound 7) (1 µmol) and DOTA-NHS ester (3 µmol) were dissolved in DMF
(5 mL). The solution was basified with DIEA (0.081 mL, 0.47 mmol) and stirred at room
temperature for overnight. The completion of the conjugation reaction was confirmed by
HPLC before the removal of the solvent under nitrogen flow. A 90% TFA in DCM (500
µL) solution was added and the mixture was stirred at room temperature for 2 h under
nitrogen. The solvent was removed by nitrogen flow and the residue was redissolved in
DMF (300 µL) for the purification via a semi-preparative Proteo C12 HPLC column with
a 15 min gradient and a flow rate of 5.0 mL/min to give the target compound.
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3.2.4 Solid-Phase Peptide Synthesis (SPPS)
Peptide (compound 5 and 6) synthesis was performed using an automated solidphase peptide synthesizer employing traditional Fmoc chemistry and using a Sieber
resin (ChemPep Inc., U.S.). Briefly, the resin (0.7 meq/g) was deprotected using
piperidine, resulting in the formation of a primary amine from which the C-terminus of
the growing peptide was anchored. The Fmoc protected amino acids (300 µmol) with
appropriate orthogonal protection were activated with COMU and sequentially added
to the resin. The resulting peptide was cleaved from the resin using 1% trifluoroacetic
acid (TFA) in dichloromethane (DCM) (5 × 3 mL) for 5 min. The filtrates were
immediately neutralized with 2% pyridine in methanol (1 mL) and evaporated to
dryness. The crude peptides were purified by HPLC with a 15 min gradient and a flow
rate of 5.0 mL/min to give the target peptides, see Table 3.1 for chromatography and
characterization details.

3.2.5 Radiolabeling of the Conjugates with 177LuCl3
Radiolabeling was performed on all conjugates by mixing 25 µg samples with 37
MBq

177

LuCl3 (Department of Energy, U.S.) in sodium acetate buffer (0.5 M, 120 µL, pH

5.5) and incubating at 90 °C for 20 min. The mixture was purified by HPLC system and
the radiolabeling efficiency (RE) was calculated based on the analysis of the
chromatograms. To remove organic eluent and perform concentration, the radioactive
conjugate was loaded onto an Empore (Eagan, MN) C18 high-performance extraction
cartridge followed by washing with water (2 × 3 mL) and elution by ethanol/saline
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solution (v/v = 6:4, 150 µL) to obtain the

Lu-labeled radioconjugate for further

177

biological experiments.

3.2.6 Distribution Coefficient (Log D7.4) of the Conjugates
In a microcentrifuge tube, 0.5mL of 1-octanol was added to 0.5 mL phosphatebuffered saline (pH7.4) containing the radiolabeled peptide (200,000 cpm). The solution
was vigorously stirred for 2 min at room temperature and subsequently centrifuged
(100g, 5 min) to yield two immiscible layers. Aliquots of 100 µL were taken from each
layer and the radioactivity of each was quantified by a

-counter. Statistical analysis

using the unpaired two-tailed Student’s t test was performed to compare the logD values
and P values < 0.05 were considered statistically signi cant.

3.2.7 The Metabolic Stability of the Radioconjugates in Human Serum
The radioconjugates (11.1 MBq, 300 µCi) was added to 300 µL 10% human serum
and incubated at 37 °C for 24 h. At predetermined time points (0, 4, and 24 h),
acetonitrile (50 µL) was added to the mixture (50 µL) was centrifuged at 12,000×g for 5
min. The supernatant was collected and dried with nitrogen flow. The sample was
reconstituted in water (100 µL) and analyzed by radio-HPLC using the gradient
described above.

3.2.8 In Vitro Competitive Cell-Binding Studies
The half maximum inhibitory concentration (IC50) of the unlabeled conjugates were
determined by competitive displacement cell-binding assays using PC-3 cells. In these
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studies,

177

Lu DOTA-SP714

(177Lu-DOTA-dSer4-PEG3-BBN

(7 14)),

which

was

synthesized according to our previous work, served as the competitive radioligand for
comparing the relative binding affinities of the conjugates. PC-3 cells (~1×106) were
suspended in 100 µL RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA)
and incubated at 37°C for 40 min in the presence of radiolabeled 177Lu DOTA-SP714 and
various concentrations of the conjugates (0.1 nM – 1 µM) in 100 µL of medium. At the
end of the incubation period, the cells were centrifuged, aspirated and washed with
media a total of three times (5 × 500 µL). The cell associated activity was measured using
a

-counter and the IC50 values determined by nonlinear regression using the one-

binding site model of GraphPad PRISM 5 (U.S.).

3.2.9 The Inhibition of Cathepsin B Activity by the Conjugates
The phosphate buffer (0.1 M, pH = 5.8) containing EDTA (1 mM), DTT (2.7 mM), and
Brij®35 (0.03%) was prepared before the assay. The solution of Z-Arg-Arg-AMC
(Bachem, Switzerland) in the assay buffer (50 µL, 1.3 mM) was mixed with the conjugate
dissolved in assay buffer at predetermined concentrations (100 µL, 0.1 nM – 1 µM). The
solution of cathepsin B (human Liver, Millipore, U.S.) in assay buffer (50 µL, 0.544 nM)
was added to the mixture which was further incubated at 37 °C for 20 min. The
fluorescence of the liberated aminomethylcoumarin at 460 nm using 355 nm excitation
was measured and the IC50 of the cathepsin B inhibition versus the samples without the
inhibitor was determined by nonlinear regression using GraphPad Prism 5 (U.S.).

3.2.10 Determination of the Km and Vmax of Cathepsin B for Z-Arg-Arg-AMC
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The solution of cathepsin B (human Liver) (50 µL, 2 nM) in assay buffer used above
was mixed with 50 µL of solution of substrate Z-Arg-Arg-AMC in the assay buffer to get
different final concentrations ([S]) (25 µM, 50 µM, 100 µM, 500 µM and 1mM). The
mixture

was

incubated

at

37

°C

and

the

fluorescence

of

the

liberated

aminomethylcoumarin at 460 nm using 355 nm excitation was measured at
predetermined time points (0, 2, 4, 6, 8, and 10 min). The fluorescence intensity was
plotted versus time and the reaction rates (V0) were calculated as the slope of the trend
lines obtained by liner regression. Km and maximum reaction rate (Vmax) were
determined by nonlinear regression using GraphPad Prism 5 (U.S.).

3.2.11 Determination of the Inhibition Constant (Ki) of the Compounds to
Cathepsin B
The cathepsin B (human Liver) in assay buffer (25 µL) was mixed with the conjugate
(25 µL) in 96-well plate. After the solution was mixed, the Z-Arg-Arg-AMC in assay
buffer (50 µL) was added to the well, yielding a final cathepsin B concentration of 1 nM,
conjugate concentration ([C]) of 50 nM, and substrate concentration ([S]) of 25 µM, 50
µM, 100 µM, 500 µM and 1mM. The mixture was incubated at 37 °C and the
fluorescence of the mixture at 460 nm using 355 nm excitation was measured at
predetermined time points (0, 2, 4, 6, 8, and 10 min). The fluorescence intensity was
plotted versus time with observed reaction rates (V0-obs) calculated as the slope of the
trend lines obtained by liner regression. The observed rate constant (Kobs) and observed
maximum reaction rate (Vmax-obs) was determined by nonlinear regression using
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GraphPad Prism 5. The Ki was calculated from the equation Kobs = Km (1 + [C]/Ki). All
measurements were in biological triplicate.

3.2.12 Cell Internalization Studies
PC-3 cells were incubated in six-well plates (1 × 106/well) overnight. The cells were
incubated with each

177

Lu radioconjugate (100, 000 cpm) at 37 °C for 4 h. At 15, 30, 60,

120 and 240-min time points, the culture medium was removed, and the cells were
washed with fresh medium (5 × 1 mL) to remove the unbound conjugates. The fraction
of surface-bound radioactivity was removed by washing the cells twice with an acidic
buffer (500 µL, 50 mM glycine HCl/0.1 M NaCl bu er, pH 2.8). The amount of
radioactivity remaining in cells was assigned as the internalized fraction. The
radioactivity for each sample was measured by

-counter. The cellular uptake of the

radioconjugates were presented as a percentage of the surface-bound and internalized
radioactivity relative to the total activity added to the tube.

3.2.13 Cellular Efflux Studies
Efflux studies were carried out under atmospheres that contain 5% CO2 and 21% O2.
PC-3 cells were incubated in six-well plates (1 × 106/well) overnight in RPMI 1640 media
(pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA). On the day of the experiment, the cells
were incubated for 2 h at 37°C in the presence of 1 mL 100,000 cpm of each

177

Lu-

radioconjugates. Upon completion of the incubation at time points 0, 2, 4, 8 and 24 h, the
media was collected to quantitate the amount of the effluxed ligand. Surface bound
radioactivity was collected by washing the cells twice with an acid wash (1 mL, 50 mM
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glycine-HCl/0.1 M NaCl buffer, pH 2.8). The cells were then lysed at 37°C using a 0.5 %
aqueous SDS solution and the lyses were collected as internalized ligand. The
radioactivity of the effluxed, surface bound and internalized fractions for each
radioconjugate at each oxygen concentration was determined using a -counter.

3.2.14 Competitive Cathepsin B Binding of the Radioconjugates with CA-074
The Cathepsin B (3 nM, 10 µL) in storing buffer (50mM sodium acetate and 1mM
EDTA, pH 5.0) was pre-incubated with the commercial cysteine proteases inhibitor CA074 (ApexBio, Houston, TX) (10 µM, 10 µL) for 30 min. The solution of radioconjugates
(200,000 cpm) in 30 µL of binding assay buffer (5 mM Tris, 5 mM MgCl2, and 2 mM DTT,
pH = 5.5) was added to the mixture and incubated on ice for 2h. Aliquot (24 µL) of the
solution was mixed with Novex Tris-Glycine SDS sample buffer (2×) (30 µL) and
NuPAGE® Sample Reducing Agent (10X) (6 µL) and incubated for further 10 min. The
mixtures (20 µL) was heated at 85 °C for 2min. The cool-downed solutions were loaded
onto a NovexTM 16% tris-glycine gel and ran at 110 V for 90 min. After shaking in
shrinking buffer (50 mL, 65% methanol, and 0.5% glycerol in DI water) at 4 °C for
overnight, the gel was dried for 6 h at room temperature and the ladders were painted
with small amount of radioactivity. The gel was then exposed to a phosphor screen for
72 h which was subsequently scanned by Typhoon FLA 9500 imaging system at a 25 µm
resolution to achieve autoradiograph image.

3.2.15 In vitro Cathepsin B Binding of the Radioconjugates
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To the PC-3 cells (1 × 106/well) seeded in 6-well plates was added the radioconjugates
(0.74 MBq, 20 µCi) in 1 mL of cell culture medium. The cells were incubated at 37 °C for
24 h and the medium was removed followed by washing with PBS (3 × 1 mL). The cells
(~3 × 106) were trypsinized and combined in microcentrifuge. The RIPA buffer (80 µL)
containing Halttm protease inhibitor (Thermo Fisher Scientific, U.S.) (100 ×, 0.8 µL) was
added to the cell pellet and vigorously vortexed for 1 min. The suspension was
incubated on ice for 15 min and centrifuged to remove the pellet. The supernatant (80 µL)
was equally divided into two portions. The first portion (40 µL) was directly analyzed by
centrifuged with Pierce™ protein concentrators (MWCO = 10kDa) to separate the low
molecular weight radioactivity. The radioactivity in each fraction was quantified using a
gamma counter to calculate the percentage of the cysteine proteases trapped
radioconjugate in the total counts. On the other hand, 32 µL of the cell lysate was mixed
with Tris-Glycine SDS sample buffer (2×) (40 µL) and NuPAGE® Sample Reducing Agent
(10X) (8 µL). The mixtures were incubated on ice for another 15 min and then reduced at
85 °C for 2 min. 30 µL of the mixture was separated by NovexTM 16% tris-glycine gel. The
autoradiograph of the SDS-PAGE gel was performed according to the same method as
described above.
Similarly, the radioconjugates (0.74 MBq, 20 µCi) was added to PC-3 cells (1 ×
106/well) seeded in 6-well plates with 1 mL of cell culture medium. After 4h incubation
at 37 °C, the medium was removed, and the plates were washed with PBS (3 × 1 mL).
Fresh 1 mL cultural medium was added to each well and the plate were returned to
incubate for another 2, 4 and 24h. In the end of incubation, the cells were wash with PBS
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(3 × 1 mL) and trypsinized. Cells lysate was prepared by using 80 µL RIPA buffer
containing 1% protease inhibitor on ice for 15min followed by vigorously vortex. The
mixtures were analysis by the same method described above to generate
autoradiography.
For blocking studies, the preparation of PC-3 cells seeded plate was the same as
described above. The radioconjugates (0.74 MBq, 20 µCi) was added to each well with
the presence of excessive unlabeled corresponding analogues (40µM, 100µL). The cells
were incubated at 37 °C for 4 h and prepared by the same method as described above for
autoradiography.

3.2.16 Confocal Microscopy of Europium (Eu)-Labelled Conjugates
PC-3 cells (3000/well) were seeded in Lab-Tek chambered borosilicate coverglass
disks (8 well) for overnight. Meanwhile, EuCl3.6H2O (13.5 µg) was added to the 100 µL
peptide (25 µg) aqueous solution and the mixture was stirred overnight at room
temperature. The completion of reaction was monitored by HPLC-MS and purified by
using 3M EmporeTM C18 cartridge. The elution was dried with nitrogen flow and
redissolved by growth medium of PC-3 cells. PC-3 cells were washed by PBS (3 × 0.5
mL), 100 µL of the Eu-labeled conjugate was added. Additionally, 100 µL LysoTracker®
Green (150 nM) was added to the cells and the mixture was incubated for 2h. The cells
then left to efflux for 4 and 24h, washed with PBS (500 µL) and fixed with formaldehyde
(500 µL) prior to imaging. The imaging was obtained by collecting far red color
wavelengths (405 nm excitation and 615 nm emission for Eu) and green color
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wavelengths (488 nm excitation and 511 nm emission for LysoTracker® Green). ImageJ
was used for the quantifying the fluorescence intensity of Eu and the co-localization
efficiency. Mean pixel intensities were normalized by the total cell number per image.

3.2.17 Biodistribution Study
Male SCID mice (6 weeks of age) received subcutaneous injections of 100 µL PC-3
cells (5 × 106) suspended in Matrigel® into the flanks. When the tumor diameter reached
50 mm, the mice were randomized into three groups and intravenously injected with 10
µCi (0.37 MBq) of the purified

177

Lu labeled conjugates via tail vein. The mice were

sacrificed and the tissues were excised at 4, 24, and 72h post-injection time points. The
blood, tumor, and excised tissues were weighed. The radioactivity for each sample was
measured using a

-counter. The percentage injected dose per gram (%ID/g) and the

radioactivity ratios between tumor and non-targeted tissues were calculated.

3.2.18 In vivo Adducts Formation of the Radioconjugates with Cathepsin B
The radioconjugates (800 µCi/mouse) were intravenously injected into PC-3 tumor
bearing mice. The mice were sacrificed and the tumor, pancreas, liver, and kidney were
excised at 24h post-injection time points. The tumor and organs were homogenized in
RIPA buffer (50 mg / 100 µL) containing Halttm protease inhibitor (100 ×, 1 µL) on ice and
centrifuged to remove the pellet. An aliquot (18 µL) of the supernatant of the sample at
24h was mixed with Novex Tris-Glycine SDS sample buffer (2×, 20 µL) and NuPAGE®
Sample Reducing Agent (10X) (2 µL). The mixture was heated at 85 °C for 2min. The
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cooled mixtures (20 µL) were loaded onto a NovexTM 16% tris-glycine gel and run at 110
V for 90 min. The autoradiograph of the SDS-PAGE was performed as described above.

3.2.19 SPECT/CT Imaging Study
1 mCi (37 MBq) of

177

Lu labeled conjugates was intravenously injected into PC-3

tumor bearing mice. Upon predetermined time point (4h, 24h and 72h post-injection),
mice were anesthetized with isoflurane and their body temperature was controlled using
warm air during scanning. 360 projections over 360° with an x-ray tube current of 140
mA and voltage of 75 kV peak (kVp) at a magni cation of 1.2 ( eld of view = 98.7 mm2)
was used to generate CT images. SPECT images was acquired by 64 projections at 10 s
per projection over 360° using a radius of rotation (ROR) of 79 mm ( eld of view = 98.7
mm2) and reconstructed using Triumph SPECT Reconstruction Application. Coregistration of anatomical CT images and functional SPECT was performed using a
VivoQuant 3.5™ software package (Invicro Boston, MA, USA).

3.3 RESULTS
3.3.1 Synthesis of Endolysosomal Trapped BB2r-Targeted Agents
The structures of the synthesized experimental and control BB2r-targeted analogs are
depicted in Figure 3.1. Basing our CC inhibitor design on E-64, the initial challenge was
to design an E-64 derivative analog, outlined in Scheme 3.1, that could be easily adapted
to be conjugated to the BB2r-targeted constructs using copper(I)-mediated alkyne-azide
cycloaddition. Starting from Fmoc- and Pbf-protected L-arginine, 2-azidoethanamine
was coupled to the carboxylic acid of the amino acid through standard amidation
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conditions. This was followed by standard peptide synthesis procedures to sequentially
add L-leucine and (+/-) trans-oxirane-2,3-dicarboxylic acid derivatives to yield the
desired Pbf-protected, epoxide-based inhibitor 3. Note that use of the ((+/-) transoxirane-2,3-dicarboxylic will result in two diastereomers. While the epoxide group (2S,
3S) in E-64 is stereochemically pure and has been demonstrated to be 7-fold more active
than its enantiomeric analog (2R, 3R) in the E-64 construct

, the overall differential in
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activities were not seen as significant enough to warrant separation for our intended
application. Thus, both diastereomers of 3 were used in the studies outlined below. For
our inactive control 4, succinic acid was utilized in place of the epoxide. With only the
removal of the oxygen, the inactive control (i.e., no CC inhibition/adduct formation) has
high structural similarity to the active inhibitor, 3, and will be utilized in our
experiments as a negative control. The 1H NMR of compound 1-4, 13NMR of compound 3
and 4, and MS spectra of compound 1-4 were showed in Figure 3.2, 3.3, 3.4 and 3.5,
respectively.
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Figure 3.1 Structure of BB2r-targated peptide incorporated with CCs inhibitor and
its matching control.
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Scheme 3.1 Synthesis of the trapping reagent and negative control.

Reagents and condition: (a) 2-azidoethanamine, EDCI, NHS, TEA, r.t., overnight,
92%; (b). 20% piperidine in DMF, 30 min, 73%; (c). Fmoc-Leu-OH, COMU, DIEA, 2h;
(d). 20% piperidine in DMF, 30 min; (e). (+/-)-trans-oxirane-2,3-dicarboxylic acid,
COMU, DIEA, 2h, 57%; (f). 20% piperidine in DMF, 30 min; (g). succinic acid, COMU,
DIEA, 2h, 49%.
a
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A

B

Figure 3.2 A-B) 1H-NMR spectra of compound 1-2.
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A

B

Figure 3.3 A-B) 1H-NMR spectra of compound 3-4.
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A

B

Figure 3.4 A-B) 13C-NMR spectra of compound 3-4.
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A

B

C

D

Figure 3.5 A-D). Mass spectrometry of compound 1-4.
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The alkyne containing agonist and antagonist BB2r-targed peptides were constructed
using standard SPPS approaches to yield the protected peptides 5 and 6, respectively.
Copper(I) mediated cycloaddition of the inhibitor (3) or control (4) was carried out with
each of the peptides to form the four conjugates, see Figure 3.1 and Scheme 3.2. The
DOTA-NHS ester was conjugated to the N-terminus of the peptide; followed by
deprotection using 90% TFA to yield the desired conjugates. For clarity, we define the
nomenclature of these conjugates as follows: BB2r-targted agonist (AG), BB2r-targted
antagonist (AN), active inhibitor (E) and inactive inhibitor (C). Following this
nomenclature yields the following BB2r-targeted agonists, E-AG and C-AG, and
antagonists, E-AN and C-AN. These conjugates were readily labeled with

177

LuCl3 at

90°C for 20min in a 0.5 M sodium acetate (pH = 5.5) to achieve a radiolabeling efficiency
that ranged from 71.5% to 84.0% (Figure 3.6). To establish the stability of the epoxide in
the E-AG and E-AN conjugates, studies were conducted on the unlabeled conjugates
under these labeling conditions and examined by LC-MS. No significant degradation of
the epoxide was observed. Additionally, the serum stability of the

177

Lu-labeled

conjugates was examined over 24h using radio-HPLC, Figure 3.7, and all were found to
be stable. HPLC purification condition, retention time and synthetic/radiochemical
yields of the conjugates and radioconjugates are listed in Table 3.1.
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Schemes 3.2 Synthesis of cystine cathepsin inhibitor-BB2r peptide conjugates with matching controls
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Figure 3.6 Radio-HPLC profile of solution of

Lu-labeling of BN conjugates with

177

radiolabeling efficiency (RE). The purifications were carried by an analytical Proteo
C12 HPLC column with a 20 min gradient (20%-35% ACN in water containing 0.1
formic acid) and a flow rate of 1.5 mL/min to give the target compounds.
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Figure 3.7 Stability study of E-AG, C-AG, E-AN and C-AN in the presence of human
serum.
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Table 3.1 HPLC purification condition and mass information of compounds E-AG, C-AG, E-AN and C-AN.
Entity

HPLC purification condition

DOTA-SP714

MW (m/z,[M +H]+)

Retention time(min)

Yields (%)e

Calcdd

Foundd

80%-70% ACN in water a

2008.0

2008.6

8.8

26.6

E-AG

90%-65% ACN in water b

2138.1

2138.0

11.0

13.4

C-AG

90%-65% ACN in water b

2124.1

2124.4

11.8

15.2

E-AN

80%-70% ACN in water c

2311.2

2131.2

9.3

12.9

C-AN

80%-70% ACN in water c

2297.2

2297.3

8.5

13.3

a. The eluent contained 0.1% formic acid and was with 16 min gradient.
b. The eluent contained 0.1% formic acid and was with 15 min gradient.
c. The eluent contained 0.1% formic acid and was with 15 min gradient.
d. The mass was calculated and determined by low resolution mass spectrometry (LRMS)
e. Total yields of the SPPS for compounds.
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3.3.2 Competitive Cell-Binding and Distribution Coefficient Studies
Using the BB2r-positive human prostate cancer PC-3 cell line, the BB2r binding
affinity of the conjugates were evaluated. In these studies, SP714 (DOTA-(D-Ser)5-PEG3Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2), the compound used in Chapter 2, was used as
the competitive ligand. All unlabeled analogues demonstrated nanomolar binding
affinities, Table 3.2, with IC50 values of 17.8 ± 3.8, 16.5 ± 3.3, 19.8 ± 3.0, and 23.5 ± 3.6 nM
for E-AG, C-AG, E-AN and C-AN, respectively. These results suggest negligible impact
of the active or inactive inhibitors on the BB2r binding efficacy of the conjugates. Using
radiometric analysis, the distribution coefficient (LogD7.4) of the radioconjugates were
evaluated. All of the radiolabeled analogs demonstrated suitable hydrophilicity with
values ranging from -3.4 ± 0.1 to -1.9 ± 0.1 (Table 3.2). As expected, the antagonistic
analogs gave significantly higher logD7.4 due to a relatively higher hydrophobic
character.
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Table 3.2 Characterization, BB2r binding affinity and Cathepsin B inhibition activity of
conjugates.

Analogue

Molecular

LogD
a

BB2r
IC50/nMb

Cst B inhibition IC50
(nM)

c

Cst B inhibition Ki
(nM)c

Formula

(pH=7.4)

E-AG

C94H148N28O28S

-3.13 ± 0.03

17.76 ± 3.79

25.85 ± 4.20

146.48 ± 7.98

C-AG

C93H150N28O27S

-3.35 ± 0.09

16.45 ± 3.28

>1000e

-

E-AN

C103H159N29O29S

-2.31 ± 0.18

19.79 ± 2.95

30.65 ± 5.92

140.99 ± 26.39

C-AN

C103H161N29O28S

-1.90 ± 0.14

23.52 ± 3.61

>1000e

-

a. The Log D values were obtained as for the 177Lu-labelled forms of conjugates. Values
represent mean ± SD (n=3)
b. Values represent mean ± SD (n=3)
c. No inhibition was observed in the test range
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3.3.3 Cathepsin B Inhibition
To assess the activity of the CC inhibitors incorporated into the BB2r-targeted agents,
the inhibitory potency of the conjugates against cysteine cathepsin B (CatB) was
examined. The IC50 values for all of the conjugates are provided in Table 3.2. The
inhibition constants (Ki) for E-AG and E-AN, based on the generated rate curves shown
in Figure 3.8, are also given in Table 3.2. Analogs containing the active inhibitor, E-AG
and E-AN, gave nM IC50 values for the inhibition of CatB, while those analogs
containing the inactive control inhibitor had no inhibition of the protease over the
concentrations investigated. The determined Ki values for E-AG and E-AN were
statistically identical, but were approximately 9 fold higher than the 15 ± 1 nM inhibition
value (data not shown) obtained for the active inhibitor 3 (no peptide attached, Pbf
group removed). The results demonstrate that the attached peptides can negatively
impact the potency of the inhibitor, but overall the influence of the peptide on the
conjugates is relatively modest and should not significantly impact our intended
application.

114

16000

25 M

14000

50 M

12000

100 M

10000

200 M

B

1000 M

8000

1500

Velocity (RFU/min)

Fluorecent Intensity

A

6000
4000
2000

1000
Km=241.9

500

0

0
0

C

2

4

6

8

10

Time (min)

0

D

50mM
100mM

15000

200mM
1000mM

10000

200

300

400

500

concentration of substrate ( M)

5000

1000
Kobs=283.4

3.7

500
Ki=146.5

8.0

0

0
0

2

4

6

8

100mM
200mM
1000mM

2000

400

600

800

1000

500

Velocity (RFU/min)

50mM

200

concentration of substrate ( M)

F

25mM

4000

0

10

Time (min)
6000

Fluorecent Intensity

100

1500

25mM

Velocity (RFU/min)

Fluorecent Intensity

20000

E

11.9

400
300
Kobs=285.3

200
100

Ki=141.0

5.8

26.4

0

0
0

2

4

6

Time (min)

8

10

0

200

400

600

800

1000

concentration of substrate ( M)

Figure 3.8 Determination of the Km and Ki of cathepsin B (human Liver) to the
substrate Z-Arg-Arg-AMC. A), C) and E) Time course of substrate hydrolysis of
cathepsin B alone, and in the presence of E-AG and E-AN respectively. B), D) and F)
The nonlinear regression of reaction rate (t = 0 - 10 min) versus the concentration of
Z-Arg-Arg-AMC in the presence of cathepsin B alone, E-AG and E-AN respectively.
The conjugate concentration was 25 nM. The Ki was calculated from the equation
Kobs = Km (1 + [C]/Ki). All measurements were in triplicate.
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3.3.4 In Vitro Internalization and Efflux Studies
The internalization and efflux profiles of the four

177

Lu-labeled conjugates were

examined using the PC-3 cell line, Figure 2. As expected, the internalization rate of the
two

agonistic

conjugates,

13.5%

to

13.2%

for

177

Lu-E-AG

and

177

Lu-C-AG,

correspondingly, far outpaced the antagonistic analogs, 1.7% to 1.8% for 177Lu-E-AN and
Lu-C-AN, by the 4h time point. The percentage of surface bound radioactivity for the

177

two antagonists was nearly two-fold higher than the corresponding internalized signal
demonstrating that the RM2 based antagonists do not efficiently, relative to the agonists,
induce receptor-mediated internalization. Efflux of the internalized radioactivity over
24h demonstrated that analogs containing the active inhibitor exhibited a higher
retention efficacy compared to the radioconjugates containing the inactive control
inhibitor. By the 24h time point, 38.8% of 177Lu-E-AG has effluxed comparing to 54.3% of
C-AG in vitro (p<0.01).
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Figure 3.9 Internalization assay depicted as percentage of internalized and surface
bond activity of 177Lu-labled conjugates in PC-3 cells. Values are mean ± SD (n=3).
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3.3.5 In Vitro Adduct Studies
Using autoradiographic SDS-PAGE, the ability of the radioconjugates to form
adducts with CatB and in live PC-3 cells was established, Figure 3.10. Incubation of the
177

Lu-labeled conjugates containing active inhibitors,

177

Lu-E-AG and

177

Lu-E-AN, with

CatB (human liver) for 2h, Figure 3.10A, produced bands with molecular weight of ~ 27
kDa, which correspond to the heavy chain of CatB. Co-incubation with CA-074, a wellknown, commercial CC inhibitor that inhibits the active site of CC completely abolishes
the ability of

Lu-E-AG and

177

177

Lu-E-AN to form adducts, indicating that these adducts

bind to the active site of CatB.
After confirmation of CatB adduct formation, all four radioconjugates were
incubated with PC-3 cells for 24h. At the end of that time, the cells were washed with
fresh media, lysed and evaluated by centrifugal filtration and SDS-PAGE. In Figure
3.10B, the SDS-PAGE of the cell lysate demonstrated that those analogs capable of CC
adduct formation,

177

Lu-E-AG and

177

Lu-E-AN, gave adduct bands, while those

radioconjugates with the inactive control inhibitor, 177Lu-C-AG and 177Lu-C-AN, showed
no signs of adduct formation.
To examine the role of BB2r-mediated internalization on adduct formation, a parallel
study to the one above was conducted by incubating PC-3 cells with

177

Lu-E-AG and

Lu-E-AN in the presence or absence of an appropriate BB2r blocking agent. The results,

177

Figure 3.10C, clearly demonstrate that adduct formation of the radioconjugates is
abolished when a blocking agent is added. This strongly implies that receptor-mediated
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internalization is primarily responsible for cellular adduct formation for both the
agonistic and antagonistic radioconjugates. Lastly, in Figure 3.10D, the time-dependent
cellular retention of 177Lu-E-AG and 177Lu-E-AN was investigated by incubation with PC3 cells for 2h, followed by washing and lysis at the desired timepoint.

177

Lu-E-AG

demonstrated strong and similar adduct formation bands at 2 and 4h modestly
decreased by 24h. Interestingly, 177Lu-E-AN gave its weakest bands at 2h; however, these
bands progressively strengthened over the 24h time course. This finding may be
attributed to surface bounds antagonist slowly internalizing and trapping in the
endolysosomal compartments over time.
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Figure 3.10 The autoradiography of the SDS-PAGE demonstrated that A) the binding
of conjugates with cathepsin B can be completely inhibited by cysteine proteases
inhibitor CA-074; B) the intracellular adducts formation can be observed when E-64conjugated BBN-peptide incubated with PC-3 cells, while control compounds cannot.
(177Lu-E-AG/E-AN was incubated with purified CatB serving as reference); C) the
intracellular adducts formation can be blocked after co-incubation with excessive
unlabeled E-AG and E-AN, respectively; D) there was a time-dependent retention of
cathepsin B-conjugates adducts in PC-3 cells after pre-incubation with radiolabeled
compounds for 4h.
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3.3.6 Cellular Trafficking Using Confocal Microscopy
To further evaluate the cellular trafficking of the conjugates, E-AG and C-AG were
labeled with EuCl3•6H2O, incubated with PC-3 cells and imaged by confocal microscopy,
Figure 3.11A. The Eu-labeled conjugates demonstrated robust signal (red) after 2h of
incubation. Examination of the efflux profiles at the 4 and 24h time points, Figure 3.11A
and 3.11B, showed that the mean fluorescent intensity per cell for Eu-E-AG remained
1.3- and 1.8-fold higher, respectively, relative to the control Eu-C-AG. Using
LysotrackerTM

(green)

to

identify

endolysosomal

compartments,

the

residence/colocalization of the Eu-labeled conjugates in these compartments was
quantified, Figure 3.11A and 3.11C. As expected, co-registration of Eu-E-AG and Eu-CAG signals with the LysotrackerTM was similar at the 0 and 4h time points, indicating
that roughly equal and increasing amounts of the two Eu-labeled conjugates are being
trafficked to the endolysosomal compartments. However, by 24h, the signal
corresponding to Eu-E-AG was at a maximum, with 93% of the signal corresponding to
the CC-rich, endolysosomal compartments, while the Eu-C-AG reduced significantly
from 91% at 4h to 70% at 24h suggesting that the conjugate/metabolites are leaving the
endolysosomal compartments and being trafficked elsewhere in the cell.
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Figure 3.11 A) The representative confocal microscopy images of PC-3 cells pre-incubated
for 4h with Europium-labeled compounds with BBN agonist backbone. Scale bar: 20 µm. B)
Time-dependent fluorescence intensity of Eu per cell as quantified from images. C) Cocolocalization efficiency of Eu(red) and Lysotracker(green). All analysis was performed in
more than 5 random images and were demonstrated as mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.001.
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3.3.7 Biodistribution Studies
The in vivo biodistribution studies of 177Lu-E-AG, 177Lu-C-AG, 177Lu-E-AN and 177LuC-AN were investigated in PC-3 tumor-bearing SCID mice, Table 3.3. All of the
conjugates demonstrated rapid blood and muscle clearance by 4h, primarily through the
renal clearance pathway. As a consequence, the kidneys were the site of the highest nontarget, non-BB2r-mediated uptake. The initial renal uptake for

177

Lu-E-AG and

177

Lu-E-

AN was 10.44 ± 3.25 and 7.37 ± 0.92 %ID/g, respectively. This was higher than the
matching control analogs,

177

Lu-C-AG and 177Lu-C-AN, which had corresponding initial

uptake values of 5.93 ± 2.05 (p<0.05) and 5.43 ± 1.74 (p<0.05) %ID/g. The renal clearance
profile of 177Lu-E-AG and 177Lu-E-AN at 24 and 72h time points was substantially slower
than the control analogs. At the 72h time point,

Lu-E-AG showed significant higher

177

retention, 68.0% of the 4h uptake value (p=0.05), compared to 177Lu-C-AG with 18.4% of
the 4h uptake (p<0.01). Similar findings were seen with the antagonists. 177Lu-E-AN and
Lu-C-AN retained 49.9 (p=0.01) and 13.1% (p<0.01), respectively, of the initial uptake at

177

72h. This renal retention is almost certainly due to the well-known uptake mechanisms
of the kidney

, which are leading to endolysosomal trapping, and thus higher

216

retention, in the renal proximal tubule.
It is well-established that both the mouse and human pancreas are BB2r-positive
tissue

. Thus, in our biodistribution the BB2r-targeting capabilities of our analogs

4, 86, 193

can be evaluated using both the PC-3 tumor xenograft and the endogenous mouse
pancreas. At the 4h time point, the tumor uptake of

177

Lu-E-AG and

177

Lu-C-AG were
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not significant different with values of 3.28 ± 1.10 and 2.86 ± 0.39 %ID/g, respectively.
However, by the 24h time point, retention of the initial uptake for 177Lu-E-AG was 89.9%
(P>0.05), while the

Lu-C-AG decreased significantly to 64.3% (P<0.01). At 72h post-

177

injection, 62.8% (2.06 ± 0.16 %ID/g) of the original uptake for
(P>0.05), whereas

177

Lu-E-AG was retained

177

Lu-C-AG exhibited only 32.9% (0.94 ± 0.14 %ID/g) retention

(p<0.0001). Similar retention profiles for these two radioconjugates were observed in the
BB2r-postive mouse pancreas. Initial pancreas uptake values were 36.46 ± 11.66 %ID/g
and 41.20 ± 18.39 %ID/g for

Lu-E-AG and

177

177

Lu-C-AG, respectively. By 72h, the

retention of the initial uptake was 72.2% (26.32 ± 1.53 %ID/g) (P>0.05) and 42.7% (17.60 ±
0.43) (p=0.04).
For the antagonists, initial PC-3 tumor uptake was substantially higher than the
agonists with statistically identical uptake values of 11.88 ± 1.68 and 13.13 ± 2.93 %ID/g
for
of

177

177

Lu-E-AN and 177Lu-C-AN, respectively. By 24 h post-injection, the tumor retention

Lu-E-AN was 53.2% (6.32 ± 0.55%ID/g) (p=0.0008), while

(3.79 ± 0.48%ID/g) (p=0.0008). At 72h,

177

Lu-E-AN and

177

Lu-C-AN was 28.9%

Lu-C-AN had retention values

177

of 31.9% (3.79 ± 0.73 %ID/g) (p<0.0001) and 14.7% (1.94 ± 0.46 %ID/g) of the initial uptake
(p=0.0003). The significantly higher retention of the active endolysosomal trapping
antagonist,

177

Lu-E-AN, clearly demonstrates that this approach can improve the

retention of RM2 based BB2r-antagonistic targeting vectors. However, the retention
values for the antagonists were substantially lower than the agonists at similar time
points, suggesting that reduced internalization rate of the antagonists reduces overall
trapping efficiency. Pancreatic uptake of the BB2r-targeted antagonists was minimal at
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the 4h time point due to the well-known clearance of these targeting vectors from the
pancreas 86, 217.
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Table 3.3 Biodistribution Studies in PC-3 Tumor–Bearing SCID Mice.
Tissue (%ID/g) *

4h

24h
177

72h

4h

Lu-E-AG

24h
177

72h

Lu-C-AG

blood

0.07 ± 0.07

0.02 ± 0.02

0.01± 0.02

0.02 ± 0.02

0.03 ± 0.04

0.01 ± 0.01

heart

0.03 ± 0.03

0.12 ± 0.16

0.06 ± 0.06

0.16 ± 0.17

0.12 ± 0.17

0.06 ± 0.10

lung

0.10 ± 0.01

0.08 ± 0.14

0.15 ± 0.11

0.04 ± 0.03

0.20 ± 0.04

0.03 ± 0.04

liver

0.44 ± 0.16

0.46 ± 0.13

0.42 ± 0.09

0.22 ± 0.05

0.18 ± 0.06

0.10 ± 0.04

pancreas

41 ± 12

34 ± 5

26.3 ± 1.5

41 ± 18

31 ± 6

17.6 ± 0.4

stomach

0.9 ± 0.5

0.4 ± 0.2

0.40 ± 0.06

0.47 ± 0.11

0.33 ± 0.02

0.10 ± 0.03

0.017 ± 0.003

0.04 ± 0.04

0.03 ± 0.01

0.05 ± 0.05

0.03 ± 0.03

0.10 ± 0.03

small intestine

1.9 ± 0.7

1.73 ± 0.08

1.13 ± 0.17

2.1 ± 0.4

0.86 ± 0.18

0.40 ± 0.05

large intestine

5.0 ± 1.1

1.8 ± 0.2

0.6 ± 0.2

5±3

1.2 ± 0.4

0.49 ± 0.15

10 ± 3

10 ± 3

7.1 ± 0.9

6±2

3.8 ± 1.4

1.09 ± 0.10

spleen

†

kidney
tumor

3.3 ± 1.1

3.0 ± 0.4

2.06 ± 0.16

2.9 ± 0.4

1.8 ± 0.3

0.94 ± 0.14

muscle

0.04 ± 0.06

0.02 ± 0.02

0.06 ± 0.06

0.06± 0.06

0.03 ± 0.05

0.02 ± 0.02

0.4 ± 0.3

0.5 ± 0.2

0.28 ± 0.09

0.01± 0.01

0.03 ± 0.05

0.08 ± 0.08

0.03 ± 0.01

0.03 ± 0.04

0.01 ± 0.01

0.01 ± 0.01

0.13 ± 0.09

0.0009 ± 0.0002

78 ± 4

84 ± 2

87.6 ± 1.2

81 ± 4

90.4 ± 1.7

93.6 ± 0.6

bone
brain
excretion

†

177

blood

Lu-E-AN

177

0.01 ± 0.01

0.04 ± 0.03

0.02 ± 0.02

Lu-C-AN

0.2 ± 0.2

0.02 ± 0.03

0.007 ± 0.004

heart

0.2 ± 0.2

0.08 ± 0.14

0.01 ± 0.01

0.6 ± 0.6

0.23 ± 0.07

0.23 ± 0.18

lung

0.5 ± 0.3

0.8 ± 0.4

0.4 ± 0.5

0.6 ± 0.3

0.9 ± 1.6

0.3 ± 0.3

liver

0.55 ± 0.07

0.66 ± 0.12

0.4 ± 0.2

0.63 ± 0.18

0.26 ± 0.14

0.22 ± 0.05

pancreas

1.1 ± 0.3

0.7 ± 0.5

0.5 ± 0.2

1.5 ± 1.0

0.4 ± 0.4

0.10 ± 0.09

stomach

0.41 ± 0.19

0.11 ± 0.06

0.02 ± 0.03

0.5 ± 0.4

0.03 ± 0.03

0.02 ± 0.03

spleen†

0.01 ± 0.02

0.02 ± 0.02

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.02

0.01 ± 0.01

small intestine

0.26 ± 0.13

0.13 ± 0.02

0.05 ± 0.03

0.26 ± 0.09

0.08 ± 0.03

0.02 ± 0.02

large intestine

0.62 ± 0.14

0.09 ± 0.03

0.06 ± 0.01

0.78 ± 0.19

0.15 ± 0.08

0.04 ± 0.04

kidney

7.4 ± 0.9

6.7 ± 1.4

3.7 ± 1.8

5.4 ± 1.7

1.6 ± 0.4

0.7 ± 0.2

tumor

11.9 ± 1.7

6.3 ± 0.6

3.8 ± 0.7

13 ± 3

3.8 ± 0.5

1.9 ± 0.5

muscle

0.15 ± 0.14

0.21 ± 0.18

0.15 ± 0.17

0.13 ± 0.13

0.2 ± 0.4

0.03 ± 0.03

bone

0.21 ± 0.16

0.6 ± 0.2

0.2 ± 0.3

0.6 ± 0.3

0.5 ± 0.9

0.07 ± 0.07

0.09 ± 0.05

0.05 ± 0.06

0.01 ± 0.01

0.06 ± 0.05

0.01 ± 0.02

0.2 ± 0.3

86 ± 2

92.4 ± 1.5

93 ± 4

83 ± 4

95.5 ± 1.5

98.0 ± 0.7

brain
excretion

†

*. Organ uptake values expressed as %ID/g and values are n 4 unless otherwise noted.
†. Excretion values (%ID) were calculated using the activity values associated with the
spleen, excreted urine and fecal material contents at the time of sacrifice.
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3.3.8 SPECT/CT Imaging
Based on the biodistribution studies, the antagonistic analogs,

177

Lu-E-AN and 177Lu-

C-AN, with their higher tumor uptake were chosen to be evaluated by SPECT/CT
imaging. These longitudinal imaging studies, Figure 3.12, were conducted in PC-3
bearing mice at 4, 24 and 72h time points. For each time point, the SPECT/CT images for
both conjugates were set on the same intensity scale. At 4h post-administration,
significant uptake was observed in the PC-3 tumors and kidney uptake for both
radioconjugates. After 24h, reductions were seen in both kidney and tumor retention. By
72h,

177

Lu-E-AN demonstrated substantially higher retention in the PC-3 tumors

compared to

177

Lu-C-AN. However, the

lower renal retention compared to

177

177

Lu-C-AN exhibited, as expected, noticeably

Lu-E-AN. Overall, the SPECT/CT imaging studies

correlated well with the previous biodistribution studies.
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Figure 3.12 Fused micro-SPECT/CT images of 177Lu-C-AN and 177Lu-E-AN in PC-3 tumor–
bearing mice at 4, 24 and 72 h after injection. Tumors and kidneys are indicated by red and
green arrows, respectively.
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3.3.9 Ex Vivo Adduct Studies
To confirm the in vivo formation of high molecular weight adducts, all four
radioconjugates were administered to PC-3 tumor bearing mice and the tumor, pancreas,
liver and kidney were excised at 24h post-injection. These tissues were lysed and
subjected to SDS-PAGE, see Figure 3.13. Unsurprisingly, the controls analogs,
AG and

177

Lu-C-

Lu-C-AN, demonstrated no bands associated with adduct formation.

177

However, both of the active endolysosomal trapping analogs,

177

Lu-E-AG and

177

Lu-E-

AN, revealed adduct formation that ranged roughly from 20-32 kDa in molecular weight,
but, interestingly, the intensities of these bands were tissues-dependent. For the 177Lu-EAG, strong signal was observed in the tumor, pancreas and kidneys. The tumor and
kidney bands were similar with the highest intensity observed at approximately 30 kDa,
whereas the highest band for the pancreas was around 25 kDa. In the case of 177Lu-E-AN,
no bands were seen in the pancreas, but were readily visualized in the tumor and kidney
lysates and weakly in lysates of the liver. The overall profile of the bands observed in the
tumor and kidney for 177Lu-E-AN were similar to the agonist.
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Figure 3.13 The autoradiography of SDS-PAGE of the lysate from tumor, liver, pancreas and
kidney at A) 24h post-injection of 177Lu-E-AG and -C-AG; B) 24h post-injection of 177Lu-EAN and -C-AN in PC-3 tumor bearing mice.
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3.4 DISCUSSION
The development of diagnostic and therapeutic BB2r-targeted radiopharmaceuticals
continues to be explored for a variety of cancer

. Initial development focused on

23, 218

agonistic analogs due to the belief that internalization was key to long-term tumor
retention. However, this perception has been challenged with the success of recently
developed antagonists

84, 219

. Exceptional work by the groups of Maecke and others have

identified antagonistic analogs that have substantially higher tumor uptake and similar
retention profiles compared to agonistic analogs

86-87, 90-91, 220-221

. Speculatively, the higher

tumor uptake may be attributable to the ability of antagonists to bind to BB2 receptors
that are G-protein bound and unbound, whereas agonists are limited to G-protein
bound receptors

89, 220

. If so, the BB2r-targeted antagonists have a much larger receptor

population to target accounting for their higher initial tumor uptake. Even though many
BB2r-antagonists have demonstrated some level of internalization, the higher than
expected retention profiles for the antagonists has been attributed to factors such as
lower disassociation constant (koff) and an increase in metabolic stability relative to
agonists 90-92.
Despite the success of BB2r- and other receptor-targeted agents, the inherently
higher diffusion and metabolic rates of low-molecular weight agents leads to rapid
tumor clearance, which diminishes the effectiveness of the diagnostic and/or therapeutic
agent. To address this challenge, our laboratory has recently begun exploring the use of
CC inhibitors to enhance the long-term retention of receptor-targeted agents

115

.
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Mechanistically, we have demonstrated that these inhibitors are able to form adducts
within

the

CC-rich,

endolysosomal

compartments

after

receptor-mediated

internalization. To continue studying this trapping-technique, we synthesized agonistic
and antagonistic BB2r-targeted analogs with the expectation of demonstrating that the
agonist preferentially benefited from our endolysosomal trapping approach given the
efficient internalization of this targeting vector. To our surprise, this turned out not to be
the case with both agonistic and antagonistic analogs demonstrating substantially higher
long-term tumor retention. Below, we discuss how our results shed light not only on the
general applicability of our endolysosomal trapping approach with BB2r-targeted agents,
but also question previous assumptions that BB2r-targeted antagonists are not,
eventually, internalized. These findings may help explain the longer than expected
retention profile of this class of agent.
Incorporation of the CC inhibitor and inactive control into the structure of the BB2rtargeted agonist and antagonist was carried out without difficulty. Labeling (177Lu or Eu)
of the epoxide containing conjugates was accomplished, even at elevated temperatures,
without degradation. Though, at elevated temperatures utilization of an ammonium
acetate buffer instead of a sodium acetate buffer did results in degradation (data not
shown), likely due to ring opening from nucleophilic attack by ammonia. Serum
stability studies demonstrated that the analogs were stable over a 24h period with no
significant degradation observed. The CatB inhibition and the competitive BB2r-binding
studies indicated that the peptides do not substantially impact the irreversible inhibition
of CatB and, vice versa, the inhibitor does not negatively impact BB2r-affinity.
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As expected, internalization of the agonists,

177

Lu-E-AG and

rapidly and was more efficient relative to the antagonists,

177

177

Lu-C-AG, proceeded

Lu-E-AN and

177

Lu-C-AN.

The surface-bound activity for the antagonists were approximately 2-fold higher than
the internalization, which is consistent with literature

86-87, 217

. Both the agonistic and

antagonistic radioconjugates containing the active CC inhibitor showed significantly
higher retention in the efflux studies, speculatively due to endolysosomal trapping upon
internalization. Using confocal microscopy, both the agonistic and antagonistic Eulabeled

conjugates

demonstrated

receptor-mediated

internalization

into

the

endolysosomal compartments of the cell. Over the course of 24h, Eu-E-AG revealed
significantly higher retention in the cells relative to Eu-C-AG. In addition, examination
of the colocalization with Lysotracker™ revealed a substantially higher tendency of EuE-AG to be retained in the CC-rich, endolysosomal compartments of the cell relative to
the control conjugate. These finding are consistent with our premise of adduct formation
with CCs in the endolysosomal compartments of the cell upon receptor-mediated
internalization.
Adduct formation studies were conducted using SDS-PAGE and centrifugal
filtration techniques. The ability of active endolysosomal trapping conjugates to form
adducts with CatB was confirmed by SDS-PAGE, whereas the inactive control
conjugates, as expected, showed no adduct formation. Examination with cell lysates
revealed multiple adduct bands for

Lu-E-AG and

177

Lu-E-AN, with the agonistic

177

demonstrating a higher adduct signal due to a higher rate of internalization over the 24h
timeframe. One of the adduct bands (~ 27 kDa) from the cell lysate studies corresponds
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to CatB (heavy chain only), which is one of, if not the most, abundant CC expressed in
endolysomal compartments of cells

. The band at ~33 kDa may be the immature CatB

222

(single chain form). Previously, applying the same approach, but under different
experimental conditions (i.e., different CC inhibitor, peptide and cell line), we confirmed
by Western blot that the CatB-adducts was the predominant species found in the cellular
lysates

115

. For this particular study; however, we did not unambiguously confirm the

identity of the adducts.
Blocking the BB2r with excess unlabeled agonist and antagonist prevented the active
endolysosomal trapping conjugates from forming CC adducts. This confirms that
adduct formation was dependent upon BB2r-mediated internalization. To examine the
time-dependence of adduct formation (Figure 3.10D), the PC-3 cells were exposed to
Lu-E-AG and

177

177

Lu-E-AN for 4h, washed to remove extracellular activity and lysed at

2, 4 and 24h. The agonist demonstrated the largest amount of adducts early on (2 and
4h), but the adduct signal diminished significantly by 24h. This results are similar to
results obtained from our previously work related to utilization of endolysosomal
trapping agents with NTR1-targeted agonist 115. We attributed this decline for the agonist
to the protein turnover (degradation) of CCs and the resulting adducts, in the
endolysosomal compartments. Interestingly, the concentration of adducts for 177Lu-E-AN
increased over the 24h time period. This is almost certainly due to a steady rate of
internalization of the surface bound radioactivity. Maecke and co-workers hypothesized
that this antagonistic targeting vector may undergo slow internalization

. Our

223-224

results lend further credence to this postulation and suggests that this particular
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antagonistic targeting vector may be better thought of as slow internalizing instead of
non-internalizing. How far these observations may be extended to other BB2r-targeted
peptides, and in general, to other receptor-targeted constructs, remains uncertain.
Though, utilization of this endolysosomal trapping approach may serve as an ideal and
convenient technique to better examine the internalization profile of a wide variety of
receptor-targeted agents.
The biodistribution studies verified that all radioconjugates, including those
containing the active CC inhibitor, provided good blood and muscle clearance data
demonstrating that the utilized CC is stable in vivo, at least over the timeframe
employed here. Initial PC-3 tumor uptake for the RM2 based antagonists were
approximately 3-4-fold higher than the agonists, which is consistent with other reports 84,
. For both the agonist and antagonistic targeting vectors, employing active

88, 225

endolysosomal trapping agents led to significantly higher levels of retention relative to
analogous controls.

177

Lu-E-AG demonstrated a 1.4- and 2.0-fold increase in tumor

retention at 24 and 72h. relative to

177

Lu-C-AG. It could be argued that endolysosomal

trapping approach had the most significant benefit for the antagonist. Relative to
C-AN,

177

177

Lu-

Lu-E-AN had PC-3 tumor retention value that were 1.8- and 2.2-fold greater at

24 and 72h, respectively. Ex vivo examination of the PC-3 tumors by centrifugal
centrifugation at 24 h post-administration revealed that for both 177Lu-E-AG and 177Lu-EAN greater than 70% of the radioactivity was associated with macromolecules (data not
shown). SDS-PAGE demonstrated that in vivo tumor adducts formation profile for both
active endolysosomal trapping radioconjugates were identical. It should be pointed out,
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that many cancers have an increase concentration of CC in their extracellular
environment

104, 226

. Indeed, this increased CC expression has been the impetus for the

development of targeted diagnostic agents

111, 227

. While the contribution of the

extracellular CC to adduct formation cannot be discounted, our in vitro data and the
similar ex vivo SDS-PAGE adduct profiles for the agonist and antagonist would, in our
opinion, argue that internalization was the primary route of in vivo adduct formation in
the tumor.
Non-target uptakes of greater that 40 %ID/g in the BB2r-positive mouse pancreas
was observed for the agonistic analogs 177Lu-C-AG and 177Lu-E-AG. As expected, adduct
formation in the pancreas for

177

Lu-E-AG was confirmed by SDS-PAGE leading to a

significant increase in retention relative to
C-AN and

177

Lu-C-AG by 24h. For the antagonists 177Lu-

Lu-E-AN, pancreas uptake was comparatively negligible by 4h, likely due

177

to the rapid clearance of this construct by this timepoint
corresponding agonist,

177

. Strikingly, unlike the

86, 217

Lu-E-AN demonstrated no signs of adduct formation by SDS-

PAGE. This suggests that, unlike the tumors, the antagonists do not induce
internalization in the mouse pancreas. Speculatively, this contrast with the human cancer
cells may be due to structural/homology differences between the mouse and human
BB2r with regard to binding/activation and/or differences in the basal endocytic activity
between these cell types.
For both the agonist and antagonists, the endolysosomal trapping approach
increased renal retention over the long term. This is almost certainly due to the well-
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known endocytic, reuptake mechanism that is present in the normal kidney

216

. Adduct

formation was observed for the radioconjugates with the active trapping agent, implying
that this reuptake mechanism leads to adduct formation in the endolysosomal
compartments of renal cells, in all probability the proximal tubule cells.

3.5 CONLUSION
In this study, the potential of a CC inhibitor to act as an endolysosomal trapping
agent to improve the tumor retention of BB2r-targeted agents was examined. Specifically,
a hydrophilic CC inhibitor, based on the well-known E-64, was incorporated into both
agonistic (BBN7-14) and antagonistic (RM2) BB2r-targeted constructs. It was found that
incorporation of the CC inhibitor into the pharmacophores did not substantially impact
either the CC inhibition potency of the inhibitor or the BB2r-affinity of the peptide. For
both the agonistic and antagonistic analogs, in vitro studies demonstrated that the CC
inhibitors prompted the formation of CC adducts when internalized into BB2r-positive
PC-3 prostate cancer cells. In vivo studies clearly demonstrated macromolecular adduct
formation and a substantial increase (approximately 2-fold) in tumor residualization for
the CC trapping, BB2r-targeted agents. Overall, this data demonstrates the potential of
the CC endolysosomal trapping approach to improve both agonistic and antagonistic
BB2r-targeted agent development. When appraised in context with our previously
published work concerning CC trapping, NTSR1-targeted agents, this technique, in our
opinion, could have broad applicability to enhance targeted drug development.
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Chapter 4. Synthesis and Evaluation of A Radiolabeled Phosphoramide
Mustard with Selectivity for Hypoxic Cancer Cells 1
4.1 INTRODUCTION
Hypoxia is a well-known characteristic of many solid cancers. This phenomenon is
attributable to the chaotic nature of tumor vasculature, leading to the inefficient delivery of oxygen and other nutrients and resulting in a heterogeneous distribution of
these materials in the tumor 228-229. Tumor hypoxia has been implicated in both drug and
radiation resistance, which has caused treatment failure in numerous cancers

.

230-231

Given this, it is not surprising that many researchers over the years have focused on the
design of prodrugs that aim to exploit tumor hypoxia for di-agnostic and therapeutic
applications 232-235.
Up to now, various hypoxia based diagnostic (e.g., 18F-FMISO) and therapeutic (e.g.,
AQ4N, PR-104 and TH-302) prodrugs have been under development

. The

142, 236-238

hypoxia-selectivity of many of these agents is based on bioreductive mechanisms,
leading to the transformation of these drugs into reactive species in hypoxic tissues

.

138

These reactive species are typically electrophilic metabolites which exhibit increased
retention in hypoxic cells by forming intracellular adducts with opportunistic
nucleophilic biomolecules. For hypoxia-selective diagnostic agents, the in-creased
formation and retention of these adducts in hypoxic tissues allows the generation of
The material presented in this Chapter was previously published: Zhang, W., Fan, W., Zhou, Z.
and Garrison, J., 2017. Synthesis and Evaluation of Radiolabeled Phosphoramide Mustard with
Selectivity for Hypoxic Cancer Cells. ACS medicinal chemistry letters. October 23, 2017; 8 (12), 1269–
1274.
1
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target-to-non-target ratios benefiting to in vivo imaging of hypoxic tissues

. From a

32

therapeutic perspective, hypoxia activated chemo-therapeutic agents typically generate
radicals (e.g., TPZ) or electrophilic mustard agents (e.g., PR-104 and TH-302) that can
induce DNA damage, which ultimately prompts cancer cell death

145, 239-240

. The

advantage of these prodrugs is the increased selectivity and cytotoxicity for hypoxic
tumors relative to normoxic non-target tissues.
Our laboratory is interested in the development of diagnostic and radiotherapeutic
agents that can utilize the hypoxic nature of cancers. Previously, we have found that
when 2-nitroimdazoles, a class of hypoxia-selective pro-drugs, are conjugated to
receptor-targeted peptides, these bioconjugates exhibit increased long-term retention in
hypoxic cells, presumably through adducts formed with intracellular biomolecules

.

32, 241

This initial work has given us the impetus for the continued investigation and
development of other prodrugs that may serve as hypoxia-selective trapping agents
(HSTAs). One of the potential candidates is the 2-nitroimidazole-5-yl-methyl based compound evofosfamide (i.e., TH-302), which is depicted as 2 in Figure 4.1. Evofosfamide is
a hypoxia-activated prodrug that has undergone several phase I/II/III clinical trials for
the treatment of advanced solid cancers, including sarco-mas, and oesophageal
adenocarcinomas

. This prodrug is activated through reduction facilitated by

242-244

cellular reductases (e.g., cytochrome P450) to generate a radical anion. Under hypoxic
conditions, the radical anion is exposed to further reduction, leading to the
fragmentation and generation of an active nitrogen mustard

. The goal of our work is

145

to develop a derivative of evosfosfamide that can be easily conjugated to imaging agents

139

(e.g., fluorophores or radioisotopes) for the in vitro and in vivo detection of hypoxia or
to targeting vectors to enhance the retention of these agents in hypoxic tissues. Herein,
we describe the synthesis of a novel 2-nitroimidazole phosphoramide nitrogen mustard
(2-NIPAM, 3) that is capable of conjugating to other moieties through the well-known
azide-alkyne cycloaddition reaction. Utilizing human prostate cancer PC-3 and DU145
cell lines, we have investigated the cytotoxicity and hypoxia selectivity of this analog
relative to evosfosfamide (2) and a negative control (i.e., non-activatable, 1). In addition,
we optimized the azide-alkyne cycloaddition reaction conditions for 2-NIPAM, radiolabeled the analog with

I and investigated the hypoxia trapping capability of this

125

radiolabeled agent under normoxic and hypoxic conditions. The results obtained from
our investigations have suggested that 2-NIPAM has the potential to serve as a hypoxiaselective imaging agent and/or trapping agent for receptor-targeted constructs.

140

Figure 4.1 Chemical structure of phosphamide mustard negative control 1,
positive control 2 and 2-NIPAM 3.
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4.2 MATERIALS AND METHODS
4.2.1. Reagents and Instruments
All solvents used for reactions and silica gel purification were ACS grade and
purchased from Fisher Scientific, unless otherwise stated. Acetonitrile utilized for HPLC
analysis and purification was HPLC grade and purchased from Fisher Scientific. Water
was deionized by Millipore® Milli Q Biocell Ultrapure Water System before use. TLC
silica gel 60 plate was purchased from EMD Millipore. CDCl3, sodium hydride was
obtained from ACROS Organics™. Dimethyl sulfoxide was obtained from Cambridge
Isotope Laboratories. 4-(Dimethylamino) pyridine (DMAP), Cu (II) chloride, CuI,
phosphorus (V) oxychloride, sodium sulfate and tetrabromomethane were obtained
from Sigma-Aldrich. Boc anhydride was obtained from Chem-Impex International.
Deuterium oxide and triphenylphosphine were purchased from Alfa Aesar®. 2Bromoethylamine hydrobromide, alamarBlue®, ammonium chloride, ethanolamine,
imidazole, L-glutamine, propargyl bromide, sodium chloride, tetrabutylammonium
fluoride (TBAF) and triethylamine (Et3N) were obtained from Thermo Fisher. (1-Methyl1H-imidazol-5-yl) was purchased from AstaTech.

Tert-Butyldimethylchlorosilane

(TBSCl) was purchased from Oakwood Chemical. (1-methyl-2-nitro-1H-imidazol-5-yl)
methanol was purchased from ChiralStar.), Dulbecco's Modified Eagle Medium
(DMEM), bovine serum albumin (BSA), hydrochloric acid and sulfuric acid, Kaighn's
Modification

of

Ham's

F-12

Medium

(F-12K

Medium),

4-(2-hydroxyethyl)-1-

piperazineethanesulfonic acid (HEPES), Penicillin-Streptomycin, phosphate buffered

142

saline (PBS) and silica gel (230-400 mesh) were obtained from Fisher Scientific. [125I] NaI
was purchased from American Radiolabeled Chemicals, Inc. The human prostate cancer
PC-3 (CRL-1435™) and DU145 (HTB-81™) was purchased from American Type Culture
Collection.
A Waters e2695 system equipped with a Waters 2489 absorption detector and a
Waters Qtof Micro electrospray ionization mass spectrometer was used to perform high
performance liquid chromatography/mass spectrometry analyses. 1H, 13C and 31P NMR
spectrums were recorded on a Bruker Avance-III HD 500 MHz instrument using as the
solvent. Triphenylphospjate was used as

31

P standard. A Phenomenex Jupiter 5u C18

300A 250× 10 mm semiprep column was used for the purification of 2-nitroimidazole
phosphoramidate mustard and its controls. A Phenomenex Jupiter C12 Proteo 250×10
mm semiprep column was used for the purification of model compounds of 5-[NatI]iodo1,2,3-triazoles. Waters 1515 binary pump equipped with a Waters 2489 absorption
detector and a Bioscan Flow Count radiometric detector system using a Phenomenex
Jupiter C12 Proteo 250×4.6 mm column. Falcon™ Polystyrene Microplates (96-well plate
and 6-well plate) were used for in vitro cytotoxicity assay and efflux study separately.
SpectraMax® M5 Multi-Mode Microplate Readers was used to quantify fluorescence
intensities. EVOS FL Cell Imaging System was used for time-dependent cytotoxicity
assay. Hypoxic PC-3 and DU145 cells were incubated in hypoxic glove box with
temperature, CO2 and humidity controller (Coy Laboratory Products INC, Grass Lake,
MI). Gamma decay detection of

125

I for the efflux studies was accomplished using a LTI

(U.S.) Multi-Wiper nuclear medicine gamma counter.
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4.2.2 Synthesis of 2-nitroimidazole Phosphoramide Mustard (2-NIPAM)
Compounds 1 through 9 were synthesized on the basis of reported methods 238, 245-249.
Similar synthetic procedures were applied to the synthesis of both the negative control,
imidazole phosphoramidate mustard 1 and the positive control, 2-nitroimidazole
phosphoramidate mustard, 2. Details of synthesis can be found in the following content.
1

H spectra are reported as chemical shifts ( ) in ppm relative to TMS ( = 0) and 31P NMR

are referenced to H3PO4 ( = 0).
tert-butyl(2-hydroxyethyl)carbamate (4). To a stirred solution of
ethanolamine (6.16 g, 100.8 mmol) in 200 mL dry CH2Cl2 was added
Et3N (19.2 mL, 137.46 mmol) at rt for 30 min and then the solution was cooled to 0 °C. To
this, a solution of Boc2O (20.0 g, 91.64 mmol) in 60 mL of dry CH2Cl2 was added
dropwise and stirred at rt overnight. The mixture was quenched with saturated aqueous
NH4Cl, and extracted with CH2Cl2 three times. The combined organic extracts were
dried over anhydrous Na2SO4, filtered and concentrated by rotary evaporation to yield 4
as a colorless oil (15.6 g, 96.8 mmol, 96%).
Rf=0.31(12.5% Et2O/petroleum ether)
1

H NMR (500 MHz, CDCl3):

5.10 (s, 1H), 3.66-3.65 (m, 2H), 3.25-3.25 (m, 2H), 3.02 (s,

1H), 1.42 (s, 9H).
MS (ESI+) m/z calcd for C7H15NO3 [M+H]+ 162.11, found 162.09.
tert-butyl(2-((tert-butyldimethylsilyl)oxy)ethyl)carbamate

(5).
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To a stirred solution of 4 (10 g, 62.03 mmol) and imidazole (12.67 g, 186.1 mmol) in 200
mL dry CH2Cl2 with DMAP (0.4 g, 3.27 mmol), TBSCl (11.22 g, 74.44 mmol) was slowly
added at 0 °C. The solution was warmed to rt and stirred overnight, then quenched with
saturated aqueous NH4Cl solution. The mixture was extracted three times with CH2Cl2
and the combined organic layers were dried over anhydrous Na2SO4, filtered and the
solvent removed by rotary evaporation. The product was purified via flash column
chromatography on silica gel using 20% Et2O in petroleum ether to elute 5 (16.8 g, 98%)
as a clear colorless oil.
Rf=0.47(20% Et2O/ petroleum ether).
1

H NMR (500 MHz, CDCl3):

4.84 (br, 1H), 3.65 (m, 2H), 3.22 (m, 2H), 1.44 (s, 9H), 0.89

(s, 9H), 0.054 (s, 6H).
13

C NMR (125 MHz, CDCl3)

155.96, 79.12, 62.26, 42.88, 28.41, 25.89, 18.30, -2.96, -5.37.

MS (ESI+) m/z calcd for C13H29NO3Si [M+H]+ 276.19, found 276.05.
tert-butyl(2-((tert-butyldimethylsilyl)oxy)ethyl)(prop-2-yn-1yl)carbamate (6). To a suspension of NaH (2.9 g, 72.61 mmol) in
100mL dry THF was added a solution of 5 (10 g, 36.3 mmol) in 30 mL dry THF at 0 °C.
The mixture was stirred at rt for 1.5 h and subsequently cooled down to 0 °C. To this
reaction mixture propargyl bromide (13.7 mL of an 80% wt solution in toluene, 90.76
mmol) was added dropwise. Allowing to warm to rt, the reaction mixture was stirred
overnight and quenched with 50mL MeOH followed by 100 mL water. The aqueous
layer was extracted three times with CH2Cl2 and the combined organic layers were dried
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over anhydrous Na2SO4, filtered and the solvent removed by rotary evaporation. The
product was purified via flash column chromatography on silica gel using (2% Et2O in
petroleum ether) to provide 6 (6.6 g, 58%) as clear colorless oil.
Rf=0.38(20% Et2O/ acetone)
1

H NMR (500 MHz, CDCl3):

4.16 (d, 2H), 3.74 (s, 2H), 3.42 (s, 2H), 2.18 (s, 1H), 1.47 (s,

9H), 0.89 (s, 9H), 0.049 (s, 6H).
13

C NMR (125 MHz, CDCl3):

155.93, 80.09, 79.05, 62.24, 48.47, ,43.08, 38.08, 32.25, 28.39,

25.87, 18.28, -5.39.
HRMS (ESI+) m/z calcd for C16H31NO3Si [M+H]+ 314.2151, found 314.2155.
tert-butyl(2-hydroxyethyl)(prop-2-yn-1-yl)carbamate (7). To a solution
of 6 (5 g, 15.95 mmol) in 100 mL CH2Cl2 was added TBAF (1M in THF)
(22.33 mL, 22.33 mmol) at 0 °C. The reaction mixture was stirred overnight at rt and
quenched with saturated aqueous NH4Cl solution, extracted three times with CH2Cl2.
The organic layers were dried over anhydrous Na2SO4, filtered and the solvent was
removed by rotary evaporation. The product was purified via flash column
chromatography on silica gel using 20% acetone in petroleum ether as the eluent to
provide 7 (2.7 g, 85%) as a clear light yellow oil.
Rf=0.54(50% Et2O/ acetone).
1

H NMR (500 MHz, CDCl3):

(s, 9H).

4.09 (br, 2H), 3.82 (m, 2H), 3.52 (m, 2H), 2.27 (s, 1H), 1.50
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13

C NMR (125 MHz, CDCl3):

207.11, 156.82, 79.54, 71.60, 62.45, 43.13, 30.88, 28.35.

MS (ESI+) m/z calcd for C10H17NO3 [M+H]+ 200.12, found 200.14.
tert-butyl(2-bromoethyl)(prop-2-yn-1-yl)carbamate

(8).

To

a

solution of 7 (2 g, 10.04 mmol) and of triphenylphosphine (3.42 g, 13.05
mmol) in 50 mL dry THF a solution of cabon tetrabromide (4.33 g, 13.05
mmol) in 30 mL acetonitrile was added dropwise while the reaction temperature was
slightly above room temperature. The reaction was stirred for 2h, and the solvent was
removed by rotor evaporation. The residue was purified via flash column
chromatography on silica gel using 20% acetone in petroleum ether as the eluent to
provide 8 (2.04 g, 77.8%) as clear light yellow oil. The product 8 was immediately used
in next step synthesis.
1

H NMR (500 MHz, CDCl3):

4.15 (dd, 2H), 3.69 (m, 2H), 3.51 (br, 2H), 2.24 (s, 1H), 1.48

(s, 9H).
MS (ESI+) m/z calcd for C10H16BrNO2 [M+H]+ 262.04, found 261.91.
N-(2-bromoethyl)prop-2-yn-1-amine hydrochloride (9). To a
solution of 8 (0.5 g, 1.92 mmol) in 50 mL Et2O was added anhydrous
hydrogen chloride gas at 0 °C continuously for 3h. 9 (0.3 g, 80%)
gradually precipitate out of solution as a white solid. The product was filtrated to
remove solvent and used for the next reaction without further purification.
1

H NMR (500 MHz, DMSO-d6):9.3245 (s, 2H), 3.99-3.98 (d, 2H), 3.90-3.88 (t, 2H), 3.77 (s,

1H).
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13

C NMR (125 MHz, DMSO-d6):

80.229, 75.331, 47.622, 36.193, 27.045.

HRMS (ESI+) m/z calcd for free base C5H8NBr [M+H]+161.9918, found 161.9921.
(2-bromoethyl)(dichlorophosphoryl)phosphoramidic

dichloride

(11). To a suspension of 2-Bromoethylamine hydrobromide (3 g, 14.6
mmol) in 50mL Et2O was added POCl3 (1.4 mL, 14.64 mmol) slowly at 5°C with stirring. Et3N (4.08 mL, 97.61 mmol) was added and the reaction mixture was
allowed to stir overnight. The solution was filtered and the filtrate was
concentrateddown. The residue was purified by distillation to provide 8 (2.7 g, 85%) as
white crystal.
1

H NMR (500 MHz, CDCl3):

4.13-4.03 (m, 2H), 3.73-3.70 (t, 2H).

13

C NMR (125 MHz, CDCl3):

50.41, 26.25.

31

P NMR (202 MHz, CDCl3):

9.44.

1-Methyl-1H-imidazol-5-yl)methyl
bromoethyl)phosphordiamidate

(1).

N,N-bis(2To

a suspension of

2-

Bromoethylamine hydrobromide (10 g, 48.8 mmol) in 100 mL
CH2Cl2 was added POCl3 (2.28 mL, 24.4 mmol) slowly at -15°C with vigorous stirring. To
this reaction mixture a solution of Et3N (10.96 mL, 97.6 mmol) in 50 mL CH2Cl2 was
added dropwise, followed by stirring at -10 °C for 2h. The solid residue was filtered and
washed with small amount 5mL of cold CH2Cl2, and the filtrate was concentrated by
rotor evaporation to about 20 mL. The residue was filtered and washed with cold
CH2Cl2 again. The resulting filtrate was concentrated down by rotor evaporation. To a
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suspension of (1-Methyl-1H-imidazol-5-yl)methanol (27.5 mg, 0.25 mmol) in 5 mL
CH2Cl2 was added solution of the residue (20 mg in 5 mL CH2Cl2) from the precious step
at 0 °C. To the reaction mixture Et3N (16.9 mg, 0.167 mmol) in 2 mL CH2Cl2 was added at
0 °C and stirred overnight in room temperature. The solvent was removed by rotor
evaporation. The residue was purified by a semi-preparative Jupiter 5u C18 HPLC
column with a flow rate of 5.0 mL/min. The final yields of 1 was 13.8% (3.4 mg) as
colorless oil.
1

H NMR (500 MHz, DMSO-d6):

7.63 (s, 1H), 6.938 (s, 1H), 4.91-4.84 (m, 4H), 3.63 (m,

3H), 3.40 (m, 4H), 3.09 (m, 4H).
31

P NMR (202 MHz, DMSO-d6):

14.82.

MS (ESI+) m/z calcd for C9H17Br2N4O2P [M+H]+ 402.95, found 402.95.
1-Methyl-2-nitro-1H-imidazol-5-yl)methyl

N
O 2N

N

O
O
P
N
HN H

Br

Br

N,N-bis(2-

bromo-ethyl)phosphordiamidate (2). Compound 2 was
synthesized by the same synthetic procedure as 1 and

2

obtained as a yellow oil in 11.7% yield.
1

H NMR (500 MHz, DMSO-d6):

7.24 (s, 1H), 4.98-4.96 (m, 4H), 3.93 (m, 3H), 3.41 (m,

4H), 2.88 (m, 4H).
31

P NMR (202 MHz, DMSO-d6):

15.30.

HRMS (ESI+) m/z calcd for C9H16Br2N5O4P [M+H]+ 447.9385, found 447.9382.
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1-Methyl-2-nitro-1H-imidazol-5-yl)methyl N,N-bis((2bromoethyl)prop-2-yn)phosphordiami-date

(3).

To

a

suspension of Compound 9 (94.6 mg, 0.484 mmol) in 0 mL
CH2Cl2 was added phosphorus trichloride (30 mg, 0.22 mmol)
at room temperature, followed by the addition of TEA (397.9 mg, 3.93 mmol) in 10 mL
CH2Cl2dropwise. The reaction mixture was stirred at room temperature for 1h and then
(1-Methyl-2-nitro-1H-imidazol-5-yl)methanol (41.2 mg, 0.26 mmol) in 5 mL CH2Cl2 was
added. After stirring for another 2h, the reaction mixture was cooled to -20°C and the
tert-butyl hydroperoxide (48 µL, 0.26 mmol, 5M in decane) was added. The solution was
warmed to room temperature and stirred for 1h. The reaction mixture was quenched
with saturated aqueous NH4Cl solution, extracted three times with CH2Cl2. The organic
layers were dried over anhydrous Na2SO4, filtered and the solvent was removed by
rotary evaporation. The residue was purified by a semi-preparative Jupiter 5u C18
HPLC column with a flow rate of 5.0 mL/min. The final yields of 3 was 7.4% (8.4 mg) as
yellow oil.
1

H NMR (500 MHz, CDCl3):

5.15-5.14(d, 2H), 4.10 (s, 3H), 3.93-3.82 (m, 8H), 3.52 (m,

4H), 2.35 (m, 2H).
31

P NMR (202 MHz, CDCl3):

15.62.

13

C NMR (125 MHz, CDCl3): 129.44, 78.95, 73.39, 56.58, 47.81, 36.28, 34.52, 29.41.

HRMS (ESI+) m/z calcd for C15H20Br2N5O4P [M+Na]+ 546.9698, found 546.9689.

4.2.3 X-ray Crystallographic Analysis
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The single crystal generated from synthesis was stored in -80°C before
characterization. Crystal data for compound 9: C6H9NBr6, MW = 574.60 g/mol,
orthorhombic, space group P212121, a = 7.30499(16) Å, b = 11.3505(2) Å, c = 16.9283(3) Å,
=

=

= 90°, V = 1403.62(5) Å, Z = 4, Dcalc = 2.719 g/cm3, µ = 20.381 mm 1, T = 100 (2) K,

Data was collected on a Bruker SMART 1K CCD. Refinement of data with I > 2 (I) (2909
independent reflections, Rint = 0.0758) gave a R1(F) = 0.0346 and a wR2(F2) = 0.0925 for all
data with a GOF = 1.061. Crystallographic data for the structural analysis has been
deposited with the Cambridge Crystallographic Data Center (CCDC 1566695). Crystal
data for compound 11: C2H4Br1Cl4N1O2P2, MW = 354.77 g/mol, orthorhombic, space
group P21/c, a = 11.2875(5) Å, b = 7.8601(4)Å, c = 12.5373(6)Å,

=

= 90°,

= 102.528(5), V

= 1085.84(9)Å, Z = 8, Dcalc = 2.188 g/cm3, µ = 16.756 mm 1, Data was collected on a Bruker
SMART 1K CCD. Refinement of data with I > 2 (I) (2215 unique reflections, Rint = 0.0473)
gave a R1(F) = 0.0477 and a wR2(F2) = 0.1527 for all data with a GOF = 0.996.
Crystallographic data for the structural analysis has been deposited with the Cambridge
Crystallographic Data Center (CCDC 1566696). Copies of this information may be
obtained free of charge from the CCDC (www: http://www.ccdc.cam.ac.uk) or from email jcgarrison@unmc.edu.

4.2.4 In Vitro Cytotoxicity Study
PC-3 and DU145 cells were separately cultured in F-12K and DMEM medium
supplemented with 10% fetal bovine serum, 2.5 mM L-glutamine, 15 mM HEPES and
1% penicillin/streptomycin. Cells were seeded 24h before the experiment in 96-well
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plates at a density of 15,000/mL with 200µL medium of PC-3 cells and 12,500/mL with
200µL medium. On the day of the experiment, serial dilutions of the test compound with
medium were administrated to cells. The plates were incubated for 2h, or longer if
indicated, under either normoxic (95% air, 5% CO2) or hypoxic (94.9% N2, 0.1% O2, 5%
CO2) conditions. After washing with fresh medium, cells were cultured for 72h in 200µL
complete medium under normoxic conditions. Cell viability was determined by
AlamarBlue. The 50% inhibitory concentration (IC50) of the test compound relative to the
untreated control were calculated by Graphpad PRISM 5.

4.2.5 Radiolabeling of 2-NIPAM with [125I]-NaI
The general procedure for the preparation of Nat/125I-labeled Azide-Alkyne
Cycloaddition conjugates were adapted from previous reported synthetic strategy 250. To
1.2 mL anhydrous acetonitrile, copper(II) chloride (4.02 mg, 30 µmol) was added to
make CuCl2/TEA solution. To this mixture, anhydrous triethylamine (4.53 mg, 45 µmol)
was added and sonicated until a clear burgundy solution was formed. The solution was
gently mixed before adding slowly over 5 min a solution of 2-NIPAM (0.1 µmol) in 20
µL acetonitrile. To this mixture, Na125I (7.4 MBq) in 6.5 µL H2O was added followed by
the addition of another 0.5 µL benzyle azide in 20 µL of anhydrous acetonitrile. The
resultant solution was heated at 60 °C for 90 min. The purification of the radiolabeled
azide-alkyne cycloaddition conjugates was performed by using RP-HPLC ( 10%).

4.2.6 Distribution Coefficient
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The distribution coefficient was determined (n = 5) for each

125

I-labeled

radioconjugate. In a 1.5 mL centrifuge tube, 0.5 mL of 1-octanol was added to 0.5 mL of
phosphate-buffered saline (pH 7.4) containing the radiolabeled peptide (400,000 cpm).
The solution was vigorously stirred for 2 min at room temperature and subsequently
centrifuged (8,000g, 5 min) to yield two immiscible layers. Aliquots of 100 µL were taken
from each layer, and the radioactivity of each was quantified by an LTI (Elburn, IL)
Multi-Wiper nuclear medicine gamma counter.

4.2.7 In vitro Efflux Study
PC-3 and DU145 cells were incubated in 6-well plates (0.5 × 106/well) under
normoxic (95% air, 5% CO2) or hypoxic (94.9 % N2, 0.1 % O2, 5 % CO2) conditions
overnight in RPMI 1640 media (pH 7.4, 4.8 mg/mL HEPES, and 2 mg/mL BSA). On the
day of the experiment, the medium was replaced with fresh medium and incubated for 2
h under normoxic or hypoxic conditions, respectively. The cells were pre-incubated for
2h at 37 °C in the presence of 100,000 cpm of

I-radioconjugates. Upon completion of
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the incubation, cells were washed thrice with medium to discard the unbound peptide.
At time points 1, 2, 4, 6 and 8 h, the medium was harvested for quantitative analysis as
the effluxed ligand. Surface bound radioactivity was collected by washing the cells twice
with an acid wash (50 mM glycine-HCl/0.1 M NaCl buffer, pH 2.8). The cells were then
lysed at 37 °C using a 10% aqueous SDS solution and the lyses were collected as
internalized ligand. The radioactivity of the effluxed, surface bounded and internalized
fractions for each radioconjugate was determined using a Multi Viper gamma counter.
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Statistical analyses were performed by two-way analysis of variance (ANOVA) using
Graphpad PRISM 5 (U.S.).

4.2.8 Statistical Analysis
IC50 values were determined by nonlinear regression using the 1-binding-site model
of GraphPad PRISM 5 (GraphPad Software, Inc). Comparisons of the 2 groups for efflux
studies were analyzed by the 2-tailed Student t test, and P values of less than 0.05 were
considered statistically significant.

4.3 RESULTS
4.3.1 Synthesis of 2-nitroimidazole Acetic Acid (2-NIAA)
Out first synthetic goal in the synthesis of 2-NIPAM, 3, was to produce the alkyne
containing secondary amine, 9. The synthesis of compound 9 (N-(2-bromoethyl)prop-2yn-1-amine hydrochloride), as outlined in Scheme 4.1, was initiated with the dual
protection of 2-aminoethan-1-ol.
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Scheme 4.1. Synthesis of N-(2-bromoethyl)prop-2-yn-1-amine hydrochloride 9a.

Reagents, conditions, and yields: (a)Et3N, CH2Cl2, 96.0%; (b) Imidazole, 4-DAMP,

a

TBDMSCl, CH2Cl2, 98.3%; (c)propargyl bromide, NaH, THF, 58.0%; (d)TBAF,
THF,85.0%; (e)CBr4, PPh3, ACN, 77.8%; (f)HCl (g), Et2O, 79.6%.
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The amine and alcohol functional groups of the starting material were protected
with Boc and tert-butyldimethylsilyl groups, respectively

. Deprotonation of

238, 245-249, 251

the protected amine using sodium hydride and subsequent reaction with propargyl
bromide yielded the protected secondary amine 6. Deprotection of the silyl protecting
groups employing a fluoride source (i.e., TBAF) provided compound 7. To this point,
compound 7 was obtained in three steps with an overall yield of 85%. An Appel reaction,
utilizing triphenylphosphine and CBr4, was employed to convert the alcohol into a
bromide, giving compound 8. After work-up, column chromatography was utilized to
purify the compound and remove byproducts (e.g., POPh3) and starting reagents (e.g.,
CBr4). Purified 8 was dissolved in Et2O and the Boc group removed by the introduction
of HCl gas yielding intermediate 9 in quantitative yield. The structure of 9 was
confirmed by x-ray crystallography (Figure 4.2 and Table 4.1), but it is noteworthy that
a molecule of CBr4 also co-crystalized with the desired com-pound. After further
investigation, it was found that additional chromatographic purifications of 8 were able
to re-move residual CBr4, resulting in the isolation of white crystalline 9. Overall, the
synthetic route in Scheme 4.1 produced compound 9 in 80% yield. The structures of the
compound synthesized in this scheme were confirmed by mass spectrometry, 1H and 13C
NMR spectra. (Figure 4.3-8, correspondingly).
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Figure 4.2 Crystal structure of compound 9. Selected bond lengths (Å) and
angles (deg): Br(1)-C(1) =1.954(7), N(1)-C(2)=1.497(9), N(1)-C(3)=1.502(8), C(2)C(1)=1.498(10),

C(3)-C(4)=1.450(10),

C(4)-C(5)

=1.181(11),

C(2)-N(1)-C(3)=

114.5(5), N(1)-C(2)-C(1) = 107.6(6), C(4)-C(3)-N(1)= 109.3(6), C(5)-C(4)-C(3)=
179.1(9), C(2)-C(1)-Br(3)= 108.9(5).
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Table 4.1 Crystal data and structure refinement for compound 9.
Identification code
wenting-1
Empirical formula

C5H8NBr6

Formula weight

574.6

Temperature/K

100

Crystal system

orthorhombic

Space group

P212121

Unit cell dimensions

a/Å= 7.30499(16)

/°= 90.00

b/Å= 11.3505(2)

/°= 90.00

c/Å= 16.9283(3)

/°= 90.00

Volume/Å3

1403.62(5)

Z

4

Density (calculated) g/cm3

2.719

Absorption coefficient /mm-1

20.381

F (000)

1048.0

Crystal size/mm3

0.4 × 0.05 × 0.05

Index ranges

-9

Reflections collected

21627

Independent reflections

2909 [Rint = 0.0758, Rsigma =
0.0346]
CuK ( = 1.54184)

Radiation
range for data collection/°

h 8, -14 k

13, -21 l 21

9.38 to 152.66

Data / restraints / parameters

2909/0/118

Goodness-of-fit on F2

1.061

Final R indices [I>=2 (I)]

R1 = 0.0346, wR2 = 0.0907

R indices (all data)

R1 = 0.0369, wR2 = 0.0925

Largest diff. peak and hole/ e.Å-3

0.94 and -0.58
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A

B

C

Figure 4.3 A-C) Mass spectrometry of compound 1-3.
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A

B
-Boc

C

Figure 4.4 A-C) Mass spectrometry of compound 4-6.
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A

CDCl3

B

TMS

CDCl3

C
TMS

O

BocN

Si

6

CDCl3

Figure 4.5 A-C) 1H-NMR spectra of compound 4-6.
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A

CDCl3

B

CDCl3
TMS

C

DMSO-d6

Figure 4.6 A-C) 1H-NMR spectra of compound 7-9.
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A

CDCl3

B

CDCl3

C

CDCl3

Figure 4.7 A-C) 13C-NMR spectra of compound 7-9.
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DMSO-d6

Figure 4.8 13C-NMR spectra of compound 9.
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Initial attempts to synthesize the phosphordiamidate mustards centered on utilizing
an asymmetric approach using a phosphoramic dichloride precursor (Scheme 4.2) 251-252.
Unfortunately, this approach yielded multiple products with one of the largest
byproducts being a bisphosphoramidate 11. The structure of 11 was confirmed by X-ray
crystallography, Figure 4.9 and Table 4.2. Attempts to obtain the desired compounds by
modifying the reaction conditions (i.e. substitution of different amines, varying reaction
times and temperatures) were unsuccessful.

165

Scheme 4.2 Attempt to synthesize asymetric phosphoramidate mustard.

Reagents, conditions, and yields: (a)propargyl bromide, Et2O, Et3N, -5°C;

a

(b)Bis(2-chloroethyl)amine hydrochloride, ACN, Et3N, pyridine, 40°C; (c) H2O.
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Figure 4.9 Crystal structure of compound 11. Selected bond lengths (Å) and
angles (deg): Br(1)-C(1) =1.952(5), P(1)-C(11)=1.979(17), P(1)-C(12)=1.996(18), P(1)O(1)=1.450(4), P(1)-N(1)=1.670(4), C(2)-C(1)=1.514(7), C(2)-N(1)=1.502(6), C(11)P(1)-C(12)= 102.95(8), O(1)-P(1)-C(11)= 115.55(17), O(1)-P(1)-C(12)= 113.10(19),
O(1)-P(1)-N(1)= 113.0(2), N(1)-C(2)-C(1) = 114.4(4), P(2)-N(1)-P(1) = 121.3(3), C(2)N(1)-P(1)= 118.2(3), C(2)-C(1)-Br(1)= 113.1(3).
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Table 4.2 Crystal data and structure refinement for compound 11.
Identification code

JG

Empirical formula

C2H4NO2P2Cl4Br

Formula weight

357.71

Temperature/K

100

Crystal system

monoclinic

Space group

P21/c

Unit cell dimensions

a/Å= 11.2852(7)

/°= 90.00

b/Å= 7.8547(5)

/°=102.540(7)

c/Å= 12.5336(9)

/°= 90.00

Volume/Å3

1084.49(12)

Z

4

Density (calculated) g/cm3

2.191

Absorption coefficient /mm-1

16.776

F (000)

688.0

Crystal size/mm3

0.2 × 0.06 × 0.03

Index ranges

-9

Reflections collected

7033

Independent reflections

2212 [Rint = 0.0480, Rsigma = 0.0378]

Radiation

CuK ( = 1.54184)

range for data collection/°

h 14, -9 k 9, -15 l 13

8.026 to 152.386

Data / restraints / parameters

2212/0/109

Goodness-of-fit on F2

1.176

Final R indices [I>=2 (I)]

R1 = 0.0464, wR2 = 0.1409

R indices (all data)

R1 = 0.0502, wR2 = 0.1524

Largest diff. peak and hole/ e.Å-3

0.81 and -1.01
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A
CDCl3

B

CDCl3

C

Figure 4.10 A-C) 1H, 13C and 31P-NMR spectra of compound 11.
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With these setbacks, we switched our approach to focus on a symmetric
phosphoramidate mustard synthesis, outlined in Scheme 4.3, to obtain 3 along with our
positive (2) and negative (1) controls. The negative control, 1, is an analog of 2 that utilizes an
imidazole instead of a nitroimidazole, thereby eliminating its ability to fragment and form
an active phosphoramidate mustard. The controls were synthesized by reaction of two
equivalents of bromoethylamine with POCl3 to yield the phosphoramidate chloride
intermediate. This intermediate was subsequently reacted under basic conditions with (1methyl-1H-imidazol-5-yl)methanol or its 2-nitroimidazole derivative to produce compound
1 in 13.8% yield and 2 in 11.7% yield, respectively. The synthesis of compound 3 was
accomplished by the sequential addition of 2.2 equivalents of 9 with PCl3, followed by
reaction with 1-methyl-2-nitro-1H-imidazol-5-yl)methanol and oxidation via tert-butyl
hydroperoxide. The structures of compound 1, 2 and 3 were confirmed by mass
spectrometric, 1H, 13C and/or 31P NMR spectra analysis (Figure 4.11-4.14).
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Scheme 4.3. Synthesis of imidazole and its nitro-derivative conjugated
phosphoramidate mustard (1-3)a

Reagents, conditions, and yields: (a) propargyl bromide, Et3N, CH2Cl2; (b) Et3N,

a

CH2Cl2, 13.8% (1), 11.7% (2); (c)compound 9, Et3N, CH2Cl2; (d)tert-butyl
hydroperoxide, Et3N, CH2Cl2, 7.4% (3).
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B

C

Figure 4.11 A-C). Mass spectrometry of compound 1-3.

172

A

TMS

B

C

N
O2N

Br
N

O
O

N
P

N

Br

3

CDCl3

Figure 4.12 A-C) 1H-NMR spectra of compound 1-3.
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Figure 4.13 13C NMR spectra of compound 3.
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Figure 4.14 31P NMR spectra of compound 1-3.
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4.3.2 Time-Dependent In Vitro Cytotoxicity Study
The cytotoxicity of compounds 1, 2 and 3 were evaluated in PC-3 and DU145 human
prostate cancer cell lines under both normoxic and hypoxic conditions using a viability
assay, results shown in Table 4.3. As expected, the negative control, 1, demonstrated an
IC50 that was > 0.85 mM for both cell lines. Due to its inability to form an active
phosphoramide mustard under hypoxic conditions, the cytotoxicity of 1 was > 100-fold
lower than either 2 or 3. Additionally, the negative control demonstrated no hypoxia
selectivity (i.e., hypoxia cytotoxicity ratio (HCR) = 1). The positive control, 2,
demonstrated increased cytotoxicity (IC50 = 4.14 ± 0.66 – 6.49 ± 0.67 µM) in both cell lines
under hypoxic conditions relative to normoxic conditions, (IC50 = 687 ± 32.6 – 842 ± 52.5
µM). The hypoxia selectivity for 2 was found to be approximately 2-fold higher in
DU145 cells (HCR=203) compared to PC-3 cells (HCR=106). These results agree with
previous reports in which evofosfamide (2) demonstrated lower hypoxia selectivity in
PC-3 cells (HCR=190) relative to DU145 cells (HCR=240)

. Compound 3, 2-NIPAM,

253

demonstrated slightly higher cytotoxicity (IC50 = 1.65 ± 0.09 – 4.70 ± 0.01 µM) compared
to the positive control under hypoxic conditions. Interestingly, relative to the positive
control, the hypoxia selectivity of 3 was 2-fold lower (HCR = 62) for PC-3 cells, but had
similar values (HCR = 225) for DU145 cells. There is no significant difference in the HCR
between compound 2 and compound 3 (P>0.05) in the DU145 cell line, but a significant
difference in PC-3 cells (P<0.05) was observed.
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Table 4.3. Cytotoxicity of prostate cancer cell lines with tested compounds
Compound
1
2
3

Cell lines

IC50(µmol/L;)

HCR

N2

air

PC-3

~1,000

~1,000

ND

DU145

851 ± 52.9

856 ± 55.2

1

PC-3

6.49 ± 0.67

687 ± 32.6

106

DU145

4.14 ± 0.66

842 ± 52.5

203

PC-3

4.70 ± 0.01

293 ± 39.6

62

DU145

1.65 ± 0.09

372 ± 41.6

225

Result (mean ± SEM) are from 2 or more independent experiments carried out in quintuplicate.
HCR: hypoxia cytotoxicity ratio. HCR= IC50(air)/ IC50(N2).
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To evaluate the timed-dependent cytotoxicity of compound 3, IC50 assays were
performed using both cell lines under different incubation times. As shown in Figure
4.15A and 4.15B, the cytotoxicity of 3 was time-dependent in both cell lines with
increased cytotoxicity as incubation time increased. As previously noted, higher
cytotoxicity for 3 was observed in DU145 cells compared to PC-3 under hypoxic
conditions. Representative images depicting the cytotoxicity for both cell lines incubated
for 2, 4 and 6h with 1

10-8 - 1

10-3 M 2-NIPAM under hypoxic and normoxic

conditions are shown in Figure 4.16 and 4.17. The IC50 of 3 after 6h incubation was
determined to be 0.78 µM in DU145 cells, and 1.69 µM in PC-3 cells, as shown in Table
4.4. At any rate, these studies demonstrate that incorporation of the alkyne groups into
the phosporamide structure did not substantially impact the cytotoxicity or hypoxia
selectivity of 3. This strongly suggests that compound 3 is able to undergo the same
activation mechanism that has already been established for 2 (i.e., TH-302) 254.
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Figure 4.15 A & B. Time-dependent cytotoxicity of compound 3 (2NIPAM) in DU145 and PC-3 cell lines, values are mean ± SEM (n=5).
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Figure 4.16 Microscopy images of hypoxia selective toxicity of 1 10-8
- 1 10-3 M 2-NIPAM with 2h, 4h and 6h administration in PC-3 cells
(inverted microscope, 20). Scale bar: 200µm.

-4

-3

10

180

6h

4h

2h

10

-8

10

-7

10

-6

10

-5

Figure 4.17 Microscopy images of hypoxia selective toxicity of 1 10-8
- 1 10-3 M 2-NIPAM with 2h, 4h and 6h administration in DU145
cells (inverted microscope, 20). Scale bar: 200µm.
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Table 4.4 Summary of time-dependent cytotoxicity of compound 3.
Compound exposure time

IC50(µmol/L; N2)
PC-3

DU145

2h

4.70 ± 0.01

1.65 ± 0.09

4h

3.00 ± 0.22

1.17 ± 0.15

6h

1.69 ± 0.41

0.78 ± 0.10

Result (mean ± SEM) are from 3 or more independent experiments carried out in
quintuplicate.
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4.3.3 Radiolabeling of 2-NIPAM with [125I]-NaI
In order to investigate the conjugation and in vitro trapping efficacy of 2-NIPAM (3),
we radiolabeled 3 with

I utilizing a Cu(I)-mediated cycloaddition reaction

125

250

.

However, before proceeding we sought to optimize the cycloaddition reaction
conditions. Our previous unpublished work demonstrated that 2-nitroimidazoles can
undergo rapid degradation when exposed to certain metals (e.g., Cu(II) salts). With that
in mind, the stability of the 2-nitroimidazole reactants and the conjugation efficacy of the
ruthenium-based and Cu(I) catalysts under various experimental conditions (i.e.,
temperature and reaction time) were examined. The coupling of 3 with benzyl azide
utilizing two common ruthenium-based catalysts (Cp*RuCl (PPh3)2 and Cp*RuCl (COD))
did not result in the desired product as evaluated by LC-MS, but instead lead to
multiple byproducts at both room and elevated temperatures. Our initial belief was that
the ruthenium catalysts, under the conditions employed, were leading to the
degradation of the 2-nitroimidazole functionality of 3. To further investigate this, we
incubated the ruthenium catalyst in the presence of 2-nitroimidazole-1- acetic acid. LCMS demonstrated the reaction led to a gradual transformation of the analog (data not
shown), presumably by reduction of the nitro group to the amine 255-256. Fortunately, the
2-nitroimidazole functionality of 3 remained stable using Cu(I)-mediated cycloaddition
conditions at both room temperature and 60°C with yields of 81.2 % and 82.7 %,
respectively.
Following the cycloaddition optimization, we employed a reported procedure by
Årstad and colleagues to incorporate

I into the resulting triazole ring of the

125
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cycloaddition products 250. Briefly, the procedure involves a one-pot reaction that utilizes
copper (II) chloride combined with Et3N to generate the cycloaddition product with the
I incorporated on the 5-position of the triazole ring. While some mechanistic studies

125

were performed, the precise mechanism of the

I-incorporation remains unclear.

125

However, some findings appear to be certain, 1) the Et3N is able to reduce a portion of
the Cu(II) species in solution to Cu(I), thereby generating the needed species to carry out
the cycloaddition reaction and 2) the incorporation of the

I is carried out by a Cu(I)

125

species. At any rate, we explored the utilization of this technique with 2-NIPAM (3), as
depicted in Scheme 4.4. Utilizing the CuCl2/ Et3N system in a water-acetonitrile mixture,
we first examined the incorporation of

I (non-radioactive) into 2-NIPAM utilizing

nat

benzyl azide. Upon completion of the 90min reaction at 60°C, the reaction progress was
evaluated by LC-MS, of which the LC spectra was shown in Figure 4.18 And the mass
spectrometric spectra of were showed in Figure 4.19. The cycloaddition product 13,
without the incorporation of the iodide, was observed at 5.0 min, while the single
iodinated product 14 was observed at 7.6 min. As can be seen from the chromatograms,
the incorporation efficiency of the iodide into the triazole was modest. In order to aid
separation and purification of the iodinated species (i.e., 14 and 15) the mobile phase
was changed from water:acetonitrile to water:methanol. The chromatogram of 14 using
the water:methanol eluent is depicted in Figure 4.20. Utilizing analogous reaction
conditions, the reaction of 3, benzyl azide and 125I was carried out and evaluated by
radio-HPLC using the same gradient. As expected, 15 had an identical retention times
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compared to non-radioactive 14. While the overall radiochemical yield for 15 was poor
(10%), the yield was more than sufficient for further in vitro characterization.
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Scheme 4.4 Synthesis of 5-[Nat/125I]Iodo-1,2,3-trizoles (13-15)
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Fig 4.18 Mass spectrometry of compound 13 and 14.
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Fig 4.19 LC-MS chromatogram profile of products of azide-2-NIPAM
cycloaddition reaction. (Eluent: ACN/H2O).
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Fig 4.20 LC-MS chromatogram profile of compound 14 aligned with
Radio-labeled HPLC profile of compound 15. (Eluent: Methanol/H2O).
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4.3.4 Determination of Distribution Coefficient and In Vitro Efflux Study
Studies were performed to determine the distribution coefficient (LogD7.4) of 15. The
I-labeled conjugate was found to have a distribution coefficient of 0.55 ± 0.06 which

125

demonstrated that the compound is hydrophobic enough to readily enter cells through
passive diffusion. In order to evaluate the cellular trapping/retention efficacy of
compound 15, we investigated the biological performance of this radiolabeled agent
using in vitro efflux studies. The PC-3 and DU145 cells were initially treated with 15 for
1h at 37 . Uptake of the 125I-labeled conjugate in both cell lines ranged from 2% to 4% of
the total radioactivity added under both normoxic and hypoxic conditions, respectively.
The efflux results for 15 over an 8 h period in both PC-3 and DU145 cells under
normoxic and hypoxic conditions are given in Figure 4.21. For all cell lines and oxygen
conditions, more than 50% of 15 was effluxed from the cells within the first 2h. However,
the

125

I-labeled conjugate demonstrated lower efflux rates under hypoxic conditions in

both cell lines relative to normoxic conditions. At 8h after efflux began, 85.8% and 88.3%
of the initial internalized radioactivity of 15 was externalized in normoxic condition in
DU145 and PC-3 cells, respectively, compared to 72.2% and 70.5% under hypoxic
conditions. The increased retention of 15 under hypoxic conditions was found to be
statistically significant (P < 0.05) in both cell lines when compared to normoxic data.
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Figure 4.21 Efflux assays depicted as percentage of initial internalized activity
for 125I-radioconjugates compound 15 in PC-3 and DU145 cells. Values are mean
± SD (n=5).
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4.4 DISSCUSSION
Our laboratory continuously pursuing the usage of hypoxia-selective trapping
agents to increase the retention time of receptor-targeted radiotracer in hypoxic cancers.
Following our initial works with 2-nitroimidazole conjugated hypoxia-selective
prodrugs, we start to explore the properties of 2-nitroimidazole-5-yl methyl based
phosphordiamidate mustards. The prototype compound evofosfamide can undergo
series of reduction in hypoxic environment and release bromo-isophosphoramide
mustard (Br-IPM). Instead of taking advantage of DNA crosslink properties of
evofosfamide, we are more interested in employing its hypoxic-selectivity and
conjugaing it to receptor-targeted radiotracers in the future. Thus, we designed
compound 3 to fulfill this purpose.
The key intermediate compound 9 was successfully synthesized in 80% yield by a
series of reactions as shown above. During the process, we tried to purified
intermediates compound 5 and 6 by distillation, which worked well for large scale
(gram level) collection. However, considering the time-cost, column chromatography
would be a better choice with high consistence from batch to batch. Meanwhile, to
deprotect Boc groups of compound 8, instead of introducing HCl gas into solutions, we
also used hydrochloric acid-ethanol solutions as solvent directly. The mixture was
stirred in room temperature for 3h and concentrated by rotary evaporation. The product
9 was precipitate out in cold Et2O as white crystal. This improvement has been used in
all our following experiments.
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In the attempt to synthesize asymmetric phosphordiamidate mustards, several
modifications had been done but the results were disappointed. Major difficulties
included complicated reaction products showed by LC-MS and incompatibility of
products with column chromatography. Attempted purification by HPLC showed that
there were no target products characterized by NMR. Thus, it encouraged us to switch
to synthesize symmetric phosphordiamidate mustard. Compared to (1-Methyl-1Himidazol-5-yl)methanol, its 2-nitroimidazole derivatives was less reactive in the
synthesis of phosphordiamidate mustards. The changes from primary amine to N,Ndialkyl phosphoramide mustards further decreased yield. During the synthesis, the
major side product that had been characterized was phosphordiamidate mustards
containing one molar of bis-bromoethylamine and two molar of 1-Methyl-1H-imidazol5-yl)methanol. Since the polarity of this side product was close to the product, carefully
modification of the gradient of column chromatography was necessary.
Considering the future application of conjugate 2-NIPAM to receptor-targeted
radiotracer, thus we choose PC-3 and DU145 prostate cancer cell lines that are
commonly used for in vitro studies based on their high receptor expression level (e.g.
gastrin-releasing peptide receptor). In cytotoxicity studies, 2-NIPAM demonstrated
similar hypoxia cytotoxicity ratio compared to TH-302 in DU145 cells. While, it showed
3-4 fold higher cytotoxicity under normoxic conditions relative to TH-302. This suggests
that either 2-NIPAM is more easily activated than TH-302 under normoxic conditions or
that the “inactive” form of 2-NIPAM is more cytotoxic than TH-302. Overall, the
comparison studies of 2-NIPAM vs controls demonstrate that incorporation of the
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alkyne groups into the phosporamide structure did not substantially impact the
cytotoxicity or hypoxia selectivity of 2-NIPAM. This strongly suggests that 2-NIPAM is
able to undergo the same activation mechanism that has already been established for
TH-302 (i.e., evofosfamide ).257 This hypoxia-selective cytotoxicity was also showed to be
time-dependent. As expected, the elongated incubation time of cells with hypoxia
trapping agents would lower IC50 values of compounds. Most likely, the enhanced
cytotoxicity is a result of the increase in cellular adducts formation.
In the selection of cycloaddition reaction conditions of 2-NIPAM, we carefully take
the activity and instability of bromo- and 2-nitroimidazole- groups into consideration.
With the success of using Cu(I) to mediate cycloaddition reactions, we decided to use
one-pot radiolabeling of 2-NIPAM with I-125 resulting in cycloaddition products with
trizole rings. The dilemma of characterizing compound 15 directly was that the MS
equipment we have is not sensitive enough to perform MS analysis of radiotracer
quantities of it. Also, the labs with high sensitivity MS would not allow us to test radiolabeled compound in their equipment. Because of that, we decided to use HPLC to
characterize compound 15 and perform retention time comparison to the nonradioactive analog (compound 14). The hydrophobicity of compound 15 allowed it
passive diffused into cells. At the end of 8h efflux studies, it had been showed that 13.6%
and 17.8% increased retention of compound 15 in DU145 and PC-3 cells under hypoxic
conditions. This is likely due to hypoxia activation and adduct formation with
intracellular biomolecules.
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4.5 CONCLUSION
In conclusion, we have designed and successfully synthesized a novel 2nitroimidazole phosphoramide mustard (2-NIPAM), modeled after evofosfamide, that
allows easy conjugation of the hypoxia-selective drug to imaging moieties and other
constructs through an azide-alkyne cycloaddition reaction. Our interest in 2-NIPAM,
and other hypoxia-selective drugs, lies in their potential for selective activation and
retention in hypoxic tissues, such as observed with many cancers. We envision that this
selectivity can be exploited for the purpose of selectively increasing the retention of
diagnostic and therapeutic agents in hypoxic tumor tissues. Our studies demonstrated
that 2-NIPAM had similar cytotoxicity and hypoxia-selectivity compared to
evofosfamide, establishing that the incorporation of the alkyne functionality did not
substantially impact the activity of the agent. Using a synthesized

125

I-labeled 2-NIPAM

conjugate, we observed that the analog demonstrated greater cellular retention under
hypoxic conditions, suggesting that retention is due to activation and adduct formation
with intracellular macromolecules. Given these results, we plan on further investigating
the potential of 2-NIPAM alone as a hypoxia diagnostic agent and in conjugation with
receptor-targeted agents for cancer imaging and targeted radiotherapeutic applications.
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Chapter 5. DISCUSSION AND FUTURE DIRECTION
Over the past several decades, the development of targeted radiopharmaceuticals for
diagnostic and therapeutic purposes has thrived. These agents contain a radionuclide(s)
and a targeting vehicle, such as a small molecule, peptide or antibody. Thus, these
agents are capable of delivering the radioisotope specifically to tumor cells or to the
tumor

microenvironment

31,

33-38

.

Compared

to

the

conventional

systematic

chemotherapeutic agents, this approach has the advantage of higher specificity to
enhance the tumor-specific targeted delivery and lower non-target tissue accumulation.
By now, many targeted radiopharmaceuticals have been successfully used in clinic for
different types of cancers, for example, 1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid
[18F-FACBC]) is used for diagnosis of prostate cancer and yttrium-90 ibritumomab
tiuxetan is utilized for treatment of B-cell lymphoma 258-259.
Among those receptors used for the development of targeted radiopharmaceuticals,
the gastrin-releasing peptide receptor (BB2r) has been intensively investigated in the
past two decades for various solid tumors including prostate cancer. It is estimated that
63-100% of primary prostatic invasion carcinomas has high to very high levels of BB2r 23.
The current standard method to treat early-stage localized prostate cancer since 1904 is
prostatectomy. For patients with prostate cancer that has metastasized beyond the
prostate capsule surgery is no longer a viable option. Initially, the growth and survival
of prostate tumors are dependent on androgens

24

. Patients suffering from advanced,

metastatic prostate cancer undergoing androgen ablation therapy can experience the
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suspension of prostate cancer progression. However, the cancer eventually is able to
bypass its androgen dependence to become androgen-independent allowing the cancer
to progress

. To date, there are no chemotherapy agents available to successfully

24-25, 260

treat patients with advanced, androgen-independent prostate tumors. However, more
than 50% of this population of androgen-independent tumors have been shown to be
BB2r-positive

. Studies have shown that the expression of BB2r in lymph node and

24-26

bone metastasis of prostate cancer was in 85.7% and 52.9% of cases, respectively 26. These
finding are the impetus for developing BB2r-targted diagnostic to detect metastatic
cancer lesions and therapeutic agents for advanced prostate cancers.
Recently, several radiolabeled (e.g. Ga-68) BB2r-targeted antagonists have shown
great potential in ongoing clinical studies with small-cohort of patients for the detection
of recurrent prostate tumors

66-68, 71-72

. These results demonstrated their favorable tumor

uptake and image contrast, and feasibility of identifying smaller tumors when compared
to standard prostate cancer imaging (CT, MRI,

18

F-NaF PET/CT, and

99m

Tc-methylene

diphosphonate bone scanning) tracers. Thus, these agents are promising candidates for
prostate cancer detection, staging and progression monitor, etc. Nevertheless, further
studies in larger patient population are necessary to evaluate the sensitivity of those
BB2r-targted agents in PET/CT and correlation regarding factors like the tumor
aggressiveness and tumor size. Meanwhile, the major challenge of radiopharmaceutical
based on receptor-avid peptides, low-molecular weight agents, is the rapid plasma
clearance and intrinsic instability in protease-rich bioenvironments. As a consequence,
their diminished residence time in tumors often limits their clinical translational
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potential, especially for therapeutic purposes.
In chapter 2 of this dissertation, we first compared several biologically variables (e.g.,
receptor expression, perfusions, etc.) in two popular mouse models, subcutaneous and
orthotopic xenograft mouse models. These factors are known to influence drug delivery,
thus we tried to evaluate the impact of them on the delivery of BB2r-trageted analogs in
vivo. This data, not only provide researchers with possible explanation of the results
obtained from mouse model studies, but also reminds them to cautiously chose which
model to employ, considering the variance of parameters between the two mouse
models.
In chapter 3 and 4, we aimed to address the low tumor retention profile of peptidebased radiopharmaceuticals by incorporating different trapping agents into the receptortargeted, peptide-based radiotracers. Upon receptor-mediated endocytosis of radioagents, we expected the trapping agents forming covalent bond with intracellular
macromolecules, which leads to significantly higher retention in tumor. This strategy is
expected to selectively increase the residence time in tumor tissues along with
optimizing tumor-to-non-target ratios. In chapter 3, we selected BB2r-targeted peptide
as our targeting vector and used the CC inhibitor, E-64, as a trapping agent for our study.
After the radiotracers were internalized through receptor-mediated endocytosis, the
conjugated CC inhibitor irreversibly bind to the enriched CCs in endolysosomal
compartments through forming thiol-ether linkages. Our studies have demonstrated a
substantially increase in the tumor retention and favorable T/NT ratios of radiolabeled
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BB2r-targeted peptides in vitro and in vivo. We believe this strategy can grant BB2rtargted agents a better chance to be translated into the clinic for diagnosis and especially
the treatment of advanced prostate cancers.
The second approach examined, as discussed in chapter 4, is to employ the 2nitroimidazole trapping moiety (2-NIPAM) as trapping agents incorporated into the
peptide radiotracer. Theoretically, after the radiotracer undergoes a similar endocytosis
process in hypoxic tumor cells, the 2-nitroaimidazole group is activated and irreversibly
bind to intracellular nucleophilic macromolecules present in the cell. In the first stage of
this study, we examined the cytotoxicity and hypoxia-selectivity of 2-NIPAM.
Incorporation of the alkyne functionality into the mustard did not substantially impact
the activity of 2-NIPAM. The synthesized 125I-labeled 2-NIPAM conjugate demonstrated
greater cellular retention under hypoxic conditions, suggesting that retention is due to
activation and adduct formation with intracellular macromolecules. Future studies
including incorporation of 2-NIPAM into BB2r-targeted analogs and in vitro/in vivo
evaluation of radioconjugates are needed.

Future Directions
1. Synthesis of 2-NIPAM incorporated BB2r-targeted analogues.
Recently, the activated prodrug of 2-NIPAM, TH-302 has been utilized in several
clinical studies targeting solid tumor

. These studies encourage us to further use 2-

261

NIPAM as hypoxia trapping agents, considering the fact that they share the same
intracellular reduction mechanism. As we already demonstrated the hypoxia selectivity
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of 2-NIPAM, and its ability to participate in click-chemistry to a compound with azide
moiety, we plan to incorporate it with a BB2r-targeted peptide backbone. This strategy
aims at enhancing the BB2r-positive tumor uptake of the radiotracer. Thus, matching
controls will be synthesized and evaluated with 2-NIPAM conjugated analogs side-byside in our following studies.
2. Synthesis and evaluation of the new series of hydrophilic cysteine cathepsin
inhibitor incorporated peptide analogues: from mice to human.
We previous used hydrophobic cysteine cathepsin inhibitors as our trapping agent
to improve the tumor uptake of receptor-targeted peptide analogues

. As a result, the
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analogues demonstrated high renal and liver uptake of the tracer, which persuaded us
to investigate the impact of total hydrophilicity of the radiotracer on the uptake of nontarget tissues. Based on our unpublished data, the increased hydrophilicity dramatically
decreases liver and kidney uptake of the tracer. Among all the hydrophilic candidates,
we choose to use E-64 as our model CC inhibitor as discussed earlier. On top of
eliminating liver uptake, we successfully demonstrated the strategy of using E-64 to
enhance tumor retention and attenuate the kidney uptake in BB2r-positive prostate
cancer mouse model.
In the future, we intend to demonstrate the applicable potential of this strategy in the
development of other receptor/small molecule-based tumor-targeted radiotracers. 1)
We’ve chosen the somatostatin receptor as our next target and the in vitro evaluation is
currently underway. 2) Further investigation of the impact of linker and chelator on the
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tumor uptake and T/NT ratio will also be examined. 3) Meanwhile, since our conjugated
E-64 derivative BB2r-antagonist showed considerable tumor retention with the most
ideal T/NT ratios, especially the tumor-to-kidney ratio, we plan to explore further its
therapeutic translation potential. To do so, the human dosimetry estimates based on our
mouse biodistribution data will be calculated first. Furthermore, the maximum tolerated
dose (MTD) of BB2r-targeted antagonist will be generated in a non-tumor bearing
mouse model.
3. Evaluation of radiolabeled peptide-targeted analogues using orthotopic and
patient-derived xenograft mouse model.
Subcutaneous mouse model is commonly used in preclinical studies, having
advantages due to low cost and faster tumor generation time. On the other hand, this
model also has limitation, such as providing insufficient reliably clinically relevant data,
for example, lack of a clinically relevant oncological microenvironment and less power
in predicting drug responses in humans

. Thus, we plan to first use subcutaneous
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model for our initial pro-drug screen. Meanwhile, with the need to overcome the above
drawbacks with this model, we have the intention to use orthotopic and patient derived
tumor xenografts mouse models to test our leading compounds. The purpose of this is to
further elucidate the in vivo behavior of our radio-tracers, thereby essentially increasing
the clinical translation potential of these agents.
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